mfn.se Ads.txt file
------------------------------------------------------------------------------
news_id: 46ca7f77-cce8-4a3e-84e8-a4abf6ab7742
group_id: 75e50be7-0297-435a-9403-2ea2364a7bf4
tags: [:regulatory], [:regulatory:mar], [sub:ci], [sub:ci:staff]
title: Greg Glenday appointed new CEO of Acast
------------------------------------------------------------------------------
Ross Adams has notified the Board that he wishes to resign from his position,
following nearly eight successful years as Chief Executive Officer of Acast AB
(publ) (“Acast”), to continue in a strategic advisory role. The Board has
resolved to appoint Greg Glenday, currently Chief Business Officer, as new
Chief Executive Officer to succeed Ross Adams. Greg Glenday will assume his
new position immediately.
“The Board would like to express its gratitude to Ross Adams for his important
contributions as CEO of Acast. Ross has been instrumental in the company's
development towards becoming the leading marketplace for podcasts, guiding it
through its IPO, market expansions, and numerous strategic acquisitions.
During his tenure as CEO, Acast's revenues have increased from less than
SEK100m to more than SEK1.9bn in 2024. The Board is thrilled that Ross will
continue to support Acast in a new role for Acast to continue to benefit from
his expertise” says John Harrobin, Chairman of the Board of Acast.
"I’m incredibly proud of the value we’ve created at Acast, building a
market-leading global podcasting platform, delivering profitability, and
having had the privilege to lead such brilliantly talented people. As I
transition into a strategic advisory role, I remain committed to supporting
the company’s continued success and delivering long-term value for
shareholders”, says Ross Adams, former CEO of Acast.
Greg Glenday has been part of Acast’s management since 2023, following over a
decade in global C-level roles, including Chief Revenue Officer of Shazam and,
more recently, CEO of Lightbox.
“The Board is confident that Greg Glenday is the right leader for Acast as we
enter our next phase of growth,” says John Harrobin. “Greg brings
results-oriented leadership experience, a profound industry understanding, and
a proven ability to scale operations globally. Greg’s leadership has been
vital in Acast’s transformation of US operations which has enabled the company
to accelerate performance and strategic expansion in the US, ultimately
achieving positive EBITDA for the first time in its ten-year history.”
“I am honored and energized to step into the role of CEO of Acast and further
its track record of being at the forefront of podcasting innovation. I look
forward to working with our immensely talented team of Acasters, our creators,
and our advertising partners to unlock podcasting’s full potential and shape
the future of the industry”, says Greg Glenday, new CEO of Acast.
For more information
------------------------------------------------------------------------------
Björn Jeffery, Vice chairman of the Acast Board
E-mail: investors@acast.com
Investor Relations:
Dennis Berggren
Tel: +46 703 00 45 33
E-mail: dennis.berggren@acast.com
About Acast
------------------------------------------------------------------------------
Since 2014, Acast has been creating the world’s most valuable podcast
marketplace, building the technology which connects podcast creators,
advertisers and listeners. Its marketplace spans over 140,000 podcasts, 3,300
advertisers and one billion quarterly listens. Crucially, those listens are
monetized wherever they happen - across any podcasting app or other listening
platform.
The company operates worldwide and is headquartered in Stockholm, Sweden.
Acast is listed on the Nasdaq First North Premier Growth Market (ACAST.ST).
Certified Adviser is FNCA Sweden AB, info@FNCA. se.
This information is information that Acast is obliged to make public pursuant
to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-22 17:00 CEST.
Attachments
------------------------------------------------------------------------------
Greg Glenday appointed new CEO of Acast
(https://storage.mfn.se/abeed8ae-025c-4115-8fb3-3ed6d1611653/greg-glenday-appointed-new-ceo-of-acast.pdf)
------------------------------------------------------------------------------
news_id: 1aac9418-f5f5-4f91-be52-5af5c128acb4
group_id: 75e50be7-0297-435a-9403-2ea2364a7bf4
tags: [:regulatory], [:regulatory:mar], [sub:ci], [sub:ci:staff]
title: Greg Glenday utsedd till ny VD för Acast
------------------------------------------------------------------------------
Efter snart åtta framgångsrika år som VD för Acast AB (publ) ("Acast") har
Ross Adams meddelat styrelsen att han önskar lämna sin befattning för att
fortsätta i en roll som strategisk rådgivare inom Acast. Styrelsen har
beslutat att utse Greg Glenday, som idag är Chief Business Officer, till ny VD
efter Ross Adams. Greg Glenday kommer tillträda sin nya befattning omedelbart.
“Styrelsen önskar uttrycka sin tacksamhet till Ross Adams för hans
betydelsefulla bidrag som VD för Acast. Ross har haft en avgörande roll i att
etablera bolaget som en ledande marknadsplats för podcasts. Han har lett Acast
genom en börsnotering, expansioner till nya marknader och genomförandet av ett
flertal strategiska förvärv. Under hans tid som VD har Acasts intäkter växt
från mindre än 100 miljoner SEK till över 1,9 miljarder SEK år 2024. Styrelsen
är glad att Ross kommer att fortsätta stödja Acast i en ny roll i syfte att
Acast ska fortsätta kunna dra nytta av hans expertis”, säger John Harrobin,
styrelseordförande i Acast.
”Jag är otroligt stolt över det värde vi har skapat på Acast – att ha byggt en
marknadsledande global podcastplattform, nått lönsamhet och haft förmånen att
leda så fantastiskt begåvade människor. När jag nu övergår till en strategisk
rådgivarroll fortsätter jag att stötta företagets fortsatta framgång och att
skapa långsiktigt värde för aktieägarna”, säger Ross Adams, tidigare VD för
Acast.
Greg Glenday har ingått i Acasts ledningsgrupp sedan 2023, och har över tio
års erfarenhet från ledande roller i globala bolag, bland annat som Chief
Revenue Officer på Shazam och VD för Lightbox.
“Styrelsen är övertygad om att Greg Glenday är rätt ledare för Acast när vi nu
går in i nästa tillväxtfas.” fortsätter John Harrobin. “Greg besitter en
resultatinriktad ledarskapserfarenhet, en djup förståelse för branschen och en
bevisad förmåga att skala verksamheter globalt. Hans ledarskap har varit
avgörande för Acasts omvandling av den amerikanska verksamheten, vilket har
möjliggjort att bolaget har kunnat accelerera sin prestation och strategiska
expansion i USA, och uppnått positivt EBITDA-resultat för första gången i sin
tioåriga historia.”
"Jag är hedrad över och motiverad att få ta över rollen som VD för Acast och
fortsätta dess tradition av att ligga i framkant inom podcastinnovation. Jag
ser fram emot att arbeta med vårt oerhört talangfulla team av Acasters, våra
kreatörer och våra annonspartners för att frigöra podcastingens fulla
potential och forma framtiden för branschen", säger Greg Glenday, nytillträdd
VD för Acast.
För mer information
------------------------------------------------------------------------------
Björn Jeffery, vice styrelseordförande
E-mail: investors@acast.com
Investor Relations:
Dennis Berggren
Tel: +46 703 00 45 33
E-mail: dennis.berggren@acast.com
Om Acast
------------------------------------------------------------------------------
Sedan 2014 har Acast utvecklat världens mest kraftfulla marknadsplats för
podcasts och byggt upp den teknik som kopplar samman poddkreatörer, annonsörer
och lyssnare. Denna marknadsplats omfattar över 140 000 podcasts, 3 300
annonsörer och har över en miljard lyssningar per kvartal. En avgörande faktor
är att dessa lyssningar genererar intäkter, var de än sker – via podcastappar
eller andra lyssningsplattformar.
Bolaget är verksamt över hela världen och har sitt huvudkontor i Stockholm,
Sverige. Acast är noterat på Nasdaq First North Premier Growth Market
(ACAST.ST). Certified adviser är FNCA Sweden AB, info@fnca.se.
Denna information är sådan information som Acast är skyldigt att offentliggöra
enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom
ovanstående kontaktpersoners försorg, för offentliggörande den 2025-06-22
17:00 CEST.
Bifogade filer
------------------------------------------------------------------------------
Greg Glenday utsedd till ny VD för Acast
(https://storage.mfn.se/8018aa3d-6cc1-4389-b92d-92c8e7fb450a/greg-glenday-utsedd-till-ny-vd-for-acast.pdf)
------------------------------------------------------------------------------
news_id: e89aa370-60c1-4e9f-8d50-fb343604c94c
group_id: f5da867e-39a7-4b15-9ac0-553402566a32
tags: [:regulatory], [:regulatory:mar], [sub:ci], [sub:ci:staff]
title: Circle Energy Sweden AB (publ): Board Member Resignations
------------------------------------------------------------------------------
Date: 2025-06-22
Circle Energy Sweden AB (publ)
Reg. No.: 559212–5685
Ticker: [CIRCLE]
Circle Energy Sweden AB (publ) Board Member Resignations
Circle Energy Sweden AB (publ) (”Bolaget”) meddelar härmed att Jan-Olav
Törner, Jan Ragnar Bardell och Helena Charlotta Ek, ledamöter i styrelsen, har
informerat Bolaget om sitt beslut att avgå från styrelsen med omedelbar
verkan.
Avgångarna förväntas inte få någon praktisk påverkan på Bolaget, eftersom dess
årsstämma (”Årsstämman”) äger rum om drygt en vecka och inga operativa frågor
påverkas.
Sedan den nya finansieringsgruppen vände Bolagets situation, har flera brister
i den tidigare styrelsens och tidigare verkställande direktörens (VD)
förvaltning under 2024 identifierats, inklusive ohållbara utgifter av bolagets
medel. Detta ledde till att revisorerna rekommenderade att aktieägarna inte
beviljar ansvarsfrihet för den tidigare styrelsen och tidigare VD:n avseende
vissa åtaganden vid Årsstämman. De kvarvarande styrelseledamöterna kommer att
rekommendera att Årsstämman även avslår ansvarsfrihet i andra ärenden. Före
sina avgångar utövade de tidigare styrelseledamöterna olika former av
påtryckningar mot revisorer, andra styrelseledamöter och aktieägare i syfte
att säkerställa ett beslut om ansvarsfrihet – dock utan framgång.
Det står klart att deras avgång endast utgör det sista kapitlet i deras
tydliga misskötsel av sitt förtroendeansvar gentemot Bolaget och dess
aktieägare.
Till följd av avgångarna uppfyller styrelsen inte längre det minsta antal
ledamöter som krävs, men ett beslut om att utse nya ledamöter är redan
planerat att behandlas vid den kommande Årsstämman den 30 juni 2025.
För ytterligare information, vänligen kontakta:
------------------------------------------------------------------------------
Martin Boulton, CEO, Circle Energy Sweden AB (publ)
martin.boulton@circleenergy.se
Telefon: +44 785 441 3030
Kort om Circle Energy Sweden AB
------------------------------------------------------------------------------
Ett bolag som producerar grön energi
Circle Energy är ett energibolag för grön energiproduktion. Bolagets
affärsmodell syftar till att förverkliga länders miljömål genom etableringar
av anläggningar som producerar grön el och värme. Bolaget säljer nyckelfärdiga
anläggningar inklusive byggnation, installation, utbildning, och service.
Circle Energy kan utöver detta även äga och driva anläggningar i egen regi, på
lokala marknader där detta är fördelaktigt, vilket då innebär att Circle
Energy själva producerar grön el och värme.
Circle Energy är därmed ett viktigt bolag i samhällets omställning till grön
energiproduktion.
Bolaget startades 2019 och är noterat på Nasdaq First North Growth Market
sedan 2020.
Bolagets Certified Adviser är Eminova Fondkommission AB | 08-684 211 10
| adviser@eminova.se
Denna information är sådan information som Circle Energy Sweden AB är skyldigt
att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen
lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-22 13:45 CEST.
Bifogade filer
------------------------------------------------------------------------------
Circle Energy Sweden AB (publ): Board Member Resignations
(https://storage.mfn.se/15292d04-935d-49d5-8869-680b24531b46/circle-energy-sweden-ab-publ-board-member-resignations.pdf)
------------------------------------------------------------------------------
news_id: 4a22fa98-647a-474f-8d74-c7f5e1ab6868
group_id: 3446884e-93a1-48ce-a983-f1637cda59f2
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: Tangiamo Touch considers investment in Bitcoin as part of the company's
long-term reserve strategy
------------------------------------------------------------------------------
The Board of Directors of Tangiamo Touch Technology AB (publ) (NGM Nordic SME:
TANGI) ("Tangiamo" or "the Company") announces today that the Company intends
to evaluate and potentially initiate investments in Bitcoin (BTC) as part of a
long-term strategy to strengthen the group's financial preparedness through an
alternative reserve asset.
Tangiamo Touch has an overall goal to achieve consolidated revenues of between
100 and 130 MSEK through 2026. As part of the Company's strategic planning,
the board is now reviewing how portions of future surplus liquidity can be
allocated in a way that is both sustainable and creates long-term value.
| "We see Bitcoin as a potential complement to traditional assets,
| particularly in times of increased inflation and financial uncertainty.
| Bitcoin has evolved into a global, liquid and regulated asset class, and
| just as our AI- and Web3-driven gaming products represent the future, we
| want our balance sheet to be equally modern," says Chris Steele, CEO of
| Tangiamo.
The evaluation encompasses four main areas:
1. Risk and volatility scenarios linked to different allocation levels to
ensure liquidity needs
2. Regulatory and accounting issues according to MiCA, MAR as well as K3/IFRS
to guarantee full regulatory compliance
3. Custody and security solutions with focus on insured cold-custody within
the EEA for maximum security
4. Internal governance and reporting including clear mandates and information
obligations toward the board, auditor and market.
Several factors make this the right time for the evaluation. In May, H100
Group AB became the first Swedish listed company with a Bitcoin treasury
strategy, a milestone for the Nordic market. Now, with the EU's MiCA
regulation fully implemented and the US federal stablecoin legislation on the
way, there are clear signs that the regulatory landscape has matured
sufficiently to make the Company's evaluation meaningful.
Bitcoin is characterized by high price volatility, potential write-down
obligation according to K3/IAS 38, certain regulatory uncertainty as well as
issues connected to energy usage. These factors will be carefully considered
and weighed against the potential benefits before an investment decision is
made.
The board expects a complete basis for decision making in the third quarter of
2025. If the investment is deemed appropriate, a decision will be made no
later than the fourth quarter of 2025, whereby the market will be immediately
informed of the decision and purchase of Bitcoin in accordance with MAR.
For more information, please contact:
Chris Steele, CEO
Email: chris.steele@tangiamo.com
Tel: +46 70 978 1081
About Tangiamo Touch Technology AB
Tangiamo Touch Technology AB (publ) is a Swedish company headquartered in
Gothenburg. The company is a leader in advanced technology for both land-based
and digital gaming, including sensor technology, visual identification, and
AI-driven systems for the gaming industry. Following its acquisition of
Trustplay, Tangiamo has expanded into the iGaming sector, now offering a
comprehensive platform for both land-based casinos and online operators. For
more information, visit www.tangiamo.com. The company’s shares (TANGI) are
traded on the NGM Nordic SME.
This information is information that Tangiamo Touch Technology is obliged to
make public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact persons set out
above, at 2025-06-22 13:00 CEST.
Attachments
Tangiamo Touch considers investment in Bitcoin as part of the company's
long-term reserve strategy
(https://storage.mfn.se/61cad4db-665c-42f3-a9bd-d142fd73fd66/tangiamo-touch-considers-investment-in-bitcoin-as-part-of-the-companys-long-term-reserve-strategy.pdf)
------------------------------------------------------------------------------
news_id: ba6880d7-4863-4654-ae85-ba65b6f8b88e
group_id: 3446884e-93a1-48ce-a983-f1637cda59f2
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: Tangiamo Touch överväger investering i Bitcoin som en del av bolagets
långsiktiga reservstrategi
------------------------------------------------------------------------------
Styrelsen i Tangiamo Touch Technology AB (publ) (NGM Nordic SME: TANGI)
(”Tangiamo” eller ”Bolaget”) meddelar idag att Bolaget avser att utvärdera och
eventuellt inleda investeringar i Bitcoin (BTC) som en del av en långsiktig
strategi för att stärka koncernens finansiella beredskap genom en alternativ
reservtillgång.
Tangiamo Touch har som övergripande mål att under 2026 uppnå en omsättning på
mellan 100 och 130 miljoner kronor för hela koncernen. Som ett led i Bolagets
strategiska planering ser styrelsen nu över hur delar av framtida
överskottslikviditet kan allokeras på ett sätt som är både hållbart och
långsiktigt värdeskapande.
| "Vi ser Bitcoin som ett potentiellt komplement till traditionella
| tillgångar, särskilt i tider av ökad inflation och finansiell osäkerhet.
| Bitcoin har utvecklats till ett globalt, likvidt och reglerat tillgångsslag,
| och precis som våra AI- och Web3-drivna spelprodukter representerar
| framtiden, vill vi att vår balansräkning ska vara lika modern," säger Chris
| Steele, VD för Tangiamo.
Utvärderingen omfattar fyra huvudområden:
1. Risk- och volatilitetsscenarier kopplade till olika allokeringsnivåer för
att säkerställa likviditetsbehov
2. Regel- och redovisningsfrågor enligt MiCA, MAR samt K3/IFRS för att
garantera fullständig regelefterlevnad
3. Förvarings- och säkerhetslösningar med fokus på försäkrad cold-custody
inom EES för maximal trygghet
4. Intern styrning och rapportering inklusive tydliga mandat och
informationsskyldigheter gentemot styrelse, revisor och marknad.
Flera faktorer gör detta till rätt tidpunkt för utvärderingen. H100 Group AB
blev i maj det första svenska börsbolag med en Bitcoin-treasury-strategi, en
milstolpe för den nordiska marknaden. Nu, med EU:s MiCA-förordning fullt
implementerad och USA:s federala stablecoin-lagstiftning på väg, finns tydliga
tecken på att det regulatoriska landskapet mognat tillräckligt för att göra
Bolagets utvärdering meningsfull.
Bitcoin kännetecknas av hög prisvolatilitet, potentiell nedskrivningsplikt
enligt K3/IAS 38, viss regulatorisk osäkerhet samt frågor kopplade till
energianvändning. Dessa faktorer kommer att beaktas noggrant och vägas mot de
potentiella fördelarna innan ett investeringsbeslut tas.
Styrelsen väntar sig ett fullständigt beslutsunderlag under tredje kvartalet
2025. Om investeringen bedöms lämplig fattas beslut senast fjärde kvartalet
2025, varvid marknaden omgående informeras vid beslut och köp av Bitcoin i
enlighet med MAR.
För mer information, vänligen kontakta:
Chris Steele, VD
Email: chris.steele@tangiamo.com
Tel: +46 70 978 1081
Om Tangiamo
Tangiamo Touch Technology AB (publ) är ett svenskt företag baserat i Göteborg.
Bolaget är ledande inom utveckling av avancerad teknologi för både
landbaserade och digitala spel, inklusive sensorteknologi, visuell
identifiering och AI-baserade system för spelindustrin. Genom ett förvärv av
Trustplay har Tangiamo expanderat till iGaming-sektorn och erbjuder nu en
omfattande plattform för både landbaserade kasinon och online-operatörer. Mer
information om verksamheten finns på www.tangiamo.com. Bolagets aktie (TANGI)
handlas på NGM Nordic SME.
Denna information är sådan information som Tangiamo Touch Technology är
skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning.
Informationen lämnades, genom ovanstående kontaktpersoners försorg, för
offentliggörande den 2025-06-22 13:00 CEST.
Bifogade filer
Tangiamo Touch överväger investering i Bitcoin som en del av bolagets
långsiktiga reservstrategi
(https://storage.mfn.se/c4a8532f-4ab6-4eae-993f-6d65bf38e40e/tangiamo-touch-overvager-investering-i-bitcoin-som-en-del-av-bolagets-langsiktiga-reservstrategi.pdf)
------------------------------------------------------------------------------
news_id: bb27c981-c0bc-4c11-9237-fa9c58a776ea
group_id: c3070a13-f74b-47cc-9657-e3667c2a2890
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: *Circle Energy Sweden AB (publ) – Samriskföretag för koldioxidkrediter*
------------------------------------------------------------------------------
*Circle Energy Sweden AB (publ) etablerar plattform för koldioxidkrediter*
*Circle Energy Sweden AB (publ)*
*Organisationsnummer: 559212–5685*
*Ticker: [CIRCLE]*
*Circle Energy Sweden AB (publ) etablerar plattform för koldioxidkrediter*
Circle Energy Sweden AB (publ) (”Bolaget”) offentliggör undertecknandet av ett
avtal med SMC Entertainment Inc. (”SMCE”), ett börsnoterat amerikanskt
företag, om bildandet av ett strategiskt samriskföretag. Samriskföretaget, som
kommer att benämnas Carbon Capital Solutions AB (”CCS”), har som målsättning
att revolutionera marknaden för koldioxidkrediter genom en innovativ digital
handelsplattform kombinerad med avancerad artificiell intelligens.
CCS kommer att etableras som ett dotterbolag till Bolaget och ska utveckla och
driva en toppmodern plattform för handel med koldioxidkrediter. Plattformen är
utformad för att möjliggöra transparenta transaktioner, verifierad
projektregistrering och rapportering i enlighet med regulatoriska krav. Som
komplement till detta kommer CCS att lansera en AI-driven plattform för
kundförvärv, vilken gör det möjligt för företagskunder att enkelt identifiera,
registrera och delta i möjligheter kopplade till koldioxidkrediter som är i
linje med deras hållbarhetsmål. CCS förväntas lansera en fullt fungerande
betaversion av plattformen senast den 20 juli 2025.
Bolaget kommer att äga en majoritetsandel om 51 % i CCS och bidra med 500 000
000 nyemitterade aktier till ett pris av 0,01 SEK per aktie, inom ramen för
Bolagets nuvarande kapitalgränser. SMCE kommer att bidra med sin proprietära
AI-plattform som apportegendom och inneha 49 % av aktierna i CCS.
Samriskföretaget kommer att etableras i enlighet med svensk lag.
Detta samriskföretag återspeglar båda företagens engagemang för hållbar
utveckling och innovation samt positionerar CCS som en ledande aktör på den
globala marknaden för koldioxidkrediter.
”Vi är mycket entusiastiska över att kombinera Circle Energys expertis inom
förnybar energi och koldioxidmarknader med SMCE:s banbrytande AI-teknologi,”
sade Martin Boulton, verkställande direktör för Circle Energy Sweden AB.
”Carbon Capital Solutions representerar en unik möjlighet att skapa ökad
effektivitet, transparens och tillgänglighet på marknaden för
koldioxidkrediter.”
Erik Blum, verkställande direktör för SMCE, tillade: ”Vår AI-plattform kommer
att göra det möjligt för företagskunder att enkelt identifiera och förvärva
koldioxidkrediter, vilket påskyndar införandet i stöd av viktiga
hållbarhetsmål.”
För ytterligare information, vänligen kontakta:
------------------------------------------------------------------------------
Martin Boulton, CEO, Circle Energy Sweden AB (publ)
martin.boulton@circleenergy.se
Telefon: +44 785 441 3030
Kort om Circle Energy Sweden AB
------------------------------------------------------------------------------
Ett bolag som producerar grön energi
Circle Energy är ett energibolag för grön energiproduktion. Bolagets
affärsmodell syftar till att förverkliga länders miljömål genom etableringar
av anläggningar som producerar grön el och värme. Bolaget säljer nyckelfärdiga
anläggningar inklusive byggnation, installation, utbildning, och service.
Circle Energy kan utöver detta även äga och driva anläggningar i egen regi, på
lokala marknader där detta är fördelaktigt, vilket då innebär att Circle
Energy själva producerar grön el och värme.
Circle Energy är därmed ett viktigt bolag i samhällets omställning till grön
energiproduktion.
Bolaget startades 2019 och är noterat på Nasdaq First North Growth Market
sedan 2020.
Bolagets Certified Adviser är Eminova Fondkommission AB | 08-684 211 10
| adviser@eminova.se
Denna information är sådan information som Circle Energy Sweden AB är skyldigt
att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen
lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-20 22:45 CEST.
Bifogade filer
------------------------------------------------------------------------------
*Circle Energy Sweden AB (publ) – Samriskföretag för koldioxidkrediter*
(https://storage.mfn.se/e2c27c0b-4477-4eba-a107-dfe94558e2b5/circle-energy-sweden-ab-publ-samriskforetag-for-koldioxidkrediter.pdf)
------------------------------------------------------------------------------
news_id: 27382185-61ff-4cda-b23e-10d2d9cb3c21
group_id: 4bb7972d-8dfb-4f78-beeb-ff06a9deb442
tags: [ext:ob], [ext:ob:non-regulatory], [sub:ci], [sub:ci:other]
title: Envipco – Final 2024 annual results
------------------------------------------------------------------------------
Amersfoort, The Netherlands – 20 June 2025 – Envipco Holding N.V. (“Envipco”
or “the Company”), a global provider of recycling systems and reverse vending
machine (RVM) technology, today reports the final 2024 annual results.
The table below summarizes the Company’s final 2024 annual results compared to
the preliminary full year results published 20 March 2025.
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| | Final | | | 1) | 2) | 3) | 4) | 5) |
| | | Preliminary | Variance | | | | | |
| EURm | results | results | | | | | | |
| | 2024 | 2024 | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Revenues | 114.0 | 117.8 | -3.8 | | -0.7 | | -3.2 | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| COGS | 71.7 | 74.7 | 3.0 | | 0.7 | | 2.3 | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Gross profit | 42.3 | 43.1 | -0.8 | | | | -0.9 | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Oper. Profit | 3.7 | 4.6 | -0.8 | | | | -0.9 | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Pretax | 0.7 | 1.6 | -0.9 | | | | -0.9 | |
| income | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Net income | -3.0 | -0.7 | -2.3 | -1.6 | | | -0.7 | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Total assets | 135.9 | 129.4 | 6.5 | -1.6 | | 4.2 | 2.3 | 1.4 |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| Total | 70.8 | 61.8 | 8.9 | | | 4.2 | 3.2 | 1.4 |
| liabilities | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| ST | 18.5 | 13.5 | 5.0 | | | 4.2 | 0.8 | |
| borrowings | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
| LT | 8.1 | 5.8 | 2.3 | | | | 2.3 | |
| borrowings | | | | | | | | |
+--------------+-------+-----------+--------+------+------+-----+------+-----+
1) Previously announced reversal of tax assets reduces net income and equity
by EUR 1.6m
2) A reclassification and elimination of sales resulted in a reduction in
revenues of EUR 0.7m and a corresponding reduction in COGS resulting in zero
effect on gross profit.
3) A reassessment on factored receivables increased ST borrowings by EUR 4.2m.
Receipts from the financial institution previously netted against trade
receivables have now been reported separately as short-term borrowings and
receivables. The transaction was settled in Q1 25.
4) A change in classification of a contract from sale to lease lowered
revenues by EUR 3.2m and net income by EUR 0.7m. The revenue and profit from
the underlying customer agreement will be recognized over the contract term.
The corresponding effect on the balance sheet is an increase in assets of EUR
2.3m and EUR 3.2m increase in financial liabilities.
5) Facility lease adjustments to include renewals increased liabilities and
total assets by EUR 1.4m
The 2024 Annual Report reflecting these final results is expected to be
published Monday 23 June 2025 along with the call for the Annual General
Meeting.
For further information please contact:
Simon Bolton, Group CEO +31 33 285 1773
Mikael Clement, CSO +47 9900 8000
www.envipco.com
investors@envipco.com (mailto:envipcoinvestorrelations@envipco.com)
About Envipco Holding N.V.
Envipco Holding N.V. (Envipco), www.envipco.com, is a Netherlands-based
holding company listed on Euronext Amsterdam and Euronext Oslo Børs (Symbols:
ENVI/ENVIP). Envipco, with operations in several countries around the globe,
is a recognized leader in the development and operation of reverse vending
machines (RVMs), automated technological systems for the recovery of used
beverage containers. Known for its innovative technology and market
leadership, Envipco holds several intellectual property rights for RVM
systems, including but not limited to beverage refund deposit markings,
material type identification, compaction, and accounting.
Attachments
Envipco – Final 2024 annual results
(https://storage.mfn.se/ed9fc74a-d7ab-4eec-b1b8-e471f2c90f52/envipco-final-2024-annual-results.pdf)
------------------------------------------------------------------------------
news_id: c077f77c-61b8-4d0f-8424-e4902d840f26
group_id: 4aaeb590-fbb6-438e-8708-b1c533f47dfe
tags: [:regulatory], [:regulatory:nsta], [ext:ob],
[ext:ob:additional-regulatory-info], [sub:ci], [sub:ci:other]
title: REC Silicon - Update to Frequently Asked Questions and Response to
Investigation
------------------------------------------------------------------------------
Moses Lake, Washington USA June 20, 2025: REC Silicon ASA (“REC Silicon” or
the “Company”) announces the publication of an update to the frequently asked
questions and accompanying answers (the “FAQ”).
The FAQ responses to stakeholder requests on topics related to the voluntary
offer by Anchor AS. The FAQ will be available on the Company’s website
www.recsilicon.com and may be updated as needed.
With respect to the request for an extraordinary general meeting and
investigation in REC Silicon ASA made on May 16, 2025, by Ro Sommernes
Advokatfirma DA on behalf of Water Street Partners, Ltd., Bay Street
Associates, Ltd., Alexander Street Partners, Ltd., and Polar Fund, Ltd., the
Company conducted an internal review with an external law firm on the factual
matters raised in the request and found no wrongdoing by the Company. If a
Norwegian court orders an investigation into the factual matters of the
request, the Company will provide the information requested by such order.
REC Silicon does not have sufficient available cash to meet debt service and
other anticipated operating cash flow requirements for this year without the
continued support of the major shareholder, Hanwha, or additional sources of
capital. Therefore, it will soon require additional financing either from
Hanwha or from other sources of capital, none of which have yet been finalized
or guaranteed.
As previously disclosed, REC Silicon continues to evaluate and look for other
financing options and mitigative actions. However, the timing and feasibility
of such options are uncertain.
Contacts
------------------------------------------------------------------------------
Nils O. Kjerstad
IR Contact
Phone: +47 9135 6659
Email: nils.kjerstad@recsilicon.com
About REC Silicon
------------------------------------------------------------------------------
REC Silicon is a leading producer of advanced silicon materials, delivering
high-purity silicon gases to the solar and electronics industries worldwide.
We combine over 40 years of experience and proprietary technology with the
needs of our customers. Listed on the Oslo Stock Exchange (ticker: RECSI), the
Company is headquartered in Lysaker, Norway.
For more information, go to: www.recsilicon.com
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2025-06-20 20:12 CEST.
Attachments
------------------------------------------------------------------------------
REC Silicon - Update to Frequently Asked Questions and Response to
Investigation
(https://storage.mfn.se/a84a223a-97cb-4a94-90e0-38b0004c7714/rec-silicon-update-to-frequently-asked-questions-and-response-to-investigation.pdf)
250620 REC Silicon FAQ
(https://storage.mfn.se/e3c7746f-c9fa-4875-8faa-5857d38041f0/250620-rec-silicon-faq.pdf)
------------------------------------------------------------------------------
news_id: 535c9224-794a-4c76-8739-9a712e6b6ad0
group_id: b8c5bf70-c15a-49b9-9c81-b43bc67343fb
tags: [:regulatory], [:regulatory:listing], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: Magnasense AB carries out previously announced directed issue of
416,666,666 shares to Atlas Special Opportunities, LLC following called upon
conversions of SEK 2.50 million
------------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW
ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA,
BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR
DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE LAWS OR REGULATIONS OR
WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. PLEASE SEE “IMPORTANT
INFORMATION” AT THE END OF THE PRESS RELEASE.
The board of directors of Magnasense AB (“Magnasense” or the “Company”) has
today, based on the authorisation from the annual general meeting 2024 and in
accordance with the press release issued on 11 June 2025, resolved on a
directed issue to Atlas Special Opportunities, LLC (“Atlas”) of a total of
416,666,666 shares at a subscription price of SEK 0.006 per share (the
“Directed Issue”). The purpose of the Directed Issue and the reason for the
deviation from the shareholders’ preferential rights is to fulfil the
Company’s commitment to Atlas pursuant to the agreements entered into
regarding a loan facility and an amendment of the terms and conditions of
outstanding convertible bonds of series 2023/2026 (the “Convertible Bonds”),
respectively, which were communicated to the market on 9 April 2024 (the
“Financing Agreements”). All shares issued through the Directed Issue have
been subscribed for and allocated. In accordance with the loan facility
agreement with Atlas, the Company could call for loans in seven (7) tranches
(the “Tranches” or each a “Tranche”) in an aggregate nominal amount of SEK
45.00 million before deduction of set-up fee (the “Loan Facility”) and
transaction costs. Magnasense has previously called for the issuance of
Tranche 1, 2 and partially 3 in accordance with the press releases issued on
13 May 2024, on 30 May 2024, 18 July 2024 and on 20 September 2024,
respectively. Disbursed funds under the Loan Facility amounts to SEK 17.50
million. After the completion of the Directed Issue SEK 27.00 million of the
Convertible Bonds remain.
The Directed Issue
Magnasense has previously announced that the Company has entered into the
Financing Agreements and that the Company intends to carry out the Directed
Issue. For more information on the Financing Agreements and the subsequent
addendum concerning the Convertible Bonds and Loan Facility (subject to
approval by the annual general meeting), readers are referred to the press
release dated 9 April 2024 (“AegirBio enters into a conditional agreement on a
MSEK 45 loan facility with Atlas Special Opportunities and an agreement to
amend the outstanding convertible bonds, subject to EGM approval”) and the
press release dated 10 April 2025 (“Magnasense AB enters into an addendum with
Atlas Special Opportunities, LLC regarding outstanding convertible bonds of
series 2023/2026 and loan facility”). In accordance with the press release on
9 April 2024, a transaction fee of SEK 7.00 million is payable to Atlas for
the issuance of the Loan Facility, the extension of outstanding Convertible
Bonds and the termination of outstanding warrants of series TO4, to be paid by
set-off against newly issued shares in Magnasense. As further announced in the
press release on 9 April 2024, Atlas has the right to call for conversion of
outstanding debt in directed issues of all or part of the nominal amount of
the called Tranches, the nominal amount of the outstanding Convertible Bonds
and the transaction fee up to and including the respective maturity date.
In view of the above and the requested conversions, the board of directors of
Magnasense has today resolved on the Directed Issue of approximately SEK 2.50
million. The proceeds from the issue are intended to be paid in full by Atlas
through set-off against the remaining SEK 2.50 million in Convertible Bonds,
whereby Convertible Bonds corresponding to SEK 2.50 million will be
terminated. After the completion of the Directed Issue, SEK 27.00 million of
the Convertible Bonds remain and SEK 17.50 million of the Loan Facility
remains. The purpose of the Directed Issue and the reason for the deviation
from the shareholders’ preferential rights is to fulfil the Company’s
obligations towards Atlas under the Financing Agreements. All shares issued
through the Directed Issue have been subscribed for and allocated.
In accordance with the Financing Agreements, the subscription price per share
in the Directed Issue has been set at a weighted price of SEK 0.006,
corresponding to 100.00 per cent of the lowest daily volume-weighted average
price according to Nasdaq First North Growth Market’s price list for the share
in the Company during the fifteen (15) trading days preceding each receipt of
conversion request, respectively, in relation to the size of each conversion
request, respectively (excluding trading days when Atlas has traded in the
stock). The method for calculating the subscription price in the Directed
Issue has, in consultation with a financial advisor and through analysis of
the Company’s capital structure and several market factors, been determined
through arm’s length negotiations with Atlas. It is the board of directors’
assessment that the subscription price through this procedure reflects current
market conditions and demand and that it thereby is market-based.
The board of directors’ considerations
Prior to the decision to enter into the Financing Agreements, the Company’s
board of directors, together with a financial advisor, carefully investigated
the conditions for a rights issue to raise the necessary capital. The board’s
assessment was that the Company, especially taking into account the Company's
existing capital structure, could not fulfil its’ capital requirements in any
other way than through the Financing Agreements with Atlas. The board of
directors has together with a financial advisor assessed that a rights issue
would require significant guarantee commitments from an underwriting
consortium, which was not deemed possible for the Company to obtain. In
addition, a rights issue would probably have been carried out at a
significantly lower subscription price than that which Atlas will be able to
convert at in accordance with the terms and conditions of the Financing
Agreements. The board of directors’ overall assessment was thus that the
reasons for entering into the Financing Agreements and subsequently carrying
out directed issues of shares to Atlas in this way outweigh the reasons that
justify the main rule of issuing shares with preferential rights for existing
shareholders, and that issues of shares with deviation from the shareholders’
preferential rights in accordance with the Financing Agreements thus are in
the interest of the Company and all shareholders. The reason why the Directed
Issue is directed to an existing shareholder is that Atlas became a
shareholder through previously completed directed issues of shares resolved to
fulfil the Company's obligations to Atlas under the Financing Agreements, as
well as through the recently completed rights issue, the outcome of which was
announced by the Company on 12 May 2025.
The Loan Facility
The Loan Facility consists of seven (7) tranches with a total nominal amount
of SEK 45.00 million. Magnasense has previously called for Tranche 1, 2 and
partially 3 corresponding to a total of SEK 17.50 million. Tranches drawn
under the Loan Facility are interest-free and mature on 9 April 2027.
Atlas has the right to call for conversion of debt in directed issues of all
or part of the nominal amount of the called Tranches and the transaction fee
up to and including the maturity date. The minimum amount to convert is SEK
0.50 million. To facilitate the administration of the conversions, the parties
have agreed that a new issue under the Loan Facility shall be made when Atlas
has called for conversion in an aggregate amount of at least SEK 2.50 million
or if the market value of the transaction fee shares is less than SEK 1.00
million. The Company will announce conversions to the market when Atlas has
called for conversions that lead to a new share issue.
For information on the Financing Agreements and the subsequent addendum
concerning the Convertible Bonds and Loan Facility (subject to approval by the
annual general meeting), readers are referred to the press release dated 9
April 2024 (“AegirBio enters into a conditional agreement on a MSEK 45 loan
facility with Atlas Special Opportunities and an agreement to amend the
outstanding convertible bonds, subject to EGM approval”) and the press release
dated 10 April 2025 (“Magnasense AB enters into an addendum with Atlas Special
Opportunities, LLC regarding outstanding convertible bonds of series 2023/2026
and loan facility”).
Change in share capital, number of shares and votes and dilution
The Directed Issue entails that the Company’s share capital will increase by
SEK 417,083.332666 to a total of SEK 1,863,849.280293. The number of shares
and votes will increase by 416,666,666 to a total of 1,861,987,293. Carrying
out the Directed Issue entails a dilution of approximately 22.38 per cent for
existing shareholders in relation to the total number of shares and votes in
the Company.
For additional information, please contact:
Marco Witteveen, CEO
Email: ir@magnasense.com
The Company’s Certified Adviser is Eminova Fondkommission AB | info@eminova.se
IMPORTANT INFORMATION
The release, publication or distribution of this press release may, in certain
jurisdictions, be restricted by law and persons in the jurisdictions where
this press release has been published or distributed should inform themselves
about and observe any such legal restrictions. The recipient of this press
release is responsible for using this press release and the information
contained herein in accordance with the applicable rules in each jurisdiction.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy or subscribe for any securities issued by the Company in any
jurisdiction in which such offer or solicitation would be unlawful.
This press release is not a prospectus within the meaning of Regulation (EU)
No 2017/1129 (the “Prospectus Regulation”) and has not been approved or
reviewed by any regulatory authority in any jurisdiction. A prospectus will
not be prepared in connection with the Directed Issue.
This press release does not identify or purport to identify any risks (direct
or indirect) that may be associated with an investment in new shares. The
information contained in this press release is for the sole purpose of
describing the background to the Directed Issue and does not purport to be
complete or exhaustive.
This press release does not constitute an offer or invitation to purchase or
subscribe for securities in the United States. The securities referred to
herein may not be sold in the United States absent registration or an
applicable exemption from registration under the U.S. Securities Act of 1933,
as amended (the “Securities Act”), or the securities laws of any state or
other jurisdiction of the United States, and may not be offered or sold in the
United States absent registration or an applicable exemption from, or in a
transaction not subject to, the registration requirements of the Securities
Act. There is no intention to register any securities referred to herein in
the United States or to make a public offering of such securities in the
United States. The information in this press release may not be announced,
published, copied, reproduced or distributed, directly or indirectly, in whole
or in part, in or into the United States, Canada, Australia, Hong Kong, New
Zealand, South Africa, South Korea, Switzerland, Singapore, Japan, Russia,
Belarus or any other jurisdiction where such announcement, publication or
distribution of this information would be unlawful or where such action is
subject to legal restrictions or would require additional registration or
other measures than those required by Swedish law. Actions contrary to this
instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements that reflect the
Company’s intentions, beliefs or expectations regarding the Company’s future
results of operations, financial condition, liquidity, performance, prospects,
anticipated growth, strategies and opportunities and the markets in which the
Company operates. Forward-looking statements are statements that are not
historical facts and can be identified by the use of words such as “believes”,
“expects”, “anticipates”, “intends”, “estimates”, “will”, “may”,
“anticipates”, “should”, “could” and, in each case, the negatives thereof, or
similar expressions. The forward-looking statements in this press release are
based on various assumptions, many of which are based on additional
assumptions. Although the Company believes that the assumptions reflected in
these forward-looking statements are reasonable, there can be no assurance
that they will materialise or that they are accurate. Because these statements
are based on assumptions or estimates and are subject to risks and
uncertainties, actual results or outcomes could differ materially from those
in the forward-looking statements for a variety of reasons. Such risks,
uncertainties, contingencies and other important factors could cause actual
events to differ materially from the expectations expressed or implied in this
press release by the forward-looking statements. The Company does not
guarantee that the assumptions underlying the forward-looking statements
contained in this press release are accurate and any reader of this press
release should not place undue reliance on the forward-looking statements
contained in this press release. The information, opinions and forward-looking
statements expressed or implied herein are made only as of the date of this
press release and are subject to change. Neither the Company nor anyone else
undertake to review, update, confirm or to release publicly any revisions to
any forward-looking statements to reflect events that occur or circumstances
that arise in relation to the content of this press release, except as
required by law or the rules of Nasdaq First North Growth Market.
About Magnasense AB
Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to
monitor and optimize the dosage of biological drugs via its unique patented
technology platform. In June 2020, Magnasense was listed on the Nasdaq First
North Growth Market. The company's ambition is, in addition to bringing
innovative diagnostic technology to the market, to make diagnostics more
accessible, easier to use and to provide accurate and easily transferable
results. For more information, see Magnasense's website www.magnasense.com.
Attachments
Magnasense AB carries out previously announced directed issue of 416,666,666
shares to Atlas Special Opportunities, LLC following called upon conversions
of SEK 2.50 million
(https://storage.mfn.se/8996a1ce-0635-406a-82ca-fc26b7b09541/magnasense-ab-carries-out-previously-announced-directed-issue-of-416-666-666-shares-to-atlas-special-opportunities-llc-following-called-upon-conversions-of-sek-2-50-million.pdf)
------------------------------------------------------------------------------
news_id: 6272ec26-1d0b-4ba6-866d-c89f26d82de8
group_id: 773492fb-6654-4431-9fce-6d1e7bc8b1de
tags: [:regulatory], [:regulatory:mar], [sub:ca], [sub:ca:ma]
title: Pandox AB (publ): Acquisition of shares in Dalata Hotel Group plc
------------------------------------------------------------------------------
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG,
JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR
ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL
PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER
SWEDISH LAW, IS PROHIBITED, OR OTHERWISE WOULD CONTRAVENE APPLICABLE
REGULATIONS IN SUCH JURISDICTION.
THIS IS AN ANNOUNCEMENT OF A POSSIBLE OFFER UNDER RULE 2.4 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)
AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7
OF THE IRISH TAKEOVER RULES.
THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, OR AS TO THE TERMS ON
WHICH ANY OFFER MIGHT BE MADE.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE 20 June 2025
Statement regarding acquisition of shares in Dalata Hotel Group plc (“Dalata”)
On 3 June 2025, a consortium formed of joint offerors Pandox AB (“Pandox”) and
Eiendomsspar AS (“Eiendomsspar” and together with Pandox, the “Consortium”)
confirmed that it had submitted a non-binding proposal to the Board of
Directors of Dalata regarding a possible all-cash offer by the Consortium to
acquire the entire issued and to be issued share capital of Dalata, other than
those Dalata shares in the beneficial ownership of the Consortium (the
“Proposal”). The Proposal comprised a cash offer of €6.05 per ordinary share
of Dalata and was rejected by the Board of Directors of Dalata on 3 June 2025.
The Consortium announces that Pandox Ireland DAC, a wholly-owned indirect
subsidiary of Pandox, has today made an on market purchase of 1,698,112
ordinary shares in Dalata, representing approximately 0.8 per cent. of the
issued share capital of Dalata, at a price of €6.30 per share.
Consequently, any firm intention to make an offer for Dalata by the Consortium
in accordance with Rule 2.7 of the Irish Takeover Rules, if made, will be at a
price of not less than €6.30 per share.
An offer of €6.30 per ordinary share of Dalata would, if made, value the
issued share capital of Dalata at approximately €1.3 billion and represent a
premium of approximately:
* 32.4 per cent. to Dalata’s closing share price of €4.76 as at close of
business on 5 March 2025, being the last trading day prior to the
announcement by Dalata of the commencement of a strategic review and formal
sale process (the “Formal Sale Process”); and
* 14.9 per cent. to the three month volume weighted average price of
approximately €5.48 for Dalata shares as at the close of business on 19 June
2025.
There can be no certainty that any offer will be made. A further announcement
will be made as appropriate. Any offer, if made, is likely to be solely in
cash, although the Consortium reserves the right to vary the form of
consideration and/or introduce other forms of consideration.
In accordance with Rule 2.6 of the Irish Takeover Rules, the Consortium is
required, by no later than 5:00pm (Irish time) on 15 July 2025, to either: (i)
announce a firm intention to make an offer for Dalata in accordance with Rule
2.7 of the Irish Takeover Rules; or (ii) announce that it does not intend to
make an offer for Dalata, in which case the announcement will be treated as a
statement to which Rule 2.8 of the Irish Takeover Rules applies. This deadline
will only be extended with the consent of the Irish Takeover Panel in
accordance with Rule 2.6(c) of the Irish Takeover Rules.
Pursuant to Rule 2.5 of the Irish Takeover Rules and as set forth in the
Proposal, the Consortium reserves the right to vary the form and / or mix of
the offer consideration and vary the transaction structure. The Consortium
also reserves the right to amend the terms of any offer (including making the
offer on less favourable terms or at a lower price than €6.30 per share):
A. with the recommendation or consent of the Board of Directors of Dalata;
B. if Dalata announces, declares or pays any dividend or any other
distribution or return of value to its shareholders after the date of this
announcement, in which case the Consortium reserves the right to make an
equivalent adjustment to any offer;
C. following the announcement by Dalata of a Rule 9 whitewash transaction
pursuant to the Irish Takeover Rules; or
D. if a third party announces a firm intention to make an offer for Dalata on
less favourable terms or at a lower price than €6.30 per share.
This announcement is made without the prior agreement or approval of Dalata.
Enquiries
Pandox
Liia Nõu + 46 8 506 205 50
Eiendomsspar
Christian Ringnes + 47 22 33 05 50
Goodbody (Financial Advisor to the Consortium) +353 (0) 1 667 0400
Andrew Hackney
Cameron Duncan
Jason Molins
William Hall
Important Notices
About Pandox
Pandox owns, develops, and leases hotel properties to skilled hotel operators
under long-term, turnover-based leases with minimum guaranteed levels. Since
its inception in 1995, it has grown into one of the largest hotel property
owners in Europe. Its portfolio consists of 163 hotel properties with
approximately 36,000 rooms across 11 countries in Northern Europe. The
portfolio's market value per 31 March 2025 was approximately SEK 74bn.
Headquartered in Stockholm, Pandox is listed on Nasdaq Stockholm.
About Eiendomsspar
Eiendomsspar is one of the largest real estate owners in Norway. The hotel
segment has been a central part of Eiendomsspar’s business for more than 20
years. Eiendomsspar owns 11 hotels in Norway, with another two hotels under
construction. Eiendomsspar controls c. 36% of the voting shares of Pandox.
Responsibility Statement
The directors of Pandox accept responsibility for the information contained in
this announcement (other than information that relates to Eiendomsspar). To
the best of the knowledge and belief of the directors of Pandox (who have
taken all reasonable care to ensure that such is the case), the information
contained in this announcement is in accordance with the facts and does not
omit anything likely to affect the import of such information.
The directors of Eiendomsspar accept responsibility for the information
contained in this announcement (other than information that relates to
Pandox). To the best of the knowledge and belief of the directors of
Eiendomsspar (who have taken all reasonable care to ensure that such is the
case), the information contained in this announcement is in accordance with
the facts and does not omit anything likely to affect the import of such
information.
Pre-conditions to the Proposal and terms and conditions of any offer
The making of an announcement of a firm intention to make an offer by the
Consortium under Rule 2.7 of the Irish Takeover Rules remains subject to
satisfaction or waiver of customary pre-conditions, including satisfactory
completion of customary due diligence. These preconditions may be waived in
whole or in part by the Consortium at its sole discretion. There can be no
certainty that an offer will be made, even if the pre-conditions are satisfied
or waived.
Any offer for Dalata under Rule 2.7 of the Irish Takeover Rules would be
subject to terms and conditions that are typical for a transaction of that
nature including, amongst other things, receipt of any necessary regulatory
and competition clearances.
Disclosure Requirements of the Irish Takeover Rules
Under Rule 8.3(a) of the Irish Takeover Rules, any person who is ‘interested’
in 1% or more of any class of ‘relevant securities’ of an offeree company or a
securities exchange offeror (being any offeror other than an offeror which has
announced that its offer is, or is likely to be, solely in cash) must make an
‘opening position disclosure’ following the commencement of the ‘offer period’
and, if later, following the announcement in which any securities exchange
offeror is first identified. An ‘opening position disclosure’ must contain,
among other things, details of the person’s ‘interests’ and ‘short positions’
in any ‘relevant securities’ of each of: (i) the offeree company; and (ii) any
securities exchange offeror(s). An ‘opening position disclosure’ by a person
to whom Rule 8.3(a) applies must be made by no later than 3:30 pm (Irish time)
on the day that is ten ‘business days’ following the commencement of the
‘offer period’ and, if appropriate, by no later than 3:30 pm (Irish time) on
the day that is ten ‘business days’ following the announcement in which any
securities exchange offeror is first identified.
Under Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes,
‘interested’ (directly or indirectly) in 1% or more of any class of ‘relevant
securities’ of the offeree company or any securities exchange offeror (being
any offeror other than an offeror which has announced that its offer is, or is
likely to be, solely in cash), all ‘dealings’ in any ‘relevant securities’ of
the offeree company or any securities exchange offeror (including by means of
an option in respect of, or a derivative referenced to, any such ‘relevant
securities’) must be publicly disclosed by not later than 3:30 pm (Irish time)
on the ‘business day’ following the date of the relevant transaction. This
requirement will continue until the ‘offer period’ ends. If two or more
persons cooperate on the basis of any agreement either express or tacit,
either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of
the offeree company, they will be deemed to be a single person for the purpose
of Rule 8.3 of the Irish Takeover Rules. A disclosure table, giving details of
the companies in whose ‘relevant securities’ ‘dealings’ should be disclosed
can be found on the Irish Takeover Panel’s website at
www.irishtakeoverpanel.ie (http://www.irishtakeoverpanel.ie/).
In general, interests in securities arise when a person has long economic
exposure, whether conditional or absolute, to changes in the price of the
securities. In particular, a person will be treated as having an ‘interest’ by
virtue of the ownership or control of securities, or by virtue of any option
in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Irish Takeover Rules, which can be
found on the Irish Takeover Panel’s website. If you are in any doubt as to
whether or not you are required to disclose a ‘dealing’ under Rule 8, please
consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie
(http://www.irishtakeoverpanel.ie/) or contact the Irish Takeover Panel at
telephone number +353 1 678 9020.
Market Abuse Regulations
The information contained within this announcement would have, prior to its
release, constituted inside information for the purposes of Article 7 of the
Market Abuse Regulation (EU) 596/2014. Upon the publication of this
announcement via a regulatory information service, this inside information
will be considered to be in the public domain. The person responsible for
arranging for the release of this information on behalf of Pandox is Anders
Berg.
Sources of information
Based on the announcement of Total Voting Rights made by Dalata on 1 May 2025,
Dalata’s issued share capital consists of 211,483,988 ordinary shares of
nominal value € 0.01 each, with no ordinary shares held in treasury.
Publication on Website
In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this
announcement will be available on the Pandox’s website at
www.pandox.se/investor-relations/possible-offer-for-dalata-hotel-group by no
later than 12.00 (noon) (Irish time) on the business day following publication
of this announcement. The content of the website referred to in this
announcement is not incorporated into, and does not form part of, this
announcement.
Other notices
Goodbody Stockbrokers UC is authorised and regulated by the Central Bank of
Ireland and in the United Kingdom, Goodbody Stockbrokers UC is authorised and
regulated by the Financial Conduct Authority. Goodbody Stockbrokers UC is
acting exclusively for the Consortium and no one else in connection with this
announcement and shall not be responsible to anyone other than Pandox for
providing the protections afforded to clients of Goodbody Stockbrokers UC, nor
for providing advice in connection with this announcement or any matter
referred to herein. Neither Goodbody Stockbrokers UC nor any of its
subsidiaries, affiliates or branches owes or accepts any duty, liability or
responsibility whatsoever (whether direct, indirect, consequential, whether in
contract, in tort, under statute or otherwise) to any person who is not a
client of Goodbody Stockbrokers UC in connection with this announcement, any
statement contained herein or otherwise.
FÖR MER INFORMATION
Anders Berg, SVP Head of Communications and IR, +46 (0) 760 95 19 40
This information is information that Pandox is obliged to make public pursuant
to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-20 15:49 CEST.
About Pandox
Pandox owns, develops, and leases hotel properties to skilled hotel operators
under long-term, turnover-based leases with minimum guaranteed levels. Since
our inception in 1995, we have grown into one of the largest hotel property
owners in Europe. Our portfolio consists of 163 hotel properties with
approximately 36,000 rooms across 11 countries in Northern Europe. The
portfolio's market value was at 31 March 2025 approximately SEK 74bn. The head
quarter is in Stockholm, and we are listed on Nasdaq Stockholm. www.pandox.se
Attachments
Pandox AB (publ): Acquisition of shares in Dalata Hotel Group plc
(https://storage.mfn.se/3869f4f1-b8b8-455d-84bc-95ae53e1355b/pandox-ab-publ-acquisition-of-shares-in-dalata-hotel-group-plc.pdf)
------------------------------------------------------------------------------
news_id: 09ca4206-84ee-484f-85cc-242b12933aca
group_id: 773492fb-6654-4431-9fce-6d1e7bc8b1de
tags: [:regulatory], [:regulatory:mar], [sub:ca], [sub:ca:ma]
title: Pandox AB (publ): Förvärv av aktier i Dalata Hotel Group plc
------------------------------------------------------------------------------
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS,
DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG,
JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I
NÅGON ANNAN JURISDIKTION DÄR SÅDAN ÅTGÄRD SKULLE KRÄVA, PROSPEKT,
REGISTRERINGS- ELLER ANDRA ÅTGÄRDER UTÖVER VAD SOM FÖLJER AV SVENSK RÄTT, ÄR
FÖRBJUDEN ELLER ANNARS STRIDER MOT TILLÄMPLIGA REGLER I SÅDAN JURISDIKTION.
DETTA ÄR ETT OFFENTLIGGÖRANDE OM ETT POTENTIELLT ERBJUDANDE ENLIGT ARTIKEL 2.4
I DE IRLÄNDSKA TAKEOVER-REGLERNA (ENG. IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022 ("IRLÄNDSKA TAKEOVER-REGLERNA") OCH ÄR INTE ETT
OFFENTLIGGÖRANDE AV EN BINDANDE AVSIKT ATT LÄMNA ETT ERBJUDANDE ENLIGT REGEL
2.7 I DE IRLÄNDSKA TAKEOVER-REGLERNA.
DET KAN INTE GARANTERAS ATT ETT ERBJUDANDE KOMMER ATT LÄMNAS ELLER PÅ VILKA
VILLKOR ETT SÅDANT ERBJUDANDE KAN KOMMA ATT LÄMNAS.
DETTA PRESSMEDDELANDE INNEHÅLLER INSIDERINFORMATION
FÖR OMEDELBART OFFENTLIGGÖRANDE 20 juni 2025
Uttalande angående förvärv av aktier i Dalata Hotel Group plc (“Dalata”)
Ett konsortium bestående av budgivare Pandox AB ("Pandox") och Eiendomsspar AS
("Eiendomsspar" och tillsammans med Pandox, "Konsortiet") som verkar i samråd,
bekräftade den 3 juni 2025 att Konsortiet lämnat ett icke-bindande förslag
till styrelsen i Dalata avseende ett eventuellt kontanterbjudande från
Konsortiet om att förvärva hela det emitterade och kommande emitterade
aktiekapitalet i Dalata, förutom de Dalata-aktier som är i Konsortiets ägo
(”Förslaget”). Förslaget omfattade ett kontanterbjudande om 6,05 EUR per
stamaktie i Dalata och avvisades av styrelsen i Dalata den 3 juni 2025.
Konsortiet meddelar att Pandox Ireland DAC, ett helägt och indirekt ägt
dotterbolag till Pandox idag, över marknaden, har förvärvat 1 698 112
emitterade stamaktier i Dalata motsvarande cirka 0,8 procent av det emitterade
aktiekapitalet i Dalata, till en köpeskilling om 6,30 EUR per aktie.
Som en konsekvens härav kommer varje bindande avsikt att lämna ett erbjudande
om att förvärva Dalata, i enlighet med de irländska Takeover-reglerna, om det
lämnas, att ske till ett pris om minst 6,30 EUR per aktie.
Ett erbjudande om 6,30 EUR per stamaktie i Dalata skulle, om det lämnades,
värdera det emitterade aktiekapitalet i Dalata till cirka 1,3 miljarder EUR
motsvarande en premie om cirka
* 32,4 procent jämfört med Dalatas stängningskurs om 4,76 EUR den 5 mars 2025,
vilket var den sista handelsdagen före Dalatas offentliggörande av
inledandet av en strategisk översyn och en formell försäljningsprocess (den
"Formella Försäljningsprocessen"); och
* 14,9 procent jämfört med den volymviktade genomsnittskursen om cirka 5.48
EUR för Dalata-aktien under tre månader per handelsdagens slut den 19 juni
2025.
Det kan inte garanteras att ett bindande erbjudande kommer att lämnas. Ett
ytterligare offentliggörande kommer att göras när så är lämpligt. Ett
eventuellt erbjudande kommer sannolikt endast att vara kontant, även om
Konsortiet förbehåller sig rätten att ändra formen av vederlag och/eller
införa andra former av vederlag.
I enlighet med regel 2.6 i de Irländska Takeover-reglerna är Konsortiet
skyldigt att senast kl. 17.00 (irländsk tid) den 15 juli 2025 antingen: (i)
offentliggöra en bindande avsikt att lämna ett bud på Dalata i enlighet med
regel 2.7 i de Irländska Takeover-reglerna; eller (ii) meddela att det inte
avser att lämna ett bud på Dalata, varvid meddelandet kommer att betraktas som
ett uttalande enligt artikel 2.8 i de Irländska Takeover-reglerna. Denna
tidsfrist kan endast förlängas med samtycke från den irländska
Takeover-panelen i enlighet med artikel 2.6(c) i de Irländska
Takeover-reglerna.
I enlighet med artikel 2.5 i de Irländska Takeover-reglerna, och som framgår
av Förslaget, förbehåller Konsortiet sig rätten att ändra formen och/eller
sammansättningen av vederlaget i erbjudandet och variera
transaktionsstrukturen. Konsortiet förbehåller sig även rätten att ändra
villkoren i ett eventuellt erbjudande (inklusive att lämna erbjudandet på
mindre förmånliga villkor eller till ett lägre pris än 6,30 EUR per aktie):
A. med rekommendation eller samtycke från Dalatas styrelse;
B. om Dalata offentliggör, utfäster eller betalar utdelning eller annan
värdeöverföring eller värdeåterföring till sina aktieägare efter dagen för
detta offentliggörande, i vilket fall Konsortiet förbehåller sig rätten
att göra en motsvarande justering av ett eventuellt erbjudande;
C. efter Dalatas tillkännagivande av en artikel 9 ”whitewash-transaktion”
(Eng. Rule 9 whitewash transaction) i enlighet med Irländska
Takeover-reglerna; eller
D. om en tredje part tillkännager en fast avsikt om att lämna ett erbjudande
avseende Dalata på mindre förmånliga villkor eller till ett lägre pris än
6,30 EUR per aktie.
Detta pressmeddelande görs utan föregående överenskommelse eller godkännande
från Dalata.
Förfrågningar
Pandox
Liia Nõu +46 8 506 205 50
Eiendomsspar
Christian Ringnes +47 22 33 05 50
Goodbody (finansiell rådgivare till Konsortiet) +353 (0)1 667 0400
Andrew Hackney
Cameron Duncan
Jason Molins
William Hall
Viktiga meddelanden
Om Pandox
Pandox äger, utvecklar och hyr ut hotellfastigheter till skickliga
hotelloperatörer under långsiktiga, omsättningsbaserade hyresavtal med
garanterade miniminivåer. Sedan starten 1995 har bolaget vuxit till en av de
största hotellfastighetsägarna i Europa. Portföljen består av 163
hotellfastigheter med cirka 36 000 rum i 11 länder i norra Europa. Portföljens
marknadsvärde uppgick per 31 mars 2025 till cirka 74 miljarder SEK.
Huvudkontoret ligger i Stockholm och Pandox är noterade på Nasdaq Stockholm.
Om Eiendomsspar
Eiendomsspar är en av de största fastighetsägarna i Norge. Hotellsegmentet har
varit en central del av Eiendomsspar verksamhet i mer än 20 år. Eiendomsspar
äger 11 hotell i Norge, med ytterligare två hotell under uppförande.
Eiendomsspar kontrollerar cirka 36% av de röstberättigade aktierna i Dalata.
Ansvarsutfästelse
Pandox styrelse är ansvarig för informationen i detta pressmeddelande (annat
än information avseende Eiendomsspars). Såvitt Pandox styrelse känner till och
tror (och har vidtagit alla rimliga försiktighetsåtgärder för att säkerställa)
överensstämmer informationen i detta pressmeddelande med de faktiska
förhållandena och utelämnar ingenting som skulle kunna påverka dess innebörd.
Eiendomsspars styrelse är ansvarig för informationen i detta pressmeddelande
(annat än information avseende Pandox). Såvitt Eiendomsspars styrelse känner
till och tror (och har vidtagit alla rimliga försiktighetsåtgärder för att
säkerställa) överensstämmer informationen i detta pressmeddelande med de
faktiska förhållandena och utelämnar ingenting som skulle kunna påverka dess
innebörd.
Förutsättningar för Förslaget och villkor för ett eventuellt erbjudande
Konsortiets offentliggörande av en fast avsikt att lämna ett erbjudande enligt
artikel 2.7 i de Irländska Takeover-reglerna är villkorat av att sedvanliga
förhandsvillkor uppfylls eller frångås, inklusive att sedvanlig due diligence
genomförs på ett tillfredsställande sätt. Dessa förhandsvillkor kan helt eller
delvis frångås av Konsortiet efter egen bedömning. Det kan inte garanteras att
ett erbjudande kommer att lämnas, även om förhandsvillkoren uppfylls eller
frångås.
Ett erbjudande avseende Dalata enligt artikel 2.7 i de Irländska
Takeover-reglerna skulle vara förenat med villkor som är typiska för en
transaktion av detta slag, inklusive bland annat erhållande av nödvändiga
myndighets- och konkurrensgodkännanden.
Upplysningskrav enligt de Irländska Takeover-reglerna
Enligt regel 8.3(a) i de Irländska Takeover-reglerna måste varje person som är
"intresserad" av 1 procent eller mer av varje slag av "relevanta värdepapper"
i ett erbjudandebolag eller en erbjudare av värdepappersutbyte (varmed avses
varje annan budgivare än en budgivare som har meddelat att dess erbjudande är,
eller sannolikt kommer att vara, enbart kontant) göra en
"öppningspositionsredovisning" efter det att "erbjudandeperioden" har inletts
och, om senare, efter det offentliggörande i vilket en erbjudare av
värdepappersutbyte först identifieras. En "öppningspositionsredovisning" måste
bland annat innehålla uppgifter om personens "intressen" och "korta
positioner" i alla "relevanta värdepapper" i var och en av (i)
erbjudandebolaget och (ii) eventuella erbjudare av värdepappersutbyte. En
person för vilken artikel 8.3(a) i de Irländska Takeover-reglerna är
tillämplig måste lämna en "öppningspositionsredovisning" senast kl. 15.30
(irländsk tid) den dag som infaller tio "arbetsdagar" efter det att
"erbjudandeperioden" har inletts och, om så är lämpligt, senast kl. 15.30
(irländsk tid) den dag som infaller tio "arbetsdagar" efter det
tillkännagivande i vilket en eventuell erbjudare av värdepappersutbyte först
identifieras.
Enligt artikel 8.3(b) i de Irländska Takeover-reglerna, om någon person är
eller blir "intresserad" (direkt eller indirekt) av 1 procent eller mer av
någon kategori av "relevanta värdepapper" i ett erbjudandebolag eller en
erbjudare av värdepappersutbyte (varmed avses varje annan budgivare än en
budgivare som har meddelat att dess erbjudande är eller sannolikt kommer att
vara enbart kontant), ska alla "affärer" med "relevanta värdepapper" i ett
erbjudandebolag eller en erbjudare av värdepappersutbyte (inklusive genom en
option avseende eller ett erbjudande om att förvärva "relevanta värdepapper" i
erbjudandebolaget eller någon erbjudare av värdepappersutbyte) offentliggöras
senast kl. 15.30 (irländsk tid) på den "affärsdag" som följer på dagen för den
relevanta transaktionen. Detta krav kommer att gälla till dess att
"erbjudandeperioden" löper ut. Om två eller flera personer samarbetar på
grundval av ett avtal, antingen uttryckligt eller underförstått, muntligt
eller skriftligt, för att förvärva ett "intresse" i "relevanta värdepapper" i
erbjudandebolaget, kommer de att anses vara en enda person i enlighet med
artikel 8.3 i de Irländska Takeover-reglerna. En tabell med uppgifter om de
bolag vars "relevanta värdepapper" och "transaktioner" ska offentliggöras
finns på den irländska Takeover-nämndens webbplats på
www.irishtakeoverpanel.ie (http://www.irishtakeoverpanel.ie/).
I allmänhet uppstår intressen i värdepapper när en person har en lång
ekonomisk exponering, villkorad eller absolut, mot förändringar i
värdepapperens pris. I synnerhet kommer en person att anses ha ett "intresse"
på grund av ägande av eller kontroll över värdepapper, eller på grund av en
option avseende, eller ett derivat som är kopplat till, värdepapper.
Termer inom citationstecken ovan är översatta från definitionerna i de
Irländska Takeover-reglerna, som finns på den irländska Takeover-nämndens
webbplats. Om ni är osäkra på om ni är skyldiga att offentliggöra en
"transaktion" enligt artikel 8, vänligen se på den irländska Takeover-nämndens
webbplats på www.irishtakeoverpanel.ie eller kontakta på den irländska
Takeover-nämndens på telefonnummer +353 1 678 9020.
Marknadsmissbruksregler
Informationen i detta pressmeddelande skulle, innan den offentliggjordes, ha
utgjort insiderinformation i den mening som avses i artikel 7 i EU:s
marknadsmissbruksförordning (EU) nr 596/2014. Vid offentliggörandet av detta
pressmeddelande via en regulatorisk informationstjänst kommer denna
insiderinformation att anses vara allmänt tillgänglig. Ansvarig för att
arrangera offentliggörandet av denna information för Pandox räkning är Anders
Berg.
Källor till information
Baserat på Dalatas tillkännagivande av totala rösträtter den 1 maj 2025 består
Dalatas emitterade aktiekapital av 211 483 988 stamaktier med ett nominellt
värde om 0,01 EUR vardera, utan några stamaktier i eget förvar.
Publicering på webbplats
I enlighet med artikel 26.1 i de Irländska Takeover-reglerna kommer en kopia
av detta pressmeddelande att finnas tillgänglig på Pandox webbplats på
www.pandox.se/investor-relations/possible-offer-for-dalata-hotel-group senast
kl. 12.00 (irländsk tid) den arbetsdag som följer på offentliggörandet av
detta pressmeddelande. Innehållet på den webbplats som hänvisas till i detta
pressmeddelande är inte integrerat i, och utgör inte en del av, detta
pressmeddelande.
Andra meddelanden
Goodbody Stockbrokers UC är auktoriserat och reglerat av den irländska
centralbanken och i Storbritannien är Goodbody Stockbrokers UC auktoriserat
och reglerat av Financial Conduct Authority. Goodbody Stockbrokers UC agerar
exklusivt för Pandox och ingen annan i samband med detta pressmeddelande och
ska inte ansvara gentemot någon annan än Konsortiet för att tillhandahålla det
skydd som erbjuds kunder hos Goodbody Stockbrokers UC, eller för att
tillhandahålla rådgivning i samband med detta pressmeddelande eller något
ärende som avses häri. Varken Goodbody Stockbrokers UC eller något av dess
dotterbolag, närstående bolag eller filialer är skyldiga eller accepterar
någon skyldighet, ansvar eller ansvar överhuvudtaget (oavsett om det är
direkt, indirekt, följd, oavsett om det är i kontrakt, skadestånd, enligt lag
eller på annat sätt) till någon person som inte är kund hos Goodbody
Stockbrokers UC i samband med detta meddelande, något uttalande häri eller på
annat sätt.
FÖR MER INFORMATION
Anders Berg, SVP Head of Communications and IR, +46 (0) 760 95 19 40
Denna information är sådan information som Pandox är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-20 15:49 CEST.
Om Pandox
Pandox äger, utvecklar och hyr ut hotellfastigheter till skickliga
hotelloperatörer under långsiktiga, omsättningsbaserade hyresavtal med
garanterade miniminivåer. Sedan starten 1995 har vi vuxit till en av de
största hotellfastighetsägarna i Europa. Vår portfölj består av 163
hotellfastigheter med cirka 36 000 rum i 11 länder i norra Europa. Portföljens
marknadsvärde uppgick per 31 mars 2025 till cirka 74 miljarder SEK.
Huvudkontoret ligger i Stockholm och vi är noterade på Nasdaq Stockholm.
www.pandox.se.
Bifogade filer
Pandox AB (publ): Förvärv av aktier i Dalata Hotel Group plc
(https://storage.mfn.se/0939db24-9387-49e3-93fc-4fe9c7622702/pandox-ab-publ-forvarv-av-aktier-i-dalata-hotel-group-plc.pdf)
------------------------------------------------------------------------------
news_id: e3768ccf-4094-42f9-8b4b-20a11d5535ef
group_id: 7d795e08-1fb1-4c35-b0e4-73f4e1db163f
tags: [:regulatory], [:regulatory:mar], [:regulatory:nsta], [sub:ci],
[sub:ci:insider]
title: Elopak ASA: Mandatory notification of trade - transfer of shares
------------------------------------------------------------------------------
Primary insider Stephen Naumann has transferred 207,227 shares to his spouse
(a close associate of the primary insider).
See the enclosed forms for further details about the transaction.
For further information, please contact:
Christian Gjerde, Head of Treasury and Investor Relations
E-mail: christian.gjerde@elopak.com
Tel: +47 980 60 909
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication at
2025-06-20 08:31 CEST.
About Elopak
Elopak is a leading global supplier of carton packaging and filling equipment.
The company’s iconic Pure-Pak® cartons are made using renewable, recyclable
and sustainably sourced materials, providing a natural and convenient
alternative to plastic bottles that fits within a low carbon circular economy.
Founded in Norway in 1957, Elopak was listed on the Oslo Stock Exchange in
2021. Today it employs 2,850 people and sells 16 billion cartons annually
across more than 70 countries.
Elopak is a UN Global Compact participant member. We have set Science Based
Targets to reduce emissions in line with the 1.5-degree trajectory and aim to
be Net-Zero by 2050. In 2023, we achieved a gold rating by EcoVadis and were
rated top 2% sustainable companies in the world.
For more information, go to www.elopak.com or follow us @Elopak on LinkedIn.
Attachments
Elopak ASA: Mandatory notification of trade - transfer of shares
(https://storage.mfn.se/7c350b39-f532-4e02-9d26-f6abf54d5f31/elopak-asa-mandatory-notification-of-trade-transfer-of-shares.pdf)
PDMR Trade Reporting Form SN 200625
(https://storage.mfn.se/8624017a-df6f-47f6-991b-c1e411b10531/pdmr-trade-reporting-form-sn-200625.pdf)
PDMR Trade Reporting Form CN 200625
(https://storage.mfn.se/01fe93f0-292d-47ed-80b3-39c353929199/pdmr-trade-reporting-form-cn-200625.pdf)
------------------------------------------------------------------------------
news_id: fd6d94fe-db07-46d3-9d32-f475b345b382
group_id: 3ca53bd0-518a-48e6-b720-7b512d2130ce
tags: [ext:ob], [ext:ob:non-regulatory], [sub:ci], [sub:ci:other]
title: Selvaag Bolig ASA: Selvaag Bolig har kjøpt tomt i Nordre Follo kommune
------------------------------------------------------------------------------
Selvaag Bolig skal utvikle et nytt boligområde i Mellomåsveien 1 i Nordre
Follo kommune. Eiendommen er godkjent regulert for ca. 525 nye boliger,
barnehage og park. Selger er Stor-Oslo Eiendom.
Tomten er på til sammen ca. 58 mål. Volvo Maskin har vært etablert på
eiendommen siden tidlig 1980-tallet, men bygget har stått ledig siden Volvo
flyttet ut i fjor høst.
Administrerende direktør Sverre Molvik sier tomten passer godt for Selvaag
Bolig.
– Vi ser frem til å skape et unikt boligområde med både rekkehus og
leiligheter, barnehage og en stor sentral park. Prosjektet vil blant annet
inneholde Selvaag Pluss som er livsstilsboliger med bemannet resepsjon,
fellesarealer og tjenester, sier Molvik.
Eiendommen har en attraktiv beliggenhet, med kun 20 minutter med buss til Oslo
S og en kort spasertur til Kolbotn jernbanestasjon. I tillegg er tomten nær
store grønne rekreasjonsområder, og det er kun 2 km til Hvervenbukta.
– Salgsstart for de første boligene er planlagt sommeren 2026. Vi ser frem til
å samarbeide med kommunen for å skape et positivt tilskudd til området, sier
Molvik.
Frem til byggestart vil tomten eies av Selvaag Boligs samarbeidsselskap Urban
Property. Selvaag Bolig har nå en tomtebank som kan gi om lag 10 500 boliger i
og rundt Stor-Oslo, Bergen, Stavanger og Stockholm.
Transaksjonen er gjennomført uten bruk av ekstern megler.
Bildetekst: Selvaag Bolig skal transformere Mellomåsveien 1 til et trivelig
område med boliger, barnehage og en stor park. (Illustrasjon: Dark/3D Estate)
Om Selvaag Plussboliger®:
Selvaag Plussboliger er et varemerkebeskyttet livsstilskonsept med bemannet
resepsjon, fellesarealer og tjenester. Målgruppen for Plussboliger er
mennesker i alle aldre og livssituasjoner som ønsker en enklere hverdag med
fellesskap og tjenester. Fellesarealene består blant annet av bemannet lounge
og resepsjon, gjesteleiligheter, treningsrom, festlokale, storkjøkken og
møterom. Selvaag Bolig har bygget over 2 000 Plussboliger siden 2004.
------------------------------------------------------------------------------
Kontaktinformasjon:
Sverre Molvik, CEO
Telefon: +47 40 10 05 85, e-post: smo@selvaagbolig.no
Line Lian Mjell, konserndirektør marked, strategi og bærekraft
Telefon: +47 975 39 225, e-post: limj@selvaagbolig.no
------------------------------------------------------------------------------
Om oss
Selvaag Bolig ASA er et boligutviklingsselskap som styrer hele verdikjeden fra
kjøp av tomt til ferdige bolig- og byområder. Selskapet viderefører Selvaags
75 år lange historie og erfaring og har flere tusen boliger under utvikling i
vekstområder i og rundt de største byene i Norge og Sverige. Selvaag Bolig har
et bredt utvalg boligtyper, og tilbyr blant annet livsstilkonseptet Selvaag
Pluss® som er boliger med fellesarealer og tjenester.
www.selvaagboligasa.no (http://www.selvaagboligasa.no/)
------------------------------------------------------------------------------
Denne meldingen ble distribuert av Line Lian Mjell, konserndirektør marked,
strategi og bærekraft, Selvaag Bolig ASA.
------------------------------------------------------------------------------
Bildevedlegg
Illustrasjon Mellomåsveien
(https://storage.mfn.se/06171bfe-d47a-489d-b3d6-a11c8f531c28/illustrasjon-mellomasveien.jpeg)
Illustrasjon 2 Mellomåsveien
(https://storage.mfn.se/89bdc465-e9d0-4a50-b3ae-ed29d7d821e1/illustrasjon-2-mellomasveien.jpeg)
Oversiktsbilde Mellomåsveien 3DEstate No
(https://storage.mfn.se/c02cb61f-f41f-4568-975b-3f4e9c5ae790/oversiktsbilde-mellomasveien-3destate-no.jpeg)
------------------------------------------------------------------------------
Vedlegg
Selvaag Bolig ASA: Selvaag Bolig har kjøpt tomt i Nordre Follo kommune
(https://storage.mfn.se/be4ae2cf-328c-4e84-9327-afa0235484e8/selvaag-bolig-asa-selvaag-bolig-har-kjopt-tomt-i-nordre-follo-kommune.pdf)
------------------------------------------------------------------------------
news_id: b367404e-b7f4-4b1f-964a-1e7307789c62
group_id: 3c61ab15-542b-49ee-bb84-1364e3e95ec2
tags: [ext:ob], [ext:ob:non-regulatory], [sub:ci], [sub:ci:other]
title: Moreld ASA: Transfer to Euronext Oslo Børs (main board)
------------------------------------------------------------------------------
Stavanger, 20 June 2025: Moreld ASA ("Moreld" or the "Company") is pleased to
announce the successful transfer of the Company's shares to the main board,
Euronext Oslo Børs, with its shares continuing to trade under the ticker
"MORLD".
CEO of Moreld, Geir Austigard, comments "We are very pleased to announce that
we are taking the step up from Euronext Growth Oslo to the main list on
Euronext Oslo Børs, in line with the plan communicated at the time of the
listing on Euronext Growth Oslo in December 2024. Since the listing, Moreld
has delivered strong operational and financial results, in line with our
communicated targets."
The shares in Moreld were admitted to trading on Euronext Growth Oslo in
December 2024, with first day of trading on 19 December 2024, following a
private placement raising approx. NOK 1 billion in gross proceeds. In 2024,
Moreld delivered revenues of NOK 9.1 billion and an adjusted EBITDA of NOK
1,075 million (proforma excl. IFRS 16 and one-offs). Supported by a strong
first quarter, the company increased its EBITDA guidance for 2025 to NOK
0.95-1.2 billion. Following the implementation of a new policy to pay
dividends on a quarterly basis, the company distributed a first dividend of
NOK 0.42 per share in May 2025.
Moreld continues its development in line with the messages conveyed in our
latest quarterly presentation on May 15 this year. In connection with the
uplisting, we have prepared a prospectus and an updated investor presentation,
which includes additional historical and background information. These
materials are available at www.moreld.com/investor/investor-relations. Please
also find enclosed a letter from Moreld’s CEO Geir Austigard to all
shareholders and potential new investors.
For more information, please contact:
CEO Geir Austigard
Telephone: +47 992 47 500
Email: Geir.austigard@moreld.com
CFO Trond Rosnes
Telephone: +47 404 14 494
Email: Trond.rosnes@moreld.com
About Moreld
Moreld is an industrial multi-disciplinary engineering group offering
full-scope services across the offshore energy and marine industries including
subsea installations. The group comprises Moreld Apply, Ocean Installer and
Global Maritime. Moreld is a major player on the Norwegian continental shelf
with an international footprint. The Group is located in 19 countries, giving
access to all major offshore markets, and has over 2,800 employees and
contractors. For more information, please visit https://moreld.com/.
Attachments
Moreld ASA: Transfer to Euronext Oslo Børs (main board)
(https://storage.mfn.se/63fa1251-e457-4d4a-ad2e-db948465d002/moreld-asa-transfer-to-euronext-oslo-bors-main-board.pdf)
Moreld CEO Letter
(https://storage.mfn.se/d208911a-3b18-4a1f-94eb-02d0b6d331df/moreld-ceo-letter.pdf)
------------------------------------------------------------------------------
news_id: f250d4a4-f0e4-40bd-812f-544e4bbfd9c9
group_id: b8fab142-6fa8-4603-9033-b168586b81cc
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: Svensk Linjebesiktning vinner avtal med E.ON värt ca 24 Mkr med option
om ytterligare 24 Mkr
------------------------------------------------------------------------------
Dlaboratory Sweden AB (publ) meddelar att det helägda dotterbolaget Svensk
Linjebesiktning AB (”SLB”) har säkrat avtal om besiktningstjänster för E.ON
till ett estimerat värde om ca 24 MSEK över tre år. Avtalet innehåller även en
option om ytterligare maximalt tre års förlängning och ytterligare ca 24 MSEK
i intäkter.
SLB har deltagit i en större upphandling med E.ON där Bolaget har fått
tilldelning vid fyra besiktningsområden av totalt 13. Sedan tidigare har
Bolaget avtal på ett nätområde var med detta avtal innebär en signifikant
ökning. Avtalet ger ca 8 Mkr i intäkter årligen exklusive tillägg och
extratjänster.
Nytt i denna upphandling är att man brutit ut den del som innefattar
nätstationer och koronabesiktning, där SLB fått 100% tilldelning. Ett kvitto
på att det omfattande utvecklingsarbetet som bedrivits sedan 2019 uppskattas
av E.ON och nu blivit en branschstandard.
”Vi är förstås otroligt glada över tilldelningen som är ett kvitto på att den
verksamhet och de tjänster vi tillhandahåller levererar stort mervärde för
våra kunder. Vi har återigen bevisat att kompetens och erfarenhet spelar roll
då vi nu tillsammans med övriga avtal vi ingått med andra elnätsbolag står för
majoriteten av upphandlad besiktning för svenska elnät. E.ON är självklart en
oerhört viktig part för oss att samarbeta med och vi känner oss komfortabla
över att kunna visa vilket mervärde vi ger”, kommenterar Rickard Jacobson VD,
dLab och Styrelseordförande Svensk Linjebesiktning
Avtalsspärr löper enligt 20 kap. 1§ lagen om upphandling inom
försörjningssektorerna (LUF) till och med 2025-06-30. Kontrakt kommer att
tecknas tidigast 2025-07-01 under förutsättning att inte överprövning sker
under denna period.
Kontakter
Rickard Jacobson, VD dLab
Telefon: +46(0)70-499 99 34
E-post: rickard.jacobson@dlaboratory.com
Hemsida: www.dlaboratory.com
Om oss
Dlaboratory Sweden AB är en cleantech-grupp som erbjuder en intelligent
digital plattform som skapar förutsättningar för energisektorn att bidra till
framtidens hållbara samhälle. Genom intelligent analys av elnätet och
förutsättningar för datadrivna beslut, skapas möjligheter till ett
moderniserat arbetssätt och ett mer motståndskraftigt elnät. dLabs
kommersiella verksamhet startade 2015 och bolaget har sitt säte i Lund.
Bolagets aktie (DLAB) är föremål för handel på Nasdaq First North Growth
Market. Certified Adviser är FNCA Sweden AB.
Denna information är sådan information som Dlaboratory Sweden är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-20 08:00 CEST.
Bifogade bilder
PM_SLB
(https://storage.mfn.se/8ab19b0b-d2c3-43e1-b45b-baa26c8cb29f/pm_slb.jpeg)
Bifogade filer
Svensk Linjebesiktning vinner avtal med E.ON värt ca 24 Mkr med option om
ytterligare 24 Mkr
(https://storage.mfn.se/618734a8-bd95-4179-9b73-b1e6de2d0f9f/svensk-linjebesiktning-vinner-avtal-med-e-on-vart-ca-24-mkr-med-option-om-ytterligare-24-mkr.pdf)
------------------------------------------------------------------------------
news_id: cfd65674-f68e-47ba-938d-058a26829e15
group_id: 78e5fa26-a728-463d-b229-ed5d80b1576b
tags: [ext:ob], [ext:ob:non-regulatory], [sub:ci], [sub:ci:other]
title: Shearwater awarded 4D survey over Equinor’s Tyrihans field in the
Norwegian Sea
------------------------------------------------------------------------------
Bergen, 20 June 2025 – Shearwater Geoservices AS (“Shearwater”) has been
contracted by Equinor to perform a 4D towed streamer seismic survey over the
Tyrihans field in Norway. It is the first project awarded under the 2021
Equinor frame agreement following a recent extension for an additional two
years.
The one-month Norwegian Sea survey commences in early August. Shearwater will
deploy the Amazon Conqueror, using Isometrix technology. The survey follows
previous 4D campaigns for Equinor, most recently at the Mariner and Heidrun
fields in 2024. Applying the same proven technology to capture repeat
high-quality seismic data over the Tyrihans area will help understand changes
to the reservoir over time in the producing field and support future
production strategies to optimise output.
“The award reflects Shearwater’s strong technical capabilities and consistent
operational reliability. Finding good solutions together with our clients is
always a priority for us. In this case, we can provide our client with updated
reservoir data to support long-term production optimisation and value
creation,” said Irene Waage Basili, the CEO of Shearwater.
For further information:
Irene Waage Basili, CEO, Shearwater Geoservices, phone: +47 90 09 86 88
Kristian Rådal, Head of Investor Relations, phone: +47 99 23 61 58
About Shearwater:
Shearwater is a global marine geoscience and technology business that
specialises in collecting data offshore. The organisation uses state-of-the
art seismic vessels and equipment to explore beneath the seabed and processes
the data using market-leading proprietary software. These insights help
clients understand the Earth and make informed decisions about accelerating
responsible use of its resources. Shearwater's headquarters is in Bergen,
Norway, with more facilities all around the globe. The company employs around
1270 people.
------------------------------------------------------------------------------
news_id: bcc50fe2-1c28-42c0-a4fb-9e44136b65c9
group_id: 00d3dda0-3a7f-4b82-b95e-d5615a919305
tags: [:regulatory], [:regulatory:nsta], [ext:ob],
[ext:ob:additional-regulatory-info], [sub:ci], [sub:ci:other]
title: BIOFISH HOLDING AS – Last day of acceptance period for offer by
Langøylaks to acquire all outstanding shares and warrants
------------------------------------------------------------------------------
NOT FOR DISTRIBUTION, RELEASE OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO
AUSTRALIA, CANADA, HONG KONG; NEW ZEALAND, SOUTH AFRICA, JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION, RELEASE OR PUBLICATION WOULD BE
UNLAWFUL OR REQUIRE PRIOR APPROVAL
Ljones, 20 June 2025: Reference is made to the stock exchange announcement
published on 6 June 2025, regarding the launch of a recommended voluntary cash
tender offer by Langøylaks Holding 2 AS ("Langøylaks" or the "Offeror") to
acquire all outstanding shares of Biofish Holding AS (the “Company” or
“BioFish”) at a price of NOK 1.77 per Share and NOK 0.47 per Warrant (the
"Offer"), as further set out in the offer document dated 6 June 2025 (the
"Offer Document"). The board of BioFish has unanimously recommended that all
shareholders accept the Offer.
The acceptance period expires at 16:30 today, 20 June 2025, subject to any
extension one or several times up until 15 August 2025. The complete terms and
conditions for the Offer, including a description of the procedures for
accepting the Offer, are set out in the Offer Document.
Shareholders who want to accept the Offer must, prior to expiry of the
acceptance period and in accordance with the procedures set out in the Offer
Document, duly complete and return the acceptance form which is included in
the Offer Document and which has also been distributed to shareholders as of 6
June 2025 with a known address. The Offer Document is available on the
receiving agent's webpage (subject to regulatory restrictions in certain
jurisdictions): https://www.sb1markets.no/en/transactions/. Shareholders who
own shares registered in the name of brokers, banks, investment companies or
other nominees, must contact such persons to accept the Offer.
The Offer is only capable of being accepted pursuant to the Offer Document.
The complete terms and conditions for the Offer, including a description of
the procedures for accepting the Offer, is set out in the Offer Document.
Advisers:
Pareto Securities AS is acting as financial advisor and Advokatfirmaet Haavind
AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is
acting as legal advisor and SpareBank 1 Markets AS is acting as financial
advisor and receiving agent to the Offeror.
Contacts
Sondre Hagerup Johnsrud, CEO of Biofish Holding AS
Mob: +47 975 79 321 Email: sondre.johnsrud@biofish.no
Johnny Duedahl, CFO of Biofish Holding AS
Mob: +47 982 06 833 Email: johnny@biofish.no
About BioFish
BioFish is a Norwegian independent producer of high-quality smolt and
post-smolt. The Company has a RAS production facility in Ljones close to the
Hardangerfjord on the west coast of Norway. Numerous Norwegian fish farming
sites are located within one day of transport.
***
The Offer and the distribution of this announcement and other information in
connection with the Offer may be restricted by law in certain jurisdictions.
When published, the Offer Document and related acceptance forms will not and
may not be distributed, forwarded or transmitted into or within any
jurisdiction where prohibited by applicable law, including without limitation,
Canada, Australia, New Zealand, South Africa, Hong Kong and Japan. The Offeror
does not assume any responsibility in the event there is a violation by any
person of such restrictions. Persons in the United States should review
"Notice to U.S. Holders" below. Persons into whose possession this
announcement or such other information should come are required to inform
themselves about and to observe any such restrictions.
This announcement is not a tender offer document and, as such, does not
constitute an offer or the solicitation of an offer to acquire the Shares.
Investors may accept the Offer only on the basis of the information provided
in the Offer Document. Offers will not be made directly or indirectly in any
jurisdiction where either an offer or participation therein is prohibited by
applicable law or where any tender offer document or registration or other
requirements would apply in addition to those undertaken in Norway.
Shareholders of the Company must rely upon their own examination of the Offer
Document. Each Shareholder should study the Offer Document carefully in order
to be able to make an informed and balanced assessment of the Offer and the
information that is discussed and described therein. Shareholders should not
construe the contents of this announcement as legal, tax or accounting advice,
or as information necessarily applicable to each shareholder. Each Shareholder
should seek independent advice from its own financial and legal advisors prior
to making a decision to accept the Offer.
No profit forecasts or estimates
No statement in this announcement is intended as a profit forecast or profit
estimate and no statement in this announcement should be interpreted to mean
that earnings or earnings per Share for the current or future financial years
would necessarily match or exceed the historical published earnings or earning
per Share.
Forward-looking statements
This announcement, oral statements made regarding the Offer, and other
information published by the Offeror and/or the Company may contain statements
which are, or may be deemed to be, "forward looking statements". Such forward
looking statements are prospective in nature and are not based on historical
facts, but rather on current expectations and on numerous assumptions
regarding the business strategies and the environment in which the group will
operate in the future and are subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or implied by
those statements. The forward-looking statements contained in this
announcement relate to the group’s future prospects, developments and business
strategies, the expected timing and scope of the Offer and other statements
other than historical facts. In some cases, these forward looking statements
can be identified by the use of forward looking terminology, including the
terms "believes", "estimates", "will look to", "would look to", "plans",
"prepares", "anticipates", "expects", "is expected to", "is subject to",
"budget", "scheduled", "forecasts", "synergy", "strategy", "goal",
"cost-saving", "projects" "intends", "may", "will" or "should" or their
negatives or other variations or comparable terminology. Forward-looking
statements may include statements relating to the following: (i) future
capital expenditures, expenses, revenues, earnings, synergies, economic
performance, indebtedness, financial condition, dividend policy, losses,
contract renewals and future prospects; (ii) business and management
strategies and the expansion and growth of the Company’s operations; and (iii)
the effects of global economic and political conditions and governmental
regulation on the Company’s business. By their nature, forward-looking
statements involve risk and uncertainty because they relate to events and
depend on circumstances that will occur in the future. These events and
circumstances include changes in the global, political, economic, business,
competitive, market and regulatory forces, future exchange and interest rates,
changes in tax rates and future business combinations or disposals. If any one
or more of these risks or uncertainties materialises or if any one or more of
the assumptions prove incorrect, actual results may differ materially from
those expected, estimated or projected. Such forward looking statements should
therefore be construed in the light of such factors. Neither the Company nor
the Offeror nor any member of their respective groups, nor any of their
respective members, associates or directors, officers or advisers, provides
any representation, assurance or guarantee that the occurrence of the events
expressed or implied in any forward-looking statements in this announcement
will actually occur. Given these risks and uncertainties, potential investors
should not place any reliance on forward looking statements.
The forward-looking statements speak only at the date of this document. All
subsequent oral or written forward-looking statements attributable to any
member of the Company group, the Offeror or any member of their respective
group, or any of their respective members, associates, directors, officers,
employees or advisers, are expressly qualified in their entirety by the
cautionary statement above.
The Company, the Offeror and each member of their respective groups expressly
disclaim any obligation to update such statements other than as required by
law or by the rules of any competent regulatory authority, whether as a result
of new information, future events or otherwise.
Notice to U.S. Holders
U.S. Holders (as defined below) are advised that the Shares are not listed on
a U.S. securities exchange and that the Company is not subject to the periodic
reporting requirements of the U.S. Securities Exchange Act of 1934, as amended
(the "U.S. Exchange Act"), and is not required to, and does not, file any
reports with the U.S. Securities and Exchange Commission (the "SEC")
thereunder. The Offer will be made to holders of Shares resident in the United
States ("U.S. Holders") on the same terms and conditions as those made to all
other holders of Shares of the Company to whom an offer is made. Any
information documents, including the Offer Document, will be disseminated to
U.S. Holders on a basis comparable to the method that such documents are
provided to the Company's other Shareholders to whom an offer is made. The
Offer will be made by the Offeror and no one else.
The Offer is made to U.S. Holders under the U.S. Exchange Act as a "Tier I"
tender offer, and otherwise in accordance with the requirements of Norwegian
law. Accordingly, the Offer is subject to disclosure and other procedural
requirements timetable, settlement procedures and timing of payments, that are
different from those that would be applicable under U.S. domestic tender offer
procedures and law.
Pursuant to an exemption from Rule 14e-5 under the U.S. Exchange Act, the
Offeror and its affiliates or brokers (acting as agents for the Offeror or its
affiliates, as applicable) may from time to time, and other than pursuant to
the Offer, directly or indirectly, purchase or arrange to purchase, Shares or
any securities that are convertible into, exchangeable for or exercisable for
such Shares outside the United States during the period in which the Offer
remains open for acceptance, so long as those acquisitions or arrangements
comply with applicable Norwegian law and practice and the provisions of such
exemption. To the extent information about such purchases or arrangements to
purchase is made public in Norway, such information will be disclosed by means
of an English language press release via an electronically operated
information distribution system in the United States or other means reasonably
calculated to inform U.S. Holders of such information. In addition, the
financial advisors to the Offeror may also engage in ordinary course trading
activities in securities of the Company, which may include purchases or
arrangements to purchase such securities.
Neither the SEC nor any securities supervisory authority of any state or other
jurisdiction in the United States has approved or disapproved the Offer or
reviewed it for its fairness, nor have the contents of the Offer Document or
any other documentation relating to the Offer been reviewed for accuracy,
completeness or fairness by the SEC or any securities supervisory authority in
the United States. Any representation to the contrary is a criminal offence in
the United States.
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2025-06-20 07:30 CEST.
Attachments
BIOFISH HOLDING AS – Last day of acceptance period for offer by Langøylaks to
acquire all outstanding shares and warrants
(https://storage.mfn.se/d969c522-b789-452e-8d73-a6a82de5c64a/biofish-holding-as-last-day-of-acceptance-period-for-offer-by-langoylaks-to-acquire-all-outstanding-shares-and-warrants.pdf)
------------------------------------------------------------------------------
news_id: 2081ab11-45cb-4da6-901f-3e68fcd77a62
group_id: 62158660-bbe7-456c-bac8-5edcdbb8c771
tags: [:regulatory], [:regulatory:nsta], [sub:ca], [sub:ca:exdate]
title: MPCC: Ex-dividend USD 0.08 today (Q1 2025)
------------------------------------------------------------------------------
From today, 20 June 2025, the shares of MPC Container Ships ASA (OSE: MPCC)
will be traded ex-dividend USD 0.08 (NOK 0.8031).
For more information, contact:
ir@mpc-container.com
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2025-06-20 07:00 CEST.
------------------------------------------------------------------------------
news_id: ae4a7f48-2691-44dd-9042-509feb440e0d
group_id: 1052f91f-f0d7-49c3-a55e-66264238cd76
tags: [:regulatory], [:regulatory:nsta], [sub:report], [sub:report:annual]
title: Dolphin Drilling AS - Integrated Annual Report 2024
------------------------------------------------------------------------------
(Oslo, 19 June 2025) Dolphin Drilling AS (Dolphin Drilling, OSE: DDRIL), has
today published the company's integrated Annual Report for 2024. The report is
attached to this press release and available on
www.dolphindrilling.com/Investor Relations.
For further information, please contact:
Ingolf Gillesdal, CFO, tel: +47 920 45 320
Dolphin Drilling | www.dolphindrilling.com
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2025-06-19 23:18 CEST.
Attachments
Dolphin Drilling Integrated Annual Report 2024
(https://storage.mfn.se/e17f5aed-a917-4e67-b6c8-88e8edfa9724/dolphin-drilling-integrated-annual-report-2024.pdf)
------------------------------------------------------------------------------
news_id: 526b2ee2-af29-4b7b-926c-6c0baf48e5b2
group_id: d3b60a3e-2a72-4d5a-8efe-c1e0015a174c
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: K33 announces successful share issue
------------------------------------------------------------------------------
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG
KONG, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR
ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD
BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH
APPLICABLE LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS
RELEASE.
Reference is made to the press release published by K33 AB (publ) (“K33” or
the “Company”) on 18 June 2025 regarding a contemplated directed share issue
(the “Directed Share Issue”) of new shares in the Company (the “Offer
Shares”). The Company is pleased to announce that the Directed Share Issue has
been successfully placed, through an allocation of 1,211,049,948 new shares in
the Company at a subscription price per share of SEK 0.1036 (the “Offer
Price”), corresponding to gross proceeds of approximately SEK 125 million. The
Directed Share Issue has been managed by Pareto Securities as sole manager and
bookrunner (the “Manager”). The net proceeds from the Directed Share Issue
will be used to buy Bitcoin (“BTC”) to hold on the balance sheet. This will,
in addition to the direct exposure to BTC, unlock real operational leverage
for the Company as a broker. It will improve the Company’s margins, enable new
product offerings, and strengthen the Company’s ability to win larger
institutional partners, fueling scalable growth without putting the BTC at
risk.
Background and reasons
K33 is a leading digital asset brokerage and research firm. As announced by
the Company in a press release on 28 May 2025, the Company has initiated an
additional area of activity in the form of a BTC accumulation strategy, aimed
at strengthening its financial position and unlocking new product and
partnership opportunities.
Through the Directed Share Issue, K33 is provided swift access to capital,
enabling the Company to deliver on its BTC accumulation strategy and pursue
favorable investment opportunities, while reinforcing the Company’s strategic
position through the involvement of strategically important investors. The net
proceeds to the Company from the Directed Share Issue will be used to
strengthen the Company’s balance sheet by acquiring BTC which will unlock real
operational leverage for the Company as a broker. It will improve the
Company’s margins, enable new product offerings, and strengthen the Company’s
ability to win larger institutional partners, fueling scalable growth without
putting the BTC at risk.
| “This raise strongly validates our strategy and marks another key milestone
| for K33 as a Bitcoin Treasury company. In just three weeks, we’ve
| successfully closed two separate funding rounds, SEK 60 million as
| previously announced on 28 May 2025, as well as SEK 125 million in this
| Directed Share Issue, securing a total of SEK 185 million to buy Bitcoin. We
| are on track toward our target of rapidly acquiring 1,000 BTC and are moving
| forward with full speed”, comments Torbjørn Bull Jenssen, CEO of the
| Company.
For more information about the Company’s new BTC accumulation strategy, please
refer to the press release published on 28 May 2025.
The Directed Share Issue
The Offer Price is equal to the closing price of the Company’s share on Nasdaq
First North Growth Market on 17 June 2025, the day preceding the announcement
of the Directed Share Issue. The Offer Price has been determined by the
Company’s Board of Directors (the “Board”) in discussions with the Manager
following a pre-sounding of the Directed Share Issue.
Certain existing shareholders as well as new investors had during the
pre-sounding phase of the Directed Share Issue pre-committed to subscribe for
SEK 85 million at the Offer Price.
The following primary insiders have been allocated Offer Shares in the
Directed Share Issue at the Offer Price:
* Muunilinst AS, the Company’s CEO, Torbjørn Bull Jenssen, has subscribed for
and has been allocated EUR 100,000 which equals 10,566,957 Offer Shares.
Allocations to the Company’s management and employees as well as members of
the Board (together with their respective close associates) may have to be
settled in a separate process.
The reason why certain existing shareholders have been allocated Offer Shares
is that the shareholders in question have expressed and shown interest in
long-term ownership in the Company, which the Board believes creates security,
stability and favorable conditions for the Company's growth and is thus
considered to be beneficial to both the Company and all shareholders.
Allocation
The Board has today, in consultation with the Manager, resolved to
conditionally allocate the Offer Shares, subject to the fulfilment of the
Conditions below.
Notification of conditional allocation and payment instruction is expected to
be sent by the Manager on or about 23 June 2025 before 09:00 CEST.
Voting undertaking
By applying for Offer Shares in the Directed Share Issue, applicants allocated
Offer Shares in the Directed Share Issue have irrevocably undertaken to vote
in favour of, or give a voting proxy to be used in favour of, item 9 in the
notice of the Extraordinary General Meeting on 3 July 2025 (the “EGM”). Such
undertaking applies to all shares in the Company held or controlled as of the
record date for the EGM.
Settlement
The payment and delivery date for the Directed Share Issue is expected to be
on or about 9 July 2025, subject to fulfilment of the Conditions. Delivery of
the Offer Shares is expected to be made on a delivery-versus-payment (“DVP”)
basis facilitated by a pre-payment agreement (the “Pre-Payment Agreement”)
between the Company and the Manager. The Offer Shares are thus expected to be
tradable on Nasdaq First North Growth Market on or about 7 July 2025, subject
to the fulfilment of the Conditions. In relation to the allocation to
management in the Company, the payment and delivery date for the Directed
Share Issue may be delayed.
Conditions for completion
Completion of the Directed Share Issue is still subject to (i) the EGM
resolving to approve item 9 in the EGM notice regarding the authorization for
the Board to issue financial instruments in the Company (the “Authorization”)
and the Company getting the Authorization registered with relevant Swedish
authorities, (ii) the Board resolving to increase the share capital of the
Company and issue the Offer Shares pursuant to the Authorization, and (iii)
the Pre-Payment Agreement remaining in full force and effect (jointly referred
to as the “Conditions”).
The Company reserves the right to cancel, and/or modify the terms of, the
Directed Share Issue at any time and for any reason prior to the notification
of conditional allocation. Neither the Company nor the Manager will be liable
for any losses incurred by applicants if the Directed Share Issue is cancelled
and/or modified, irrespective of the reason for such cancellation or
modification.
Deviation from the shareholders’ preferential rights
Prior to the Directed Share Issue, the Board has carefully considered the
possibility of and explored the interest in raising capital through other
means, including through a rights issue, but concluded that the Directed Share
Issue, including the deviation from existing shareholders’ preferential
rights, serves the best interests of the Company and its shareholders as (i) a
rights issue would take longer time to implement which, especially under
current markets conditions, would entail an exposure to potential market
volatility; (ii) the Directed Share Issue can be carried out at a
significantly lower cost and complexity than a rights issue; (iii) the speed
of the process enables the Company to deliver on its BTC accumulation strategy
and pursue favorable investment opportunities, while at the same time
maintaining a flexible and balanced capital structure; and (iv) the Directed
Share Issue diversifies and strengthens the Company's shareholder base with
strategically important investors, thereby broadening the base of financially
strong shareholders and strengthening the liquidity of the Company's share.
Furthermore, based on the current market climate, a rights issue would likely
have required significant underwriting commitments from an underwriting
syndicate, which would have entailed additional costs and/or further dilution
depending on the type of consideration paid for such underwriting. A rights
issue would likely also have needed to be realized at a lower subscription
price given the discount levels of rights issues recently realized in the
market.
With the above considered, the Board has made the assessment that the reasons
to carry out the Directed Share Issue outweigh the reasons that justify the
main rule of issuing shares with preferential rights for existing shareholders
and that the Directed Share Issue is the most favorable alternative for the
Company to carry out the capital raising.
The Company has conducted an investor pre-sounding process with investors to
obtain the best possible terms for the Directed Share Issue. The Offer Price
was determined by the Board in discussions with the Manager following a
pre-sounding of the Directed Share Issue with certain investors who made
pre-commitments in the Directed Share Issue and negotiations at arms-length,
taking into account the Company's financing needs and the alternative cost of
other financing. The Offer Price in the Directed Share Issue is equal to the
closing price of the Company’s share on Nasdaq First North Growth Market on 17
June 2025, the day preceding the announcement of the Directed Share Issue. It
is the Board's judgement, based on the above factors, that the Offer Price
reflects current market conditions and current demand. Against this
background, the Board considers the Offer Price to be on market terms.
Share capital, shares and dilution
As a result of the Directed Share Issue, the number of shares in the Company
will increase by 1,211,049,948 shares, from 12,206,639,239 shares to
13,417,689,187 shares, and the Company’s share capital will increase by SEK
4,418,786.830652, from SEK 44,538,655.738259 to SEK 48,957,442.568911,
corresponding to a dilution of the number of shares and votes in the Company
of up to approximately 9.03 percent, based on the current share capital and
number of shares in the Company.
Advisors
Pareto Securities has been appointed Manager in connection with the Directed
Share Issue. Törngren Magnell & Partners is acting as legal adviser to the
Company and Advokatfirman Schjødt is acting as legal adviser to the Manager in
connection with the Directed Share Issue.
For further information, please contact:
Torbjørn Bull Jenssen, CEO, K33 AB (publ)
E-mail: ir@k33.com
Web: k33.com/ir
About K33
K33 AB (publ), listed on Nasdaq First North Growth Market, is the new gold
standard for investments in digital assets. K33 offers market-leading
execution, actionable insights, and superior support to private and
institutional partners across EMEA. Mangold Fondkommission serves as the
Certified Adviser for K33 AB (publ).
Important information
The release, announcement or distribution of this press release may, in
certain jurisdictions, be subject to restrictions according to law and
recipients of this press release in jurisdictions where this press release has
been published or distributed should inform themselves of and follow such
legal restrictions. The recipient of this press release is responsible for
using this press release, and the information contained herein, in accordance
with applicable rules in each jurisdiction. This press release does not
constitute an offer to sell, or a solicitation of any offer, to acquire or
subscribe for any securities in the Company in any jurisdiction, where such
offer would be considered illegal or require registration or other measures.
This press release does not constitute or form part of an offer or
solicitation to purchase or subscribe for securities in the United States. The
securities referred to herein may not be sold in the United States absent
registration or an exemption from registration under the US Securities Act of
1933, as amended (the “Securities Act”), and may not be offered or sold within
the United States absent registration or an applicable exemption from, or in a
transaction not subject to, the registration requirements of the Securities
Act. There is no intention to register any securities referred to herein in
the United States or to make a public offering of the securities in the United
States. The information in this press release may not be announced, published,
copied, reproduced or distributed, directly or indirectly, in whole or in
part, within or into the United States, Australia, Belarus, Canada, Hong Kong,
Japan, New Zealand, Russia, South Africa, South Korea, Switzerland or in any
other jurisdiction where such announcement, publication or distribution of the
information would not comply with applicable laws and regulations or where
such actions are subject to legal restrictions or would require registration
or other measures than what is required under Swedish law. Actions taken in
violation of this instruction may constitute a crime against applicable
securities laws and regulations.
This press release is not a prospectus as set forth in Regulation (EU)
2017/1129 (the “Prospectus Regulation”) and has not been approved by any
regulatory authority in any jurisdiction. The Company has not approved any
securities offering to the public in any member state of the EES and no
prospectus has been published or will be published in connection with the
Directed Share Issue. In each member state of the EES, this message is only
directed towards “qualified investors” in that member state in accordance with
the definition in the Prospectus Regulation.
In the United Kingdom, this document and any other materials in relation to
the securities described herein is only being distributed to, and is only
directed at, and any investment or investment activity to which this document
relates is available only to, and will be engaged in only with, “qualified
investors” (according to the definition in article 86(7) of the British
Financial Services and Markets Act 2000) who are (i) persons having
professional experience in matters relating to investments who fall within the
definition of “investment professionals” in Article 19(5) of the British
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”); or (ii) high net worth entities falling within Article 49(2)(a)-(d)
of the Order (all such persons together being referred to as “relevant
persons”). In the United Kingdom, any investment or investment activity to
which this communication relates is available only to, and will be engaged in
only with, relevant persons. Persons who are not relevant persons should not
take any action on the basis of this press release and should not act or rely
on it.
This press release does not identify, or purport to identify, the risks
(direct or indirect) that may be associated with an investment in the
Company’s shares. Any investment decision to acquire or subscribe for new
shares in the Directed Share Issue must be made on the basis of all publicly
available information relating to the Company and the Company’s shares. Such
information has not been verified by the Manager. The Manager acts for the
Company in connection with the Directed Share Issue and no one else. The
Manager will not be responsible to anyone other than the Company for providing
the protections afforded to its clients nor for giving advice in relation to
the Directed Share Issue or any other matter referred to herein.
This press release does not constitute a recommendation for any investors'
decisions regarding the Directed Share Issue. Each investor or potential
investor should conduct an examination on their own, analysis and evaluation
of the business and information described in this press release and any
publicly available information. The price and value of the securities can
decrease as well as increase. Achieved results do not provide guidance for
future results. Neither the contents of the Company's website nor any other
website accessible through hyperlinks on the Company's website are
incorporated into or form part of this press release.
Failure to follow these instructions may result in a breach of the Securities
Act or applicable laws in other jurisdictions.
Forward-looking statements
This press release contains forward-looking statements that reflect the
Company’s intentions, assessments, or expectations about the Company’s future
results, financial position, liquidity, performance, prospects, anticipated
growth, strategies and opportunities and the markets in which the Company
operates. Forward-looking statements are statements that do not relate to
historical facts and may be identified by the inclusion of words such as
“believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”,
“will”, “should”, “could”, “aim” or “might”, or, in each case, their negative,
or similar expressions. The forward-looking statements in this press release
are based upon various assumptions, many of which are based, in turn, upon
further assumptions. Although the Company believes that the assumptions
reflected in these forward-looking statements are reasonable, it cannot be
guaranteed that they will materialize or prove to be correct. Because these
assumptions are based on assumptions or estimates and are subject to risks and
uncertainties, the actual results or outcome could differ materially from
those set out in the forward-looking statements as a result of many factors.
Such risks, uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations expressed or
implied in this release by such forward-looking statements. The Company does
not guarantee that the assumptions underlying the forward-looking statements
in this press release are free from errors and readers of this press release
should not place undue reliance on the forward-looking statements in this
press release. The information, opinions and forward-looking statements that
are expressly or implicitly contained herein speak only as of the date of this
press release and are subject to change. Neither the Company nor anyone else
undertake to review, update, confirm or to release publicly any revisions to
any forward-looking statements to reflect events that occur or circumstances
that arise in relation to the content of this press release, unless this is
required under law or the Nasdaq First North Growth Market Rulebook for
Issuers of Shares.
Information to distributors
In order to comply with the product governance requirements contained in: (a)
Directive 2014/65/EU of the European Parliament and of the Council on markets
in financial instruments, as consolidated, ("MiFID II"); (b) Articles 9 and 10
of Commission Delegated Directive (EU) 2017/593, which complements MiFID II;
and (c) national implementing measures (together, the "MiFID II Product
Governance Requirements") and to disclaim any extra-contractual,
intra-contractual or other liability to which any "manufacturer" (within the
meaning of the MiFID II Product Governance Requirements) may otherwise be
subject, the shares of K33 have been subject to a product approval process,
which has determined that these shares are: (i) suitable for a target market
consisting of retail investors and investors meeting the criteria of
professional clients and eligible counterparties, as defined in MiFID II (the
"Positive Target Market"); and (ii) suitable for distribution through all
distribution channels permitted under MiFID II. Distributors should note that:
the price of the K33 shares may fall and investors may lose all or part of
their investment; the K33 shares are not subject to any guarantee of return or
capital protection; and an investment in the K33 shares is only suitable for
investors who are not in need of a guaranteed return or capital protection and
who (alone or with the assistance of an appropriate financial or other
adviser) are capable of evaluating the merits and risks of such investment and
have sufficient resources to bear the losses that may result from such
investment. Conversely, an investment in the shares of K33 is not suitable for
investors who need full capital protection or full repayment of the amount
invested, cannot bear any risk or who require a guaranteed or predictable
return (the "Negative Target Market", and together with the Positive Target
Market, the "Target Market"). The Target Market assessment is without
prejudice to any other requirements regarding contractual, legal or regulatory
sales restrictions in relation to the Directed Share Issue. Furthermore, it
should be noted that notwithstanding the Target Market assessment, the Manager
will only provide investors who meet the criteria of professional clients and
eligible counterparties.
For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest
in, or purchase, or take any other action whatsoever with respect to the
shares in K33.
Each distributor is responsible for undertaking its own target market
assessment in respect of the shares in K33 and determining appropriate
distribution channels.
This information is information that K33 AB (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-19 21:54 CEST.
Attachments
K33 announces successful share issue
(https://storage.mfn.se/2f9cce37-a01f-484e-a644-7697dffd5511/k33-announces-successful-share-issue.pdf)
------------------------------------------------------------------------------
news_id: bb27cea9-1f4c-46ba-897d-f7fa29ca0ec3
group_id: 963433ff-04a3-4c3a-a057-e22ae0e1f8ad
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Prostatype Genomics AB announces last day of trading in BTU and first
day of trading in warrants of series TO5
------------------------------------------------------------------------------
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG,
SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER
JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS
RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES
BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT
THE END OF THIS PRESS RELEASE.
Prostatype Genomics AB’s (“Prostatype Genomics” or the “Company”) rights issue
of units, with a subscription period ending on 4 June 2025, has now been
registered at the Swedish Companies Registration Office. The Company hereby
announces that the last day of trading in BTU (paid subscribed unit) is 25
June 2025, and the cut-off date is 27 June 2025. The first day of trading in
warrants of series TO5 is 2 July 2025.
In May/June 2025, Prostatype Genomics carried out a rights issue of units
which provided the Company with approximately SEK 27.3 million before
transaction related costs. The rights issue has now been registered at the
Swedish Companies Registration Office. The last day of trading in BTU is 25
June 2025 and the cut-off date is 27 June 2025. Shares and warrants of series
TO5 are expected to be distributed to VP accounts/depots on 1 July 2025.
The total number of shares in the Company now amounts to 34,176,065 and the
share capital amounts to SEK 3,417,606.50. There are also 20,505,639 warrants
of series TO5. When the previously announced directed issue to underwriters
also has been registered at the Swedish Companies Registration Office, the
total number of shares in the Company will amount to 37,000,265, the share
capital will amount to SEK 3,700,026.50 and there will be a total of
22,623,789 outstanding warrants of series TO5.
Terms for warrants of series TO5
One (1) warrant of series TO5 gives the holder the right to subscribe for one
(1) new share in Prostatype Genomics during the period that runs from and
including 3 September 2025, to and including 17 September 2025. The exercise
price for the warrants of series TO5 will be set within an interval between
SEK 0.10 and SEK 1.50 and will be set with a 30 percent discount of the 20-day
volume weighted average price prior to the second day before the exercise
period. The Company may receive a maximum of approximately SEK 33.9 million
from the exercise of warrants of series TO5, before deduction of transaction
related costs.
The warrants will be admitted to trading on Nasdaq First North Growth Market
with the first day of trading being 2 July 2025. The last day of trading in
TO5 is expected to be 15 September 2025.
Advisors
Navia Corporate Finance AB and Gemstone Capital ApS are financial advisors in
connection with the transaction. Advokatfirman Lindahl is the legal advisor.
Nordic Issuing AB is the issuing agent.
For more information about the transaction, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com
or
Gemstone Capital ApS
E-mail: info@gemstonecapital.com
Website: www.gemstonecapital.com
For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com
Certified Adviser
DNB Carnegie Investment Bank AB
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
About Prostatype Genomics
Prostatype® is a genomic test that is available to patients and treating
urologists as a complementary decision basis for the question of treatment or
no-treatment of prostate cancer. The test was developed by a leading research
group at Karolinska Institute and is provided by Prostatype Genomics AB. The
Company’s Certified Adviser is DNB Carnegie.
Important information
The information in this press release neither contains nor constitutes an
offer to acquire, subscribe or otherwise trade in shares, warrants or other
securities in Prostatype Genomics. No action has been taken, and no action
will be taken to permit an offer to the public in any jurisdictions other than
Sweden. The invitation to interested persons to subscribe for shares in
Prostatype Genomics takes place solely through the prospectus that Prostatype
Genomics has published.
The information contained in this press release may not be disclosed,
published or distributed, directly or indirectly, within or to the United
States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand,
Switzerland, Singapore, South Africa or any other jurisdiction where such
action would be illegal, subject to legal restrictions or require measures
other than those that follow from Swedish law. Actions contrary to this
instruction may constitute a violation of applicable securities legislation.
No shares or other securities of Prostatype Genomics have been registered, and
no shares or other securities will be registered, under the United States
Securities Act of 1933 from time to time ("Securities Act") or the securities
laws of any state or other jurisdiction of the United States and may not be
offered, sold or otherwise transferred, directly or indirectly, in or to the
United States, except pursuant to an applicable exemption from, or in a
transaction not subject to, the registration requirements of the Securities
Act and pursuant to the securities laws of the relevant state or other
jurisdiction in the United States. This communication is distributed to and
directed solely to persons in the United Kingdom who are (i) professional
investors falling within the scope of Article 19(5) of the U.K. from time to
time in force; Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 ("the Order") or (ii) high net worth subjects and other persons to
whom this notice may lawfully be addressed, who are subject to Article
49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as
"Relevant Persons"). Persons who are not Relevant Persons may not act on or
rely on the information in this communication. An investment or investment
measure referred to in this communication is only possible for Relevant
Persons and will only be completed with Relevant Persons. Persons who
disseminate this communication must themselves ensure that such dissemination
is permitted.
Forward-looking Statements
This press release contains forward-looking statements that refer to the
Company's intentions, assessments or expectations regarding the Company's
future results, financial position, liquidity, development, prospects,
expected growth, strategies and opportunities as well as the markets in which
the Company operates. Forward-looking statements are statements that do not
relate to historical facts and can be identified by the inclusion of
expressions such as "believes", "expects", "anticipates", "intends",
"estimates", "will", "may", "assumes", “should" "could" and, in each case,
negations thereof, or similar expressions. The forward-looking statements in
this press release are based on various assumptions, which in several cases
are based on additional assumptions. Although the Company believes that the
assumptions reflected in these forward-looking statements are reasonable,
there can be no assurance that they will occur or that they are accurate. As
these
assumptions are based on assumptions or estimates and are subject to risks and
uncertainties, the actual result or outcome may, for many different reasons,
differ materially from what appears in the forward-looking statements.
Such risks, uncertainties, contingencies and other material factors may cause
actual events to differ materially from the expectations expressed or implied
in this press release through the forward-looking statements. The Company does
not warrant that the assumptions underlying the forward-looking statements in
this press release are correct and any reader of the press release should not
place undue reliance on the forward-looking statements in this press release.
The information, opinions and forward-looking statements expressed or implied
herein are provided only as of the date of this press release and are subject
to change. Neither the Company nor anyone else undertakes to revise, update,
confirm or publicly announce any revision of any forward-looking statement to
reflect events occurring or circumstances occurring with respect to the
contents of this press release, except as required by law or Nasdaq First
North Growth Markets' regulations for issuers.
Attachments
Prostatype Genomics AB announces last day of trading in BTU and first day of
trading in warrants of series TO5
(https://storage.mfn.se/07d4558e-e890-4058-ac6f-bba1681e7caa/prostatype-genomics-ab-announces-last-day-of-trading-in-btu-and-first-day-of-trading-in-warrants-of-series-to5.pdf)
------------------------------------------------------------------------------
news_id: 889369cd-84a8-4d6a-8302-941234d33a57
group_id: 963433ff-04a3-4c3a-a057-e22ae0e1f8ad
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Prostatype Genomics AB meddelar sista dag för handel med BTU och första
dag för handel med teckningsoptioner av serie TO5
------------------------------------------------------------------------------
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER
INDIREKT, I USA, AUSTRALIEN, JAPAN, KANADA, NYA ZEELAND, SYDAFRIKA, HONGKONG,
SCHWEIZ, SINGAPORE, SYDKOREA, RYSSLAND, VITRYSSLAND ELLER I NÅGON ANNAN
JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA
PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER
ANDRA ÅTGÄRDER ÄN DE SOM FÖLJER AV SVENSK RÄTT. VÄNLIGEN SE ”VIKTIG
INFORMATION” I SLUTET AV DETTA PRESSMEDDELANDE.
Prostatype Genomics AB (”Prostatype Genomics” eller ”Bolaget”)
företrädesemission av units, vars teckningstid avslutades den 4 juni 2025, har
nu registrerats på Bolagsverket. Bolaget meddelar härmed att sista dag för
handel med BTU (Betald Tecknad Unit) är den 25 juni 2025 och stoppdag är den
27 juni 2025. Första dag för handel med teckningsoptioner av serie TO5 är den
2 juli 2025.
I maj/juni 2025 genomförde Prostatype Genomics en företrädesemission av units,
vilken tillförde Bolaget cirka 27,3 MSEK före transaktionsrelaterade
kostnader. Företrädesemissionen har nu registrerats på Bolagsverket. Sista dag
för handel med BTU är den 25 juni 2025 och stoppdag är den 27 juni 2025.
Aktier och teckningsoptioner förväntas att distribueras till respektive
konto/depå den 1 juli 2025.
Det totala antalet aktier i Bolaget uppgår nu till 34 176 065 och
aktiekapitalet uppgår till 3 417 606,50 SEK. Därutöver finns 20 505 639
teckningsoptioner av serie TO5. När även den sedan tidigare aviserade riktade
emissionen till garanter har registrerats hos Bolagsverket kommer det totala
antalet aktier i Bolaget att uppgå till 37 000 265, aktiekapitalet kommer att
uppgå till 3 700 026,50 SEK och det kommer att finnas totalt 22 623 789
utestående teckningsoptioner av serie TO5.
Villkor för teckningsoptioner av serie TO5
En (1) teckningsoption av serie TO5 ger innehavaren rätt att teckna en (1) ny
aktie i Prostatype Genomics under perioden som löper från och med den 3
september 2025 till och med den 17 september 2025. Lösenpriset för
teckningsoptionerna av serie TO5 kommer att fastställas inom ett intervall
mellan 0,10 SEK och 1,50 SEK och kommer att fastställas med en rabatt om 30
procent på den volymvägda genomsnittskursen under 20 dagar före den andra
dagen före lösenperioden. Bolaget kan komma att tillföras högst cirka 33,9
MSEK vid nyttjande av teckningsoptioner av serie TO5, före avdrag för
transaktionsrelaterade kostnader.
Teckningsoptionerna kommer att tas upp till handel på Nasdaq First North
Growth Market med första handelsdag den 2 juli 2025. Sista dag för handel med
TO5 förväntas vara den 15 september 2025.
Rådgivare
Navia Corporate Finance AB och Gemstone Capital ApS är finansiella rådgivare i
samband med transaktionen. Advokatfirman Lindahl är legal rådgivare. Nordic
Issuing AB är emissionsinstitut.
För mer information om transaktionen, vänligen kontakta:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Hemsida: www.naviacorporatefinance.com
eller
Gemstone Capital ApS
E-mail: info@gemstonecapital.com
Hemsida: www.gemstonecapital.com
För mer information om Bolaget, vänligen kontakta:
Fredrik Rickman, VD Prostatype Genomics AB
Telefon: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com
Certified Adviser
DNB Carnegie Investment Bank AB
Telefon: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
Om Prostatype Genomics
Prostatype® är ett gentest som finns tillgängligt för patienter och
behandlande urologer som ett
kompletterande beslutsunderlag inför frågeställningen behandling eller inte
behandling av
prostatacancer. Testet är utvecklat av en forskargrupp på Karolinska
Institutet och tillhandahålls av
Prostatype Genomics AB. Bolagets Certified Adviser är DNB Carnegie.
Viktig information
Informationen i detta pressmeddelande varken innehåller eller utgör ett
erbjudande att förvärva, teckna eller på annat sätt handla med aktier,
teckningsoptioner eller andra värdepapper i Prostatype Genomics. Ingen åtgärd
har vidtagits, och ingen åtgärd kommer att vidtas, för att tillåta ett
erbjudande till allmänheten i någon annan jurisdiktion än Sverige. Inbjudan
till berörda personer att teckna aktier i Prostatype Genomics sker endast
genom det prospekt som Prostatype Genomics offentliggjort.
Informationen i detta pressmeddelande får inte offentliggöras, publiceras
eller distribueras, vare sig direkt eller indirekt, inom eller till USA,
Vitryssland, Ryssland, Australien, Hongkong, Japan, Kanada, Nya Zeeland,
Schweiz, Singapore, Sydafrika eller någon annan jurisdiktion där sådan åtgärd
skulle vara olaglig, föremål för legala restriktioner eller kräva andra
åtgärder än de som följer av svensk rätt. Åtgärder i strid med denna
instruktion kan utgöra brott mot tillämplig värdepapperslagstiftning. Inga
aktier eller andra värdepapper i Prostatype Genomics har registrerats, och
inga aktier eller andra värdepapper kommer att registreras, enligt den vid var
tid gällande United States Securities Act från 1933 (”Securities Act”) eller
värdepapperslagstiftningen i någon delstat eller annan jurisdiktion i USA och
får inte erbjudas, säljas eller på annat sätt överföras, direkt eller
indirekt, i eller till USA, förutom i enlighet med ett tillämpligt undantag
från, eller i en transaktion som inte omfattas av, registreringskraven i
Securities Act och i enlighet med värdepapperslagstiftningen i relevant
delstat eller annan jurisdiktion i USA. Detta pressmeddelande distribueras och
riktar sig endast till personer i Storbritannien som är (i) professionella
investerare som omfattas av artikel 19(5) i den vid var tid gällande brittiska
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(”Ordern”) eller (ii) förmögna personer och andra personer till vilka detta
pressmeddelande lagligen kan riktas och som omfattas av artikel 49(2)(a)-(d) i
Ordern (alla sådana personer benämns gemensamt ”Relevanta Personer”). Personer
som inte är Relevanta Personer får inte agera på eller förlita sig på
informationen i detta meddelande. En investering eller investeringsåtgärd som
avses i detta meddelande är endast möjlig för Relevanta Personer och kommer
endast att slutföras med Relevanta Personer. Personer som sprider denna
kommunikation måste själva försäkra sig om att sådan spridning är tillåten.
Framåtblickande uttalanden
Detta pressmeddelande innehåller framåtriktade uttalanden som avser Bolagets
avsikter, bedömningar eller förväntningar avseende Bolagets framtida resultat,
finansiella ställning, likviditet, utveckling, framtidsutsikter, förväntad
tillväxt, strategier och möjligheter samt de marknader inom vilka Bolaget är
verksamt. Framåtriktade uttalanden är uttalanden som inte hänför sig till
historiska fakta och kan identifieras genom att de innehåller uttryck som
”anser”, ”förväntar”, ”förutser”, ”avser”, ”uppskattar”, ”kommer”, ”kan”,
”antar”, ’bör’, ”skulle kunna” och, i varje enskilt fall, negationer därav,
eller liknande uttryck. De framåtriktade uttalandena i detta pressmeddelande
är baserade på olika antaganden, vilka i flera fall är baserade på ytterligare
antaganden. Även om Bolaget anser att de antaganden som återspeglas i dessa
framåtriktade uttalanden är rimliga, kan det inte garanteras att de kommer att
inträffa eller att de är korrekta. Eftersom dessa antaganden är baserade på
antaganden eller uppskattningar och är föremål för risker och osäkerheter, kan
det faktiska resultatet eller utfallet av många olika skäl skilja sig
väsentligt från vad som framgår av de framåtriktade uttalandena.
Sådana risker, osäkerheter, oförutsedda händelser och andra väsentliga
faktorer kan medföra att faktiska händelser skiljer sig väsentligt från de
förväntningar som uttrycks eller antyds i detta pressmeddelande genom de
framåtriktade uttalandena. Bolaget garanterar inte att de antaganden som
ligger till grund för de framåtriktade uttalandena i detta pressmeddelande är
korrekta och läsare av detta pressmeddelande bör inte fästa otillbörlig vikt
vid de framåtriktade uttalandena i detta pressmeddelande. Den information, de
åsikter och de framåtriktade uttalanden som uttrycks eller antyds i detta
pressmeddelande gäller endast per dagen för detta pressmeddelande och kan
komma att ändras. Varken Bolaget eller någon annan åtar sig att revidera,
uppdatera, bekräfta eller offentligt tillkännage någon revidering av något
framåtriktat uttalande för att återspegla händelser som inträffar eller
omständigheter som inträffar med avseende på innehållet i detta
pressmeddelande, förutom vad som krävs enligt lag eller Nasdaq First North
Growth Markets regelverk för emittenter.
Bifogade filer
Prostatype Genomics AB meddelar sista dag för handel med BTU och första dag
för handel med teckningsoptioner av serie TO5
(https://storage.mfn.se/f3782e96-9fa6-4122-ad34-2bd732ab5d7c/prostatype-genomics-ab-meddelar-sista-dag-for-handel-med-btu-och-forsta-dag-for-handel-med-teckningsoptioner-av-serie-to5.pdf)
------------------------------------------------------------------------------
news_id: 23b5ac8b-dc56-493f-b97f-1c9ee93fff07
group_id: 97d7eba8-2cd0-4499-8851-957039b6d7ed
tags: [:regulatory], [:regulatory:mar], [:regulatory:nsta], [ext:ob],
[ext:ob:inside-information], [sub:ci], [sub:ci:other]
title: Seacrest Petroleo Bermuda Limited: Information to Bondholders of 16.00%
Senior Unsecured Bonds due 2027
------------------------------------------------------------------------------
Hamilton, Bermuda, 19 June 2025: Seacrest Petroleo Bermuda Limited (in
Provisional Liquidation) ("Seacrest Petroleo" or the "Company") refers to its
announcement on 7 March 2025 regarding the appointment of Mike Penrose and
Igal Wizman as Joint Provisional Liquidators ("JPLs") over the Company.
The JPLs make reference to the attached Update Letter to the Bondholders (the
"Bondholders") of the Seacrest Petroleo Bermuda Limited 16.00% senior
unsecured USD 120,000,000 bonds 2024/2027 (ISIN: NO0013134759) from the JPLs
updating the Bondholders on the status of the provisional liquidation of the
Company.
For further information, please contact:
Seacrest Petroleo Bermuda Limited (in Provisional Liquidation)
c/o EY Bermuda Ltd.
3 Bermudiana Road
Hamilton HM08
SPBL.JPLs@bm.ey.com
The JPLs act as agents of the Company and without personal liability.
Important information
Matters discussed in this press release may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believes",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this release
speak only as at the date of this release and are subject to change without
notice.
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication at
2025-06-19 21:00 CEST.
Attachments
Seacrest Petroleo Bermuda Limited (in Provisional Liquidation) Update Letter
To Bondholders
(https://storage.mfn.se/d6657a59-d1d8-4e71-84e9-27b5fcde3194/seacrest-petroleo-bermuda-limited-in-provisional-liquidation-update-letter-to-bondholders.pdf)
------------------------------------------------------------------------------
news_id: 6f28f537-1499-449e-a8d8-f08da8d0b854
group_id: 132cc63c-cff6-4ed7-818b-9f192b2335d9
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: H100 Group Confirms Signing of Tranche 5 Allocations with Eagles Rising
AB and Karl Lindstedt
------------------------------------------------------------------------------
H100 Group AB (“H100 Group” or the “Company”) confirms that Eagles Rising AB
and Karl Lindstedt have now requested participation and signed the convertible
loan agreements for their respective allocations in Tranche 5, pursuant to
their rights under the existing investment agreement. Karl Lindstedt
participates based on a partial assignment of tranche rights from Eagles
Rising AB.
As previously announced, Adam Back has already executed the convertible loan
agreement for Tranche 5.
The Tranche 5 is allocated as follows between the three investors;
Adam Back; SEK 53,156,250; Eagles Rising AB; SEK 29,235,800 and Karl
Lindstedt: SEK 7,973,400
Adam Back previously requested immediate conversion into shares of his
allocation in tranche 5 as announced on 16 June 2025. The allocations to
Eagles Rising AB and Karl Lindstedt remain outstanding loans, which may be
converted at any time at the investors’ discretion. The agreed conversion
price for Tranche 5 is SEK 5.00 per share.
Contact
------------------------------------------------------------------------------
Sander Andersen, CEO H100 Group AB
E-mail: sander.andersen@h100.group
About H100 Group
------------------------------------------------------------------------------
H100 Group AB is a health technology company operating in the health and
longevity industry. The company’s business idea is to support providers of
health and lifestyle services through AI-powered automation, digital growth
tools, and integrated platform solutions, with the goal of helping people live
healthy lives to 100 and beyond.
H100 follows a clear growth strategy focused on building a seamless ecosystem
where AI integration enhances efficiency and expands service offerings. Growth
is further accelerated through strategic acquisitions of key players within
its ecosystem, aiming to consolidate and scale the business.
The company is listed on NGM Nordic SME. For more information, visit
www.h100.group.
This information is information that H100 Group is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-19 19:15 CEST.
Attachments
------------------------------------------------------------------------------
H100 Group Confirms Signing of Tranche 5 Allocations with Eagles Rising AB and
Karl Lindstedt
(https://storage.mfn.se/a254e0fb-b44d-48cb-9441-ce96ae0e5769/h100-group-confirms-signing-of-tranche-5-allocations-with-eagles-rising-ab-and-karl-lindstedt.pdf)
------------------------------------------------------------------------------
news_id: 76516be0-01ae-48dc-874f-ebf0d75670b2
group_id: c91add1e-736c-4c3c-9ee7-5035b35dbf20
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: FlexQube wins order worth 0.9 MUSD in the USA
------------------------------------------------------------------------------
FlexQube has received an order worth approximately 0.9 MUSD from a car
manufacturer in the USA. The company is a new customer to FlexQube and the
customer is now taking the first step in implementing a new material transport
system. The order is the single largest for FlexQube in three years and the
largest ever in North America for products that are part of FlexQube's tugger
train concept. The products will be delivered in the fourth quarter of 2025.
CEO Anders Fogelberg comments: "We are pleased that yet another player in the
automotive industry chooses FlexQube's proven concept to optimize its material
flow. This order confirms the value of our robust and flexible tugger train
solutions and strengthens our presence in the American automotive industry.
The order is our largest to date in North America for an end-user manufacturer
of passenger cars."
For more information, contact:
CEO, Anders Fogelberg
anders.fogelberg@flexqube.com
+46 702 86 06 74
About FlexQube
FlexQube is a technology company headquartered in Gothenburg, Sweden with
subsidiaries in USA, Mexico, Germany and England. FlexQube offers solutions
for cart-based material handling using a patented modular concept. FlexQube
develops and designs customized solutions for both robotic and mechanical cart
logistics. Through the own developed and unique automation concept FlexQube
can offer robust and self-driving robotic carts. FlexQube has more than 1200
customers in 40 countries with primary markets being North America and Europe.
FlexQube’s customers can be found within the manufacturing industry,
distribution- and warehousing. We represent some of the most successful
companies in the world with a significant share being represented on the
Fortune 500 list. These companies exist within automotive, electric vehicle
manufacturing, online retail, heavy-duty trucks, industrial automation and
retail logistics.
This information is information that FlexQube is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-19 18:30 CEST.
Attachments
FlexQube wins order worth 0.9 MUSD in the USA
(https://storage.mfn.se/9bb52fd0-9089-4372-9770-fcceca937097/flexqube-wins-order-worth-0-9-musd-in-the-usa.pdf)
------------------------------------------------------------------------------
news_id: 62399051-ef12-41d4-9cba-ad4f4bc86084
group_id: c91add1e-736c-4c3c-9ee7-5035b35dbf20
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: FlexQube vinner order värd 8,5 MSEK i USA
------------------------------------------------------------------------------
FlexQube har fått en order värd ca 8,5 MSEK till en personbilstillverkare i
USA. Företaget är en ny kund till FlexQube och kunden tar nu första steget i
införandet av ett nytt materialtransportsystem. Ordern är den enskilt största
för FlexQube på tre år och den största någonsin i Nordamerika för produkter
som ingår i FlexQubes tågtransportkoncept. Produkterna kommer att levereras i
det fjärde kvartalet 2025.
VD Anders Fogelberg kommenterar: ”Vi gläder oss över att ännu en aktör inom
bilindustrin väljer FlexQubes beprövade koncept för att optimera sitt
materialflöde. Den här ordern bekräftar värdet av våra robusta och flexibla
tågtransportlösningar och stärker vår närvaro i den amerikanska bilindustrin.
Ordern är vår största hittills i Nordamerika till en sluttillverkare av
personbilar.”
För mer information, kontakta:
VD, Anders Fogelberg
anders.fogelberg@flexqube.com
+46 702 86 06 74
Om FlexQube
FlexQube är ett teknikföretag med huvudkontor i Göteborg och dotterbolag i
USA, Mexiko, Tyskland och England. FlexQube erbjuder lösningar för vagnbaserad
materialhantering med hjälp av ett patenterat modulärt koncept. FlexQube
utvecklar och designar kundanpassade lösningar för både robotiserad och
mekanisk vagnlogistik. Genom det egenutvecklade och unika automationskonceptet
kan FlexQube erbjuda robusta och självkörande robotvagnar. FlexQube har mer än
1200 kunder i 40 länder med primära marknader i Nordamerika och Europa.
FlexQubes kunder finns inom tillverkningsindustri, distributions- och lager.
Vi representerar några av de mest framgångsrika företagen i världen med en
betydande andel representerad på Fortune 500-listan. Dessa företag finns inom
fordonsindustrin, elfordonstillverkning, e-handel, tunga lastbilar,
industriell automation och detaljhandelslogistik.
Denna information är sådan information som FlexQube är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-19 18:30 CEST.
Bifogade filer
FlexQube vinner order värd 8,5 MSEK i USA
(https://storage.mfn.se/ed21d90d-0d45-4825-b6b6-781aad5d61f3/flexqube-vinner-order-vard-8-5-msek-i-usa.pdf)
------------------------------------------------------------------------------
news_id: 215cbcfd-f497-4dd2-9f57-3fd406334ccf
group_id: ca08631a-66dc-4d18-b5b1-726e79682183
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Intellego's CEO transfers shares between personal accounts
------------------------------------------------------------------------------
Intellego Technologies AB (publ) ("Intellego") announces that the company’s
CEO, Claes Lindahl, has transferred shares between two of his personal
securities accounts for compliance-related reasons.
The transaction will be formally registered as an insider trade in accordance
with applicable regulations. No change in Claes Lindahl’s total shareholding
in Intellego has occurred as a result of the transfer.
Contacts
------------------------------------------------------------------------------
For further information, please contact:
Claes Lindahl, CEO Intellego Technologies AB
E-mail: claes.lindahl@intellego-technologies.com
Phone: +46 735 344 634
About Us
------------------------------------------------------------------------------
Intellego Technologies develops and manufactures color indicators that show
the effect of irradiation with, among other things, invisible ultraviolet
light, UV light. Color indicators are used globally in, for example, the
disinfection industry, the sunscreen industry, and the manufacturing industry.
Intellego's indicators have been developed from the company's patented
photochromic ink, which can be adapted to different wavelengths of light and
various application areas across a range of different industries. Intellego
Technologies was founded in 2011, is headquartered in Stockholm, and is listed
on the Nasdaq First North Growth Market.
The company's Certified Adviser on the Nasdaq First North Growth Market
Stockholm is Mangold Fondkommission AB.
Intellego's website: https://intellego-technologies.com/en/
Subscribe to Intellego's press releases:
https://intellego-technologies.com/sv/pressmeddelanden/
Contact the communications team: communications@intellego-technologies.com
Attachments
------------------------------------------------------------------------------
Intellego's CEO transfers shares between personal accounts
(https://storage.mfn.se/ed95ba4c-7415-454d-8095-c90e2fabb124/intellegos-ceo-transfers-shares-between-personal-accounts.pdf)
------------------------------------------------------------------------------
news_id: 44f89dcd-ca7e-4287-8cff-bf9e66a1b5db
group_id: 592f9c5f-a25b-49e6-88e2-93cbf9e7b235
tags: [:regulatory], [:regulatory:listing], [ext:nsm], [ext:nsm:hol],
[sub:ci], [sub:ci:shareholder-announcement]
title: Holding(s) in Company
------------------------------------------------------------------------------
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B7KR2P84
Issuer Name
EASYJET PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
Bank of America Corporation
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the
notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
17-Jun-2025
6. Date on which Issuer notified
18-Jun-2025
7. Total positions of person(s) subject to the notification obligation
+-----------------+-------------+----------------+-------------+-------------+
| . | % of voting | % of voting | Total of | Total |
| | rights | rights through | both in % | number of |
| | attached to | financial | (8.A + 8.B) | voting |
| | shares | instruments | | rights held |
| | (total of | (total of 8.B | | in issuer |
| | 8.A) | 1 + 8.B 2) | | |
+-----------------+-------------+----------------+-------------+-------------+
| Resulting | 0.288919 | 8.651449 | 8.940368 | 67768881 |
| situation on | | | | |
| the date on | | | | |
| which threshold | | | | |
| was crossed or | | | | |
| reached | | | | |
+-----------------+-------------+----------------+-------------+-------------+
| Position of | 0.275129 | 8.731891 | 9.007020 | |
| previous | | | | |
| notification | | | | |
| (if applicable) | | | | |
+-----------------+-------------+----------------+-------------+-------------+
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
8A. Voting rights attached to shares
+-----------------+-------------+---------------+-------------+--------------+
| Class/Type of | Number of | Number of | % of direct | % of |
| shares ISIN | direct | indirect | voting | indirect |
| code(if | voting | voting rights | rights | voting |
| possible) | rights | (DTR5.2.1) | (DTR5.1) | rights |
| | (DTR5.1) | | | (DTR5.2.1) |
+-----------------+-------------+---------------+-------------+--------------+
| GB00B7KR2P84 | | 2187654 | | 0.288605 |
| | | | | |
+-----------------+-------------+---------------+-------------+--------------+
| US2778562098 | | 2377 | | 0.000314 |
| | | | | |
+-----------------+-------------+---------------+-------------+--------------+
| Sub Total 8.A | 2190031 | | 0.288919% | |
+-----------------+-------------+---------------+-------------+--------------+
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
+------------+------------+-------------------+------------------+-----------+
| Type of | Expiration | | Number of voting | % of |
| financial | date | Exercise/conversion | rights that may | voting |
| instrument | | period | be acquired if | rights |
| | | | the instrument | |
| | | | is | |
| | | | exercised/converted | |
+------------+------------+-------------------+------------------+-----------+
| Right to | N/A | N/A | 307138 | 0.040519 |
| Recall | | | | |
+------------+------------+-------------------+------------------+-----------+
| Physical | 17/01/2029 | N/A | 5626 | 0.000742 |
| Option | | | | |
+------------+------------+-------------------+------------------+-----------+
| Physical | 20/06/2025 | N/A | 63807 | 0.008418 |
| Option | | | | |
+------------+------------+-------------------+------------------+-----------+
| Physical | 12/02/2026 | N/A | 788000 | 0.103956 |
| Swaps | | | | |
+------------+------------+-------------------+------------------+-----------+
| Sub Total | | | 1164571 | 0.153635% |
| 8.B1 | | | | |
+------------+------------+-------------------+------------------+-----------+
8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))
+------------+------------+--------------+------------+----------+-----------+
| Type of | Expiration | | Physical | Number | % of |
| financial | date | Exercise/conversion | or cash | of | voting |
| instrument | | period | settlement | voting | rights |
| | | | | rights | |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 04/07/2025 | N/A | Cash | 4667945 | 0.615816 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 14/07/2025 | N/A | Cash | 93862 | 0.012383 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 15/07/2025 | N/A | Cash | 60140 | 0.007934 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 29/08/2025 | N/A | Cash | 10690 | 0.001410 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 15/09/2025 | N/A | Cash | 20749166 | 2.737321 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 16/10/2025 | N/A | Cash | 1410908 | 0.186133 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 11/12/2025 | N/A | Cash | 897062 | 0.118344 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 30/01/2026 | N/A | Cash | 381124 | 0.050280 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 27/02/2026 | N/A | Cash | 18 | 0.000002 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 03/03/2026 | N/A | Cash | 3405015 | 0.449204 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 06/03/2026 | N/A | Cash | 5777091 | 0.762139 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 18/03/2026 | N/A | Cash | 136996 | 0.018073 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 30/03/2026 | N/A | Cash | 10430527 | 1.376041 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 31/03/2026 | N/A | Cash | 9080 | 0.001198 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 02/04/2026 | N/A | Cash | 13559646 | 1.788848 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 15/04/2026 | N/A | Cash | 1650000 | 0.217675 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 29/05/2026 | N/A | Cash | 108505 | 0.014314 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 09/06/2026 | N/A | Cash | 13782 | 0.001818 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 10/06/2026 | N/A | Cash | 7367 | 0.000972 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 11/06/2026 | N/A | Cash | 120 | 0.000016 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 12/06/2026 | N/A | Cash | 2250 | 0.000297 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 15/06/2026 | N/A | Cash | 5153 | 0.000680 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 17/06/2026 | N/A | Cash | 17711 | 0.002337 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 19/06/2026 | N/A | Cash | 28089 | 0.003706 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 22/06/2026 | N/A | Cash | 6520 | 0.000860 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 23/06/2026 | N/A | Cash | 4015 | 0.000530 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 30/06/2026 | N/A | Cash | 3002 | 0.000396 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 03/07/2026 | N/A | Cash | 4909 | 0.000648 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 06/07/2026 | N/A | Cash | 3635 | 0.000480 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 10/07/2026 | N/A | Cash | 2543 | 0.000335 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 13/07/2026 | N/A | Cash | 834335 | 0.110069 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 14/07/2026 | N/A | Cash | 5772 | 0.000761 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 16/07/2026 | N/A | Cash | 6322 | 0.000834 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 31/07/2026 | N/A | Cash | 18689 | 0.002466 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 21/08/2026 | N/A | Cash | 7737 | 0.001021 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 31/08/2026 | N/A | Cash | 33787 | 0.004457 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 07/09/2026 | N/A | Cash | 3839 | 0.000506 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 16/09/2026 | N/A | Cash | 29043 | 0.003831 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 03/12/2026 | N/A | Cash | 8696 | 0.001147 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 04/12/2026 | N/A | Cash | 3870 | 0.000511 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 07/12/2026 | N/A | Cash | 4514 | 0.000596 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 04/06/2027 | N/A | Cash | 9908 | 0.001307 |
+------------+------------+--------------+------------+----------+-----------+
| Swaps | 15/02/2028 | N/A | Cash | 896 | 0.000118 |
+------------+------------+--------------+------------+----------+-----------+
| Sub Total | | | | 64414279 | 8.497814% |
| 8.B2 | | | | | |
+------------+------------+--------------+------------+----------+-----------+
9. Information in relation to the person subject to the notification
obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)
+---------------+-----------------+-------------+--------------+-------------+
| Ultimate | Name of | % of voting | % of voting | Total of |
| controlling | controlled | rights if | rights | both if it |
| person | undertaking | it equals | through | equals or |
| | | or is | financial | is higher |
| | | higher than | instruments | than the |
| | | the | if it equals | notifiable |
| | | notifiable | or is higher | threshold |
| | | threshold | than the | |
| | | | notifiable | |
| | | | threshold | |
+---------------+-----------------+-------------+--------------+-------------+
| Bank of | Bank of | | 3.373055 | 3.373368% |
| America | America, | | | |
| Corporation | National | | | |
| | Association | | | |
+---------------+-----------------+-------------+--------------+-------------+
| Bank of | BofA | | | |
| America | Securities, | | | |
| Corporation | Inc. | | | |
+---------------+-----------------+-------------+--------------+-------------+
| Bank of | Merrill Lynch | | | |
| America | B.V. | | | |
| Corporation | | | | |
+---------------+-----------------+-------------+--------------+-------------+
| Bank of | Merrill Lynch | | 3.634638 | 3.700832% |
| America | International | | | |
| Corporation | | | | |
+---------------+-----------------+-------------+--------------+-------------+
| Bank of | BofA Securities | | | |
| America | Europe SA | | | |
| Corporation | | | | |
+---------------+-----------------+-------------+--------------+-------------+
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
18-Jun-2025
13. Place Of Completion
United Kingdom
------------------------------------------------------------------------------
news_id: 9361cc7e-f070-431f-ae58-424db8deef71
group_id: 4bb5b42f-9df1-40c1-ad72-b0cf52cabe8e
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: SpectraCure offentliggör preliminärt utfall i företrädesemission
------------------------------------------------------------------------------
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER
INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA,
NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON
ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV
DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE
REGISTRERINGS- ELLER ANDRA ÅTGÄRDER.
SpectraCure AB (publ) (”SpectraCure” eller ”Bolaget”) offentliggör härmed det
preliminära utfallet i den företrädesemission av units, bestående av aktier
och teckningsoptioner av serie TO5 med företrädesrätt för befintliga
aktieägare, som beslutades av styrelsen den 29 april 2025 och som godkändes av
bolagsstämman den 30 maj 2025 (”Företrädesemissionen”). Det preliminära
utfallet indikerar att 270 869 379 units, motsvarande cirka 58,10 procent av
Företrädesemissionen, tecknats. Därmed kommer garantiåtaganden ej att
utnyttjas. Företrädesemissionen kommer att tillföra Bolaget en likvid om cirka
48,8 MSEK före emissionskostnader. Vid fullt utnyttjande av samtliga
teckningsoptioner av serie TO5 förväntas Bolaget att tillföras ytterligare upp
till cirka 97,5 MSEK före emissionskostnader.
Preliminärt utfall i Företrädesemissionen
Teckningsperioden i Företrädesemissionen avslutades den 19 juni 2025. Det
preliminära utfallet indikerar att 248 975 602 units, motsvarande cirka 53,40
procent av Företrädesemissionen, har tecknats med stöd av uniträtter i
Företrädesemissionen. Därtill har anmälningar mottagits om att teckna 21 893
777 units utan stöd av uniträtter, motsvarande cirka 4,70 procent av
Företrädesemissionen. Således indikerar det preliminära utfallet att
Företrädesemissionen, med och utan stöd av uniträtter, är tecknad till cirka
58,10 procent och att inga garantiåtaganden kommer att utnyttjas.
Tilldelning av units tecknade utan stöd av uniträtter
Tilldelning av units som tecknats utan stöd av uniträtter har skett i enlighet
med de principer som anges i det prospekt som Bolaget offentliggjorde den 2
juni 2025 med anledning av Företrädesemissionen. Besked om sådan tilldelning
meddelas separat genom utskickad avräkningsnota. Förvaltarregistrerade
aktieägare erhåller besked om tilldelning i enlighet med instruktioner från
respektive förvaltare.
Slutligt utfall och handel i betalda tecknade units (”BTU”)
Det slutgiltiga utfallet i Företrädesemissionen förväntas offentliggöras den
24 juni 2025. Sista dag för handel med BTU beräknas vara den 9 juli 2025.
Handel med de nya aktierna och teckningsoptioner av serie TO5 tecknade med och
utan stöd av uniträtter förväntas inledas på Nasdaq First North Growth Market
omkring den 15 juli 2025.
Rådgivare
Mangold Fondkommission AB är finansiell rådgivare och Advokatfirman Lindahl KB
är legal rådgivare
till Bolaget i samband med Företrädesemissionen.
Denna information är sådan information som SpectraCure är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-19 17:45 CEST.
För ytterligare information:
Masoud Khayyami, tf. VD
E-post: ir@spectracure.com
Hemsida: www.spectracure.com
SpectraCure är ett medicinteknikbolag som fokuserar på att utveckla ett nytt
medicintekniskt behandlingssystem för lokaliserad prostatacancer. Målet är att
erbjuda en fokal behandling med hög precision, som har möjligheten att bli en
mer individualiserad och minimalinvasiv lösning för prostatacancer. Systemet
har potential att i framtiden även anpassas för andra typer av inre solida
tumörer som exempelvis cancer i bröst, bukspottkörtel samt i huvud- och
halsregionen. En klinisk studie för patienter med återfall av prostatacancer
pågår, vid ledande kliniker inom prostatacancer i Nordamerika och Europa. Vi
är i processen av att inleda ytterligare en klinisk studie, för patienter med
primär lokaliserad prostatacancer.
Bolaget är noterat i Premier-segmentet på Nasdaq First North Growth Market med
Amudova AB som Certified Adviser och handlas med kortnamn SPEC.
Viktig information
Publicering, offentliggörande eller distribution av detta pressmeddelande kan
i vissa jurisdiktioner vara föremål för restriktioner enligt lag och personer
i de jurisdiktioner där detta pressmeddelande har offentliggjorts eller
distribuerats bör informera sig om och följa sådana legala restriktioner.
Mottagaren av detta pressmeddelande ansvarar för att använda detta
pressmeddelande och informationen häri i enlighet med tillämpliga regler i
respektive jurisdiktion. Detta pressmeddelande utgör inte ett erbjudande om,
eller inbjudan att, förvärva eller teckna några värdepapper i SpectraCure i
någon jurisdiktion, varken från SpectraCure eller från någon annan.
Detta pressmeddelande utgör inte ett erbjudande om eller inbjudan avseende att
förvärva eller teckna värdepapper i USA. Värdepapperna som omnämns häri får
inte säljas i USA utan registrering, eller utan tillämpning av ett undantag
från registrering, enligt den vid var tid gällande U.S. Securities Act från
1933 ("Securities Act"), och får inte erbjudas eller säljas i USA utan att de
registreras, omfattas av ett undantag från, eller i en transaktion som inte
omfattas av registreringskraven enligt Securities Act. Det finns ingen avsikt
att registrera några värdepapper som omnämns häri i USA eller att lämna ett
offentligt erbjudande avseende sådana värdepapper i USA. Informationen i detta
pressmeddelande får inte offentliggöras, publiceras, kopieras, reproduceras
eller distribueras, direkt eller indirekt, helt eller delvis, i eller till
Australien, Belarus, Hongkong, Japan, Kanada, Nya Zeeland, Ryssland, Schweiz,
Singapore, Sydafrika, Sydkorea, USA eller någon annan jurisdiktion där sådant
offentliggörande, publicering eller distribution av denna information skulle
stå i strid med gällande regler eller där en sådan åtgärd är föremål för
legala restriktioner eller skulle kräva ytterligare registrering eller andra
åtgärder än vad som följer av svensk rätt. Åtgärder i strid med denna
anvisning kan utgöra brott mot tillämplig värdepapperslagstiftning.
Detta pressmeddelande innehåller viss framåtriktad information som återspeglar
Bolagets aktuella syn på framtida händelser samt finansiell och operationell
utveckling. Ord som "avses", "bedöms", "förväntas", "kan", "planerar", "tror",
"uppskattar" och andra uttryck som innebär indikationer eller förutsägelser
avseende framtida utveckling eller trender, och som inte är grundade på
historiska fakta, utgör framåtriktad information. Framåtriktad information är
till sin natur förenad med såväl kända som okända risker och
osäkerhetsfaktorer eftersom den är avhängig framtida händelser och
omständigheter. Framåtriktad information utgör inte någon garanti avseende
framtida resultat eller utveckling och verkligt utfall kan komma att
väsentligen skilja sig från vad som uttalas i framåtriktad information.
Bifogade filer
SpectraCure offentliggör preliminärt utfall i företrädesemission
(https://storage.mfn.se/d88b99af-1d34-4ddb-815e-74032bedba06/spectracure-offentliggor-preliminart-utfall-i-foretradesemission.pdf)
------------------------------------------------------------------------------
news_id: 7e9fef5e-56e2-4792-ad38-4f18aeab8e53
group_id: dd1ffe34-4534-441b-acab-91534d17c993
tags: [:regulatory], [:regulatory:mar], [sub:ci], [sub:ci:sales],
[sub:ci:sales:order]
title: Net Insight wins record sports venue deal in the U.S.
------------------------------------------------------------------------------
Stockholm, Sweden – Net Insight has secured a landmark live media transport
deal with one of our existing customers, involving the delivery of its most
advanced media solutions for U.S. sports venues. The deal is valued at USD 6
million and represents one of the largest media contracts in the company’s
history.
The agreement was secured among strong competition and includes fully equipped
Nimbra 1060s, Net Insight’s latest generation of live media transport
solutions for managed networks. It marks an important step in expanding Net
Insight’s presence in the U.S. market and enables the customer to deliver
high-quality, uninterrupted live broadcast experiences while reinforcing Net
Insight’s leading position within the managed solutions segment. The greater
part of the order is scheduled for delivery during 2025, starting in Q2.
Fully aligned with the company’s strategic focus on the American market and
enabling live sports broadcasts through cutting-edge technology, the agreement
reinforces this direction. This deal underscores the growing need for
increased network capacity at venues and remote production capabilities. Here,
Net Insight is at its strongest, with plans to launch a groundbreaking 400G IP
platform at the turn of the year 2025/2026.
“With continued geopolitical uncertainty, it is particularly satisfying to
close this deal, which we have been working on for a long time. It
demonstrates the competitiveness of our offering and is a clear sign of the
trust our long-standing global customer places in our technology and
expertise.” says Crister Fritzson, CEO of Net Insight. “It confirms key
elements of our strategic direction, including a focus on the U.S. market and
highlights the value we deliver to live sports media ecosystem through our
reliable, scalable, and future-proof solutions for both managed as well as
unmanaged networks.”
For further information, please contact:
Crister Fritzson, CEO of Net Insight AB, +46 8 685 04 00,
crister.fritzson@netinsight.net
About Net Insight
Net Insight (Nasdaq: NETI B) provides the highest-performing, most open video
transport and media cloud technology for content providers as the industry
standard for flexibility and service across live contribution, distribution
and remote production media workflows.
For over 25 years, the world’s leading content owners, broadcasters,
production companies, service providers and enterprises have trusted Net
Insight’s Emmy® Award winning Nimbra technology to guarantee media delivery.
Today, Net Insight partners with hundreds of customers in over 85 countries to
ensure media flows across managed and unmanaged IP networks, and the cloud –
from anywhere, to everywhere. It enables customers to get the best from any
mix of virtualized, cloud and IP technology and is the only platform to
support all the major industry standards, protocols and clouds.
In addition, Net Insight provides a GNSS/GPS-independent time synchronization
solution for 5G and other critical networks, offering high accuracy and
performance, reducing costs and accelerating rollouts.
For more information, please visit netinsight.net (https://netinsight.net/)
Follow us on LinkedIn: linkedin.com/company/net-insight
(http://www.linkedin.com/company/net-insight/)
This information is information that Net Insight is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-19 16:35 CEST.
Attachments
------------------------------------------------------------------------------
Net Insight wins record sports venue deal in the U.S.
(https://storage.mfn.se/e98ecaeb-f701-4e92-8bdd-0590755af51f/net-insight-wins-record-sports-venue-deal-in-the-u-s.pdf)
------------------------------------------------------------------------------
news_id: 2f7ccee1-2950-44f3-ae34-8ced6e2ece4c
group_id: dd1ffe34-4534-441b-acab-91534d17c993
tags: [:regulatory], [:regulatory:mar], [sub:ci], [sub:ci:sales],
[sub:ci:sales:order]
title: Net Insight vinner rekordavtal för sportarenor i USA
------------------------------------------------------------------------------
Stockholm – Net Insight har säkrat ett betydelsefullt avtal för live
mediatransport med en av bolagets befintliga kunder, vilket innebär leverans
av bolagets mest avancerade medielösningar för amerikanska sportarenor.
Avtalet är värderat till 6 MUSD och representerar ett av de största avtalen
inom media i bolagets historia.
Avtalet säkrades i stark konkurrens och inkluderar fullt utrustade Nimbra
1060, Net Insights senaste generation av lösningar för managerade nätverk inom
live mediatransport. Det markerar ett viktigt steg i att utöka Net Insights
närvaro på den USA-marknaden och gör det möjligt för kunden att leverera
högkvalitativa upplevelser med direktsändningar, samtidigt som Net Insights
ledande position inom segmentet för managerade lösningar förstärks.
Majoriteten av ordern är planerad att levereras under 2025, med början i andra
kvartalet.
Avtalet är helt i linje med företagets strategiska fokus på den amerikanska
marknaden och möjliggör direktsändningar av sport genom avancerad teknologi,
och förstärker denna riktning. Denna affär understryker det växande behovet av
ökad nätverkskapacitet på arenor och kapacitet för distansproduktion. Här är
Net Insight som starkast, med planer på att lansera en banbrytande 400G
IP-plattform runt årsskiftet 2025/2026.
”Med fortsatt geopolitisk osäkerhet, är det särskilt tillfredställande att
slutföra den här affären, som vi har arbetat med under en längre tid. Det
visar på konkurrenskraften i vårt erbjudande och är ett tydligt tecken på det
förtroende som vår långvariga globala kund har för vår teknologi och
expertis,” säger Crister Fritzson, VD på Net Insight. ”Det bekräftar viktiga
delar av vår strategiska inriktning, inklusive ett fokus på USA-marknaden, och
belyser det värde vi levererar till ekosystemet för livesportmedia genom våra
pålitliga, skalbara och framtidssäkra lösningar för både managerade och
icke-managerade nät.”
För mer information, kontakta:
Crister Fritzson, VD på Net Insight AB, 08-685 0400,
crister.fritzson@netinsight.net
Om Net Insight
Net Insight (Nasdaq: NETI B) erbjuder marknadens mest högpresterande och öppna
lösningar för videotransport och molntjänster till innehållsleverantörer, och
utgör branschstandard i fråga om flexibilitet och tjänster för kontribution,
distribution och distansproduktion av liveinnehåll.
I över 25 år har världens ledande rättighetsägare, tv-bolag, produktionsbolag,
tjänsteleverantörer och företagskunder förlitat sig på Net Insights
Emmy®-vinnande Nimbra-lösning för att garantera sina medialeveranser. Idag
samarbetar Net Insight med hundratals kunder, för att säkerställa
mediatransport över alla IP-nätverk och cloud, i över 85 länder. Med den
optimala mixen av virtualiserade, molnbaserade och IP-baserade lösningar är
Net Insights produktportfölj den enda på marknaden som stöder alla stora
industristandarder, protokoll och cloud.
Dessutom erbjuder Net Insight en GNSS/GPS-oberoende
tidssynkroniserings-lösning för 5G och andra kritiska nätverk, som levererar
hög noggrannhet och prestanda, minskar kostnader och påskyndar utrullning.
För mer information, se netinsight.net (https://netinsight.net/)
Följ oss på LinkedIn: linkedin.com/company/net-insight
(http://www.linkedin.com/company/net-insight/)
Denna information är sådan information som Net Insight är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-19 16:35 CEST.
Bifogade filer
------------------------------------------------------------------------------
Net Insight vinner rekordavtal för sportarenor i USA
(https://storage.mfn.se/3e56c244-7c29-440d-bbb9-1e0a57f06ace/net-insight-vinner-rekordavtal-for-sportarenor-i-usa.pdf)
------------------------------------------------------------------------------
news_id: 515f4fe0-0683-41f2-bd48-e755d58896c2
group_id: cd8a1a7a-fd68-44c9-be04-0503859a2874
tags: [:regulatory], [:regulatory:mar], [sub:report], [sub:report:interim],
[sub:report:interim:q4]
title: Trainimal AB bokslutskommuniké för räkenskapsåret 2024/2025
------------------------------------------------------------------------------
Trainimal AB (publ) presenterar idag sin bokslutskommuniké för det brutna
räkenskapsåret maj 2024 – april 2025.
Det fjärde kvartalet i sammandrag
• Nettoomsättning ökade med 7 % till 3 118 (2 917) TSEK
• Rörelseresultatet ökade till 286 (-565) TSEK
• EBITDA uppgick till 914 (-22) TSEK
• Periodens resultat före skatt ökade till 331 (-585) TSEK
• Resultat per aktie uppgick till 0,14 (-0,25) kr
• Kassaflödet från den löpande verksamheten blev -243 (417) TSEK
Helår i sammandrag
• Nettoomsättning minskade marginellt med 1,5 % till 10 758 (10 920)
TSEK
• Rörelseresultatet ökade till -266 (-1 010) TSEK
• EBITDA ökade med 136 % till 2 162 (916) TSEK
• Periodens resultat före skatt ökade till -245 (-1 058) TSEK
• Resultat per aktie uppgick till -0,10 (-0,45) kr
• Kassaflödet från den löpande verksamheten förbättrades till 1 098
(458) TSEK
” Verksamhetsåret 2024/2025 är avslutat, och vi kan se tillbaka på ett år
präglat av arbetet med att återfå lönsamheten i bolaget med sparsamhet, parat
med väl avvägda åtgärder för att samtidigt öka våra intäkter. Detta har vi
lyckats med, vi har minskat kostnaderna från kvartal till kvartal och ökat
marginalerna kraftigt utan att intäkterna har tagit stryk genom kundavhopp
trots att vi höjt våra priser för första gången på 7 år. Effekten märks i
sista kvartalet, ett kvartal som lämnade vinst även på sista raden, vilket vi
absolut är mycket nöjda med.” säger Olga Rönnberg, vd för Trainimal.
”Trainimal-plattformen utvecklas och förbättras ständigt, vi har bara under
2025 släppt 10 nya versioner med nya och uppdaterade funktioner men även nya,
specialiserade erbjudanden. Vi fortsätter ändå att vara försiktiga med
kostnaderna för marknadsföringen. Den engelska versionen av våra medlemskap är
nu i drift sedan slutet på april och vi kommer att börja marknadsföra dem
aktivt under det kommande året.” fortsätter Olga Rönnberg.
För fullständig rapport, se bifogad pdf.
Kontakter
Olga Rönnberg, VD
Tel: +46 735 040 326
E-post: olga.ronnberg@trainimal.com
Investor Relations
ir@trainimal.com
Om oss
Trainimal tillhandahåller individanpassad träning och kostrådgivning digitalt
genom egenutvecklad smart teknologi. Bolagets mest kända produkt går under
namnet MammaFitness, som är skapad av den välkända träningsprofilen Olga
Rönnberg. MammaFitness har hjälpt över 30 000 kunder att bli den bästa version
av sig själv. Trainimals vision är att alla ska kunna uppnå fysisk hälsa och
välbefinnande, oavsett sociala, ekonomiska och geografiska förutsättningar.
Denna information är sådan information som Trainimal är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-19 16:30 CEST.
Bifogade filer
Trainimal Q4 2024
(https://storage.mfn.se/22ee1638-6f70-48da-9878-ca2caad09f93/trainimal-q4-2024.pdf)
------------------------------------------------------------------------------
news_id: 7c53a8fb-acd7-4542-9944-661d2b9197fc
group_id: 52b982c2-9f7b-44ce-a605-690df95ddaf3
tags: [ext:nq], [ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: Cardeons portföljbolag TEQCools Strategiska väg till marknaden
------------------------------------------------------------------------------
Hjärnskador utgör fortfarande en av de mest förödande och underbehandlade
globala hälsoutmaningarna. TEQCool AB tar nu modiga och regulatoriskt
anpassade steg för att lansera sitt banbrytande, icke-invasiva kylsystem för
hjärnan – ett system som kan förändra hur vi behandlar akuta hjärnskador och
rädda liv i kritiska skeden.
"Vår mission är enkel: att förhindra sekundära hjärnskador innan de uppstår.
Vår metod är banbrytande – snabb, fokal kylning av hjärnan utan behov av
sedering eller systemisk hypotermi. Framtiden för neuroprotektion börjar här,"
säger Anders Sjögren, VD för TEQCool.
Kliniska prövningar i sikte – ett viktigt steg mot marknaden
Efter starka prekliniska resultat förbereder sig TEQCool för att inleda sina
första kliniska prövningar under slutet av 2026, i samarbete med ledande
neurokliniker i Sverige och Europa. Fokus ligger initialt på patienter med
traumatisk hjärnskada och stroke, där behovet av snabb neuroprotektion är som
störst. Målet är att generera det kliniska underlag som krävs för
CE-märkning och på sikt även godkännande på andra viktiga marknader, inklusive
USA.
Mot börsen – planerad notering efter sommaren 2025
Som en del av bolagets tillväxtstrategi planerar TEQCool att genomföra en
börsnotering på en svensk tillväxtmarknad efter sommaren 2025. Syftet är att
säkra kapital för att påskynda den regulatoriska processen, skala upp
produktion och förbereda för internationell lansering.
"Vi står inför ett avgörande skede. Med det stöd vi ser från både vårdsektorn
och investerare, är det rätt tid att ta nästa steg. En notering gör det
möjligt för oss att bygga vidare på vår vision – att göra snabb, säker
hjärnkylning till en ny standard inom akutsjukvården," säger Anders Sjögren.
Strategiska samarbeten i samband med kliniska studier
I samband med de kommande kliniska prövningarna initierar TEQCool även
samarbeten med potentiella industriella och kommersiella partners. Dessa
partnerskap syftar till att validera teknologin i klinisk praxis, samt att
förbereda för framtida distribution och marknadstillträde.
"De kliniska studierna utgör inte bara ett medicinskt bevis för vår lösning –
de är också en katalysator för strategiska allianser. Vi ser ett starkt
intresse från både medtech-sektorn och vårdgivare som vill vara med i
frontlinjen för framtidens neuroprotektion," avslutar Anders Sjögren.
För ytterligare information avseende TEQCool, kontakta:
Anders Sjögren, VD TEQCool AB, E-mail: ir@teqcool.com
För ytterligare information avseende Cardeon, kontakta:
Masoud Khayyami, VD Cardeon AB, E-mail:ir@cardeon.se
Amudova AB är Cardeons Mentor. Tel: 08-546 017 58 E-mail: info@amudova.se
Om oss
Cardeon är ett svenskt investmentbolag grundat 2006 som, sedan fusionen den 24
november 2022, investerar i innovativa företag och startups inom medicinteknik
och lifescience. Bolagets affärsidé är att genom investeringar bistå i
utvecklingen av en idé sprungen ur ett forskningsresultat till kommersiell
produkt. Målbolagen ska bedömas ha potential att förändra den globala
marknaden. Cardeon investerar i både noterade och onoterade företag.
Bifogade filer
Cardeons portföljbolag TEQCools Strategiska väg till marknaden
(https://storage.mfn.se/be4a02ca-8d64-4106-a251-1dae8027f1b9/cardeons-portfoljbolag-teqcools-strategiska-vag-till-marknaden.pdf)
------------------------------------------------------------------------------
news_id: e9a6cb34-87a0-4172-918a-f32449dbb8e5
group_id: 2828a063-cdbc-4305-aa53-104dcb4adb06
tags: [:regulatory], [:regulatory:mar], [ext:nq],
[ext:nq:company-announcement], [sub:ci], [sub:ci:other]
title: Magnasense intends to carry out a directed issue of shares to Atlas
Special Opportunities, LLC due to called on conversions totalling SEK 2.50
million
------------------------------------------------------------------------------
DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN
OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW
ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY
OTHER JURISDICTION IN WHICH SUCH RELEASE, DISTRIBUTION OR PUBLICATION OF THIS
PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR
OTHER MEASURES. PLEASE SEE ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS
RELEASE.
Magnasense AB ("Magnasense" or the "Company") announced on 9 April 2024 that
it had entered into a SEK 45 million loan facility agreement (the ”Loan
Facility”) under which the Company could call loans in seven (7) tranches
(hereinafter the "Tranches" or each individually the "Tranche") and an
agreement to amend the terms and conditions (the "Amendment Agreement") of the
outstanding convertible bonds of series 2023/2026 (the "Convertible Bonds"),
the amendment of the terms and conditions of which was approved by the general
meeting of shareholders on 26 April 2024. Atlas Special Opportunities, LLC
("Atlas") has the right to call for conversion of outstanding debt in directed
issues of all or part of the principal amount of the called Tranches and the
principal amount of the Convertible Bonds up to and including the respective
maturity date. To facilitate the administration of the conversions, the
parties have previously agreed that a new share issue under the Loan Facility
and the Amendment Agreement (the "Agreements") shall occur when Atlas has
called for conversion in an aggregate amount of at least SEK 2.50 million (the
"Threshold") or if the market value of the transaction fee shares is less than
SEK 1.00 million, after which the Company will notify the market. The Company
today announces that Atlas has requested conversions totalling SEK 2.50
million. The issue is intended to be carried out with the support of the
authorisation from the annual general meeting on 28 June 2024 through a
directed issue of a total of 416,666,666 shares to Atlas. The proceeds from
the issue are intended to be paid in full by Atlas by way of set-off against
approximately SEK 2.50 million in Convertible Bonds, whereby Convertible Bonds
corresponding to SEK 2.50 million will be terminated. In accordance with the
Agreements, the subscription price per share in the directed issue in respect
of the accumulated conversions has been set at a weighted price of SEK 0.006,
corresponding to 100.00 per cent of the lowest daily volume weighted average
price according to Nasdaq First North Growth Market's price list for the share
in the Company during the fifteen (15) trading days preceding the respective
receipt of the conversion request in relation to the size of the respective
conversion request. After the completion of the directed issue and the
termination of the Convertible Bonds, SEK 27.00 million of the Convertible
Bonds remain and SEK 17.50 million of the Loan Facility remains. No
transaction fee remains.
The Loan Facility and the Amendment Agreement
For information on the Agreements and the subsequent addendum concerning the
Convertible Bonds and Loan Facility (subject to approval by the annual general
meeting), readers are referred to the press release dated 9 April 2024
(“AegirBio enters into a conditional agreement on a MSEK 45 loan facility with
Atlas Special Opportunities and an agreement to amend the outstanding
convertible bonds, subject to EGM approval”) and the press release dated 10
April 2025 (“Magnasense AB enters into an addendum with Atlas Special
Opportunities, LLC regarding outstanding convertible bonds of series 2023/2026
and loan facility”).. Magnasense will, as previously communicated, only inform
the market of conversions once the Threshold requiring a new share issue has
been reached.
As a result of the directed issue of shares, the share capital in Magnasense
will increase by SEK 417,083.332666 to a total of SEK 1,863,849.280293 and the
number of shares will increase by 416,666,666 to a total of 1,861,987,293,
which entails a dilution of approximately 22.38 per cent of the total number
of shares and votes in the Company after registration of the new shares with
the Swedish Companies Registration Office.
Considerations of the Board of Directors
Prior to the decision to enter into the Agreements, the Company's board of
directors, together with a financial advisor, carefully investigated the
conditions for a rights issue to raise the necessary capital. The board’s
assessment was that the Company, especially taking into account the Company's
existing capital structure, could not fulfil its’ capital requirements in any
other way than through the Agreements with Atlas. The board of directors has
together with a financial advisor assessed that a rights issue would require
significant underwriting commitments from an underwriting consortium, which
was not been deemed possible for the Company to obtain. In addition, a rights
issue would likely have been carried out at a significantly lower subscription
price than that which Atlas will be able to convert at in accordance with the
terms and conditions of the Agreements. The board of directors’ overall
assessment was thus that the reasons for entering into the Agreements and
subsequently carrying out directed issues of shares to Atlas in this way
outweigh the reasons that justify the main rule of issuing shares with
preferential rights for existing shareholders, and that new issues of shares
with deviation from the shareholders’ preferential rights in accordance with
the Agreements thus are in the interest of the Company and all shareholders.
The reason why the issue is directed to an existing shareholder is that Atlas
became a shareholder through previously completed issues of shares resolved to
fulfil the Company's obligations to Atlas under the Agreements, as well as
through the recently completed rights issue, the outcome of which was
announced by the Company on 12 May 2025.
The basis for the calculation of the subscription price has, in consultation
with a financial advisor and by analysing the Company's existing indebtedness
and several market factors, been determined through arm's length negotiations
with Atlas. It is the Board's assessment that the subscription price through
this procedure reflects current market conditions and demand and that it is
thereby market-based.
For further information, please contact:
For further information, please contact:
Marco Witteveen, CEO
E-mail: ir@magnasense.com
The Company's Certified Adviser is Eminova Fondkomission AB |
adviser@eminova.se
IMPORTANT INFORMATION
The publication, release or distribution of this press release may, in certain
jurisdictions, be restricted by law and persons in the jurisdictions where
this press release has been published or distributed should inform themselves
about and observe any such legal restrictions. The recipient of this press
release is responsible for using this press release and the information
contained herein in accordance with the applicable rules in each jurisdiction.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy or subscribe for any securities issued by the Company in any
jurisdiction, neither from the Company nor anyone else in which such offer or
solicitation would be unlawful.
This press release is not a prospectus within the meaning of Regulation (EU)
No. 2017/1129 (the “Prospectus Regulation”) and has not been approved or
reviewed by any regulatory authority in any jurisdiction. The Company has not
authorised any offer to the public of shares or rights in any member state of
the EEA and no prospectus has been or will be prepared in respect of the
directed issue. In any EEA Member State, this announcement is only addressed
to and is only directed at “qualified investors” in that Member State within
the meaning of the Prospectus Regulation.
This press release does not identify or purport to identify any risks (direct
or indirect) that may be associated with an investment in new shares. The
information contained in this press release is for the sole purpose of
describing the background to the Directed Issue and does not purport to be
complete or exhaustive.
This press release does not constitute an offer or invitation to purchase or
subscribe for securities in the United States. The securities referred to
herein may not be sold in the United States absent registration or an
applicable exemption from registration under the U.S. Securities Act of 1933,
as amended (the “Securities Act”), or the securities laws of any state or
other jurisdiction of the United States, and may not be offered or sold in the
United States absent registration or an applicable exemption from, or in a
transaction not subject to, the registration requirements of the Securities
Act. There is no intention to register any securities referred to herein in
the United States or to make a public offering of such securities in the
United States. The information in this press release may not be announced,
published, copied, reproduced or distributed, directly or indirectly, in whole
or in part, in or into Australia, Belarus, Canada, Hong Kong, Japan, New
Zealand, Russia, Singapore, South Africa, South Korea, Switzerland, the United
States or any other jurisdiction where such announcement, publication or
distribution of this information would be unlawful or where such action is
subject to legal restrictions or would require additional registration or
other measures than those required by Swedish law. Actions contrary to this
instruction may constitute a violation of applicable securities legislation.
In the United Kingdom, this document and any other materials in relation to
the securities referred to herein is only being distributed to, and is only
directed at, and any investment or investment activity to which this document
relates is available only to, and will be engaged in only with “qualified
investors” (as defined in section 86(7) of the Financial Services and Markets
Act 2000) who are (i) persons who have professional experience in matters
relating to investments and who fall within the definition of “investment
professionals” in Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities
referred to in Article 49(2)(a) to (d) of the Regulations (all such persons
together being referred to as “relevant persons”). Any investment or
investment activity to which this communication relates is available in the
United Kingdom only to relevant persons and will be engaged in only with
relevant persons. Persons who are not relevant persons should not take any
action based on this document and should not act or rely on it. This press
release does not constitute a recommendation as to any investor's decision
with respect to the directed issue. Each investor or potential investor should
conduct his or her own investigation, analysis and evaluation of the
activities and information described in this press release and any other
publicly available information. The price and value of the securities may go
down as well as up and past performance is no guide to future results.
Forward-looking statements
This press release contains forward-looking statements that reflect the
Company’s intentions, beliefs or current expectations regarding the Company’s
future results of operations, financial condition, liquidity, performance,
prospects, anticipated growth, strategies and opportunities and the markets in
which the Company operates. Forward-looking statements are statements that are
not historical facts and can be identified by the use of words such as
“believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”,
“anticipates”, “should”, “could” and, in each case, the negatives thereof, or
similar expressions. The forward-looking statements in this press release are
based on various assumptions, many of which are based on additional
assumptions. Although the Company believes that the assumptions reflected in
these forward-looking statements are reasonable, there can be no assurance
that they will materialise or that they are accurate. Because these statements
are based on assumptions or estimates and are subject to risks and
uncertainties, actual results or outcomes could differ materially from those
in the forward-looking statements for a variety of reasons. Such risks,
uncertainties, contingencies and other important factors could cause actual
events to differ materially from the expectations expressed or implied in this
press release by the forward-looking statements. The Company does not
guarantee that the assumptions underlying the forward-looking statements in
this press release are free from error and does not accept any responsibility
for the future accuracy of the opinions expressed in this press release or any
obligation to update or revise the statements in this press release to reflect
subsequent events. Readers of this press release should not place undue
reliance on the forward-looking statements contained in this press release.
The information, opinions and forward-looking statements expressed or implied
herein are made only as of the date of this press release and are subject to
change. Neither the Company nor anyone else undertake to review, update,
confirm or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this press release, except as required by law or the rules of
Nasdaq First North Growth Market.
About Magnasense AB
Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to
monitor and optimize the dosage of biological drugs via its unique patented
technology platform. In June 2020, Magnasense was listed on the Nasdaq First
North Growth Market. The company's ambition is, in addition to bringing
innovative diagnostic technology to the market, to make diagnostics more
accessible, easier to use and to provide accurate and easily transferable
results. For more information, see Magnasense's website www.magnasense.com.
This information is information that Magnasense is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2025-06-19 16:00 CEST.
Attachments
Magnasense intends to carry out a directed issue of shares to Atlas Special
Opportunities, LLC due to called on conversions totalling SEK 2.50 million
(https://storage.mfn.se/21885564-ce12-43c5-a2ee-6791b7f0c8df/magnasense-intends-to-carry-out-a-directed-issue-of-shares-to-atlas-special-opportunities-llc-due-to-called-on-conversions-totalling-sek-2-50-million.pdf)
------------------------------------------------------------------------------
news_id: ae9be02e-48e0-48f7-8b3f-3bf110d81fb7
group_id: 124a2797-e18c-440b-aeb4-37d2087c84d0
tags: []
title: Alzinovas ALZ-101 normaliserar skyddande antikroppsnivåer hos
Alzheimerpatienter
------------------------------------------------------------------------------
Alzinova meddelar nya lovande kliniska resultat för sin vaccinkandidat ALZ-101
vid behandling av Alzheimers sjukdom. En fas I-studie har visat att kandidaten
ökar nivåerna av skyddande antikroppar hos patienter till nivåer jämförbara
med friska äldre individer. BioStock kontaktade vd Tord Labuda för en
kommentar.
Läs hela artikeln på biostock.se:
https://biostock.se/2025/06/alzinovas-alz-101-normaliserar-skyddande-antikroppsnivaer-hos-alzheimerpatienter/
Detta är ett pressmeddelande från BioStock - Connecting Innovation & Capital.
https://www.biostock.se/
Följ BioStock
Läs de senaste nyheterna, håll dig uppdaterad kring kommande event, se de
senaste videoinslagen och lyssna på de senaste poddarna! Prenumerera på våra
nyhetsbrev på https://www.biostock.se/nyhetsbrev/
Följ BioStock på sociala medier LinkedIn
(https://www.linkedin.com/company/biostock/) och Facebook
(https://www.facebook.com/biostock.se%22%20/t%20%22_blank)!
Om BioStock
BioStock är den självklara knutpunkten för life science-sektorn i Norden. Med
fokus på bioteknik, medicinteknik, diagnostik och läkemedelsutveckling
erbjuder vi dagliga nyhetsuppdateringar, djupgående analyser, exklusiva
intervjuer och innovationsdrivande nätverksevent – allt för att hålla dig
uppdaterad om branschens utveckling.
BioStock – Connecting Innovation & Capital.
------------------------------------------------------------------------------
news_id: c508d563-fa58-432e-a854-e66779ee0412
group_id: 257f61b8-7b3c-49af-addc-70a37f025129
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: Offentliggörande av rekonstruktörens berättelse samt ansökan om
planförhandling för ASFT Industries AB
------------------------------------------------------------------------------
SARSYS AB meddelar att rekonstruktörens berättelse för dotterbolaget ASFT
Industries AB kommer att offentliggöras i samband med att rekonstruktionsplan
och rekonstruktörens berättelse lämnas in till tingsrätten som underlag inför
beslut om planförhandling. Inkluderad MAR stämpel
Rekonstruktörens berättelse utgör en del av den formella processen enligt
lagen om företagsrekonstruktion, och innehåller en beskrivning av
dotterbolagets ekonomiska situation samt förutsättningarna för en lyckad
rekonstruktion.
Finansiell information
I rekonstruktörens berättelse framgår följande:
* SARSYS AB (moderbolaget) prognostiserar ett negativt resultat för helåret
2025 om cirka -400 000 SEK.
* ASFT Industries AB (dotterbolaget) prognostiserar ett negativt resultat för
helåret 2025 om cirka -550 000 SEK.
Prognoserna inkluderar inte effekten som den föreslagna skuldnedskrivningen
har på Moderbolagets och Bolagets resultat.
* Ackumulerad förlust i ASFT Industries AB uppgår till cirka -3 700 000 SEK
för perioden januari–april 2025.
Bolaget vill betona att detta offentliggörande inte innebär att koncernen
kommer att börja lämna finansiella prognoser som en del av sin löpande
informationsgivning. Uppgifterna lämnas uteslutande med anledning av att de
enligt lag ska ingå i rekonstruktörens berättelse, som nu blir en offentlig
handling i och med inlämningen till tingsrätten.
Balansräkning per 30 april 2025
Rekonstruktörens berättelse innehåller även en översikt över bolagets
tillgångar och skulder per den 30 april 2025. Balansräkningen sammanfattas
enligt följande (avrundade belopp, Mkr):
+-------------------------+------------+------------------------+------------+
| Tillgångar | Belopp | Skulder | Belopp |
+-------------------------+------------+------------------------+------------+
| Anläggningstillgångar | 10,8 Mkr | Långfristiga skulder | 10,5 Mkr |
+-------------------------+------------+------------------------+------------+
| Omsättningstillgångar | 13,5 Mkr | Kortfristiga skulder | 26,1 Mkr |
+-------------------------+------------+------------------------+------------+
| Summa tillgångar | 24,3 Mkr | Summa skulder | 36,6 Mkr |
+-------------------------+------------+------------------------+------------+
Det negativa egna kapitalet speglar de utmaningar som bolaget fortsatt arbetar
med inom ramen för företagsrekonstruktionen.
Nästa steg i rekonstruktionsprocessen
Tingsrätten har tidigare beslutat att rekonstruktionen av ASFT Industries AB
får fortgå till och med den 15 september 2025. Inlämningen av rekonstruktörens
berättelse och rekonstruktionsplan markerar ett viktigt steg i processen med
att säkra en långsiktig lösning för bolaget.
Köpingebro 2025-06-19
Mirel Bikic, VD
Kontakter
För mer information kontakta VD Mirel Bikic på telefon +46 (0) 73 543 16 78
alternativt e-mail mbi@sarsys-asft.com eller investor ansvarig Stefan
Nordström på telefon +46 (0) 70 560 44 50 eller
email stefan.nordstrom@nordstrominvest.se
Om oss
SARSYS AB är det ledande bolaget i världen inom utveckling och tillverkning av
flygplats- och vägsäkerhetssystem. Bolaget har tre affärsområden,
friktionsmätning, väderinformation och beslutsstödsystem. Bolaget har kunder i
alla världsdelar och återfinns bland offentliga och privata flygplatser och
vägar, flygvapen i olika länder, servicebolag för underhåll av vägar och
flygplatser. Moderbolaget har sitt huvudkontor i Köpingebro och är listat på
Nordic SME sedan 2017. I gruppen finns även dotterbolagen ASFT Industries AB
och SARSYS-ASFT Inc, USA. Mer information finns på www.sarsys-asft.com
(http://www.sarsys-asft.com/) och www.ngm.se (http://www.ngm.se/)
Denna information är sådan information som SARSYS är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersoners försorg, för offentliggörande den
2025-06-19 14:52 CEST.
Bifogade filer
Offentliggörande av rekonstruktörens berättelse samt ansökan om
planförhandling för ASFT Industries AB
(https://storage.mfn.se/2f1ce5d7-2d88-4f3f-9f90-6bbea8e622a1/offentliggorande-av-rekonstruktorens-berattelse-samt-ansokan-om-planforhandling-for-asft-industries-ab.pdf)
------------------------------------------------------------------------------
news_id: 23636b0e-f773-4475-9d01-c326c8dfb45e
group_id: bae2aa63-b858-45f4-a510-6c12d781794a
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Offentliggörande av rekonstruktörens berättelse samt ansökan om
planförhandling för ASFT Industries AB
------------------------------------------------------------------------------
SARSYS AB meddelar att rekonstruktörens berättelse för dotterbolaget ASFT
Industries AB kommer att offentliggöras i samband med att rekonstruktionsplan
och rekonstruktörens berättelse lämnas in till tingsrätten som underlag inför
beslut om planförhandling.
Rekonstruktörens berättelse utgör en del av den formella processen enligt
lagen om företagsrekonstruktion, och innehåller en beskrivning av
dotterbolagets ekonomiska situation samt förutsättningarna för en lyckad
rekonstruktion.
Finansiell information
I rekonstruktörens berättelse framgår följande:
* SARSYS AB (moderbolaget) prognostiserar ett negativt resultat för helåret
2025 om cirka -400 000 SEK.
* ASFT Industries AB (dotterbolaget) prognostiserar ett negativt resultat för
helåret 2025 om cirka -550 000 SEK.
Prognoserna inkluderar inte effekten som den föreslagna skuldnedskrivningen
har på Moderbolagets och Bolagets resultat.
* Ackumulerad förlust i ASFT Industries AB uppgår till cirka -3 700 000 SEK
för perioden januari–april 2025.
Bolaget vill betona att detta offentliggörande inte innebär att koncernen
kommer att börja lämna finansiella prognoser som en del av sin löpande
informationsgivning. Uppgifterna lämnas uteslutande med anledning av att de
enligt lag ska ingå i rekonstruktörens berättelse, som nu blir en offentlig
handling i och med inlämningen till tingsrätten.
Balansräkning per 30 april 2025
Rekonstruktörens berättelse innehåller även en översikt över bolagets
tillgångar och skulder per den 30 april 2025. Balansräkningen sammanfattas
enligt följande (avrundade belopp, Mkr):
+-------------------------+------------+------------------------+------------+
| Tillgångar | Belopp | Skulder | Belopp |
+-------------------------+------------+------------------------+------------+
| Anläggningstillgångar | 10,8 Mkr | Långfristiga skulder | 10,5 Mkr |
+-------------------------+------------+------------------------+------------+
| Omsättningstillgångar | 13,5 Mkr | Kortfristiga skulder | 26,1 Mkr |
+-------------------------+------------+------------------------+------------+
| Summa tillgångar | 24,3 Mkr | Summa skulder | 36,6 Mkr |
+-------------------------+------------+------------------------+------------+
Det negativa egna kapitalet speglar de utmaningar som bolaget fortsatt arbetar
med inom ramen för företagsrekonstruktionen.
Nästa steg i rekonstruktionsprocessen
Tingsrätten har tidigare beslutat att rekonstruktionen av ASFT Industries AB
får fortgå till och med den 15 september 2025. Inlämningen av rekonstruktörens
berättelse och rekonstruktionsplan markerar ett viktigt steg i processen med
att säkra en långsiktig lösning för bolaget.
Köpingebro 2025-06-19
Mirel Bikic, VD
Kontakter
För mer information kontakta VD Mirel Bikic på telefon +46 (0) 73 543 16 78
alternativt e-mail mbi@sarsys-asft.com eller investor ansvarig Stefan
Nordström på telefon +46 (0) 70 560 44 50 eller
email stefan.nordstrom@nordstrominvest.se
Om oss
SARSYS AB är det ledande bolaget i världen inom utveckling och tillverkning av
flygplats- och vägsäkerhetssystem. Bolaget har tre affärsområden,
friktionsmätning, väderinformation och beslutsstödsystem. Bolaget har kunder i
alla världsdelar och återfinns bland offentliga och privata flygplatser och
vägar, flygvapen i olika länder, servicebolag för underhåll av vägar och
flygplatser. Moderbolaget har sitt huvudkontor i Köpingebro och är listat på
Nordic SME sedan 2017. I gruppen finns även dotterbolagen ASFT Industries AB
och SARSYS-ASFT Inc, USA. Mer information finns på www.sarsys-asft.com
(http://www.sarsys-asft.com/) och www.ngm.se (http://www.ngm.se/)
Bifogade filer
Offentliggörande av rekonstruktörens berättelse samt ansökan om
planförhandling för ASFT Industries AB
(https://storage.mfn.se/2d5b72a3-b124-4597-854d-7f44659cd1ec/offentliggorande-av-rekonstruktorens-berattelse-samt-ansokan-om-planforhandling-for-asft-industries-ab.pdf)
------------------------------------------------------------------------------
news_id: 32e9af59-d04f-4cff-bad2-977446a58c7c
group_id: 3055d7fc-f6db-49a0-82fc-5857580c87c8
tags: [:regulatory], [:regulatory:listing], [sub:ci], [sub:ci:staff]
title: Magnus Jägre lämnar sin roll som hållbarhets- och innovationschef på
Studentbostäder i Norden AB (publ)
------------------------------------------------------------------------------
I samband med detta har Studentbostäder i Norden AB (publ) ("SBS") beslutat
att istället omstrukturera ansvaret inom ledningsgruppen.
– Vi vill tacka Magnus för hans värdefulla insatser och engagemang under sin
tid på Studentbostäder i Norden. Han har spelat en viktig roll i bolagets
utveckling och vi önskar honom all framgång i framtiden, säger Rebecka
Eidenert, VD på Studentbostäder i Norden.
För ytterligare information kontakta:
------------------------------------------------------------------------------
Rebecka Eidenert, VD Studentbostäder i Norden
+46-70 786 54 54, rebecka.eidenert@sbsstudent.se
Om Studentbostäder i Norden (SBS)
------------------------------------------------------------------------------
SBS äger, förvaltar och utvecklar studentbostäder i långsiktiga partnerskap
med kommuner, regioner och högskolor. Vi erbjuder prisvärda studentboenden av
hög kvalitet och en helt digitaliserad hyreshantering. Vår ambition är att bli
Nordens ledande studentbostadsbolag och det givna valet för studenter på väg
mot sitt drömyrke.
Certified Adviser
------------------------------------------------------------------------------
FNCA Sweden AB är bolagets Certified Adviser
Bifogade filer
------------------------------------------------------------------------------
Magnus Jägre lämnar sin roll som hållbarhets- och innovationschef på
Studentbostäder i Norden AB (publ)
(https://storage.mfn.se/f2d3adc5-102c-4e35-9d12-7fb0128abe6f/magnus-jagre-lamnar-sin-roll-som-hallbarhets-och-innovationschef-pa-studentbostader-i-norden-ab-publ.pdf)
------------------------------------------------------------------------------
news_id: 4092673f-4f96-4446-bd05-ae2f6a4b7892
group_id: e916b11c-0185-4938-b9d8-7ee49a5181f3
tags: [:regulatory], [:regulatory:listing], [sub:ci], [sub:ci:staff]
title: New Chief Commercial Officer at AVTECH Sweden AB (publ)
------------------------------------------------------------------------------
AVTECH strengthens its leadership team with the appointment of Christian
Sandén as new Chief Commercial Officer (CCO)
On August 18, Christian Sandén will join AVTECH as the new Chief Commercial
Officer (CCO). He succeeds Lars Wernblom, who has held the role on an interim
basis since February 2024.
During his time as interim sales and marketing director, Lars Wernblom has
implemented significant and positive changes in the sales organisation,
strengthening its structure, performance, and team delivery. His efforts have
laid a solid foundation and momentum for the next phase of AVTECH’s commercial
development.
Christian brings over 20 years of experience in sales, marketing, and
commercial leadership across both established and fast-growing SaaS companies.
Most recently, he served as CCO at Braathens Regional Airways, and previously
held senior roles in sales and go-to-market strategy at Telia, Sekoia, and
Matilda Foodtech.
In his new position, Christian will take over leadership of AVTECH’s teams
across sales, marketing, customer success, and commercial strategy. He will be
a member of the executive leadership team.
”We are thrilled to welcome Christian Sandén to AVTECH as our new Chief
Commercial Officer and executive team member. He brings valuable expertise and
experience that will be critical to our continued growth journey and to
meeting the high expectations of our customers and the market”, said David
Rytter, CEO of AVTECH.
AVTECH is in a dynamic and exciting phase of growth. This appointment is a
strategic step aligned with the company’s ambition to further strengthen its
commercial organization, gain additional market share, and enhance its
competitive positioning. With recent additions to its executive leadership
team, AVTECH is boosting its strategic capacity, scalability, and ability to
meet growing market demand and take the next leap in its growth journey.
Pressreleases are available at:
------------------------------------------------------------------------------
https://www.avtech.aero/press-release-english
For more information, please contact
------------------------------------------------------------------------------
David Rytter, CEO, +46 (0) 8 544 104 80
About AVTECH Sweden AB (publ)
------------------------------------------------------------------------------
AVTECH develops products and services for digital air traffic control systems.
Customers are the aviation industry's various players such as airlines,
airports, aviation, technology companies and aircraft manufacturers. With the
help of the company's products and services, each individual flight or the
entire flight operation can be optimized in terms of economy, noise and
emissions, efficiency, punctuality and safety. The head office is in
Stockholm. AVTECH Sweden AB (publ) is listed on NASDAQ First North Growth
Market and has appointed Redeye AB to certified adviser.
Attachments
------------------------------------------------------------------------------
New Chief Commercial Officer at AVTECH Sweden AB (publ)
(https://storage.mfn.se/fa0fea4c-ae16-4e9d-8eb6-ab5905ff8332/new-chief-commercial-officer-at-avtech-sweden-ab-publ.pdf)
------------------------------------------------------------------------------
news_id: 2a69017c-49c6-436f-89fe-1fa818587897
group_id: e916b11c-0185-4938-b9d8-7ee49a5181f3
tags: [:regulatory], [:regulatory:listing], [sub:ci], [sub:ci:staff]
title: Ny Chief Commercial Officer på AVTECH Sweden AB (publ)
------------------------------------------------------------------------------
AVTECH stärker ledningsgruppen genom att utnämna Christian Sandén till ny
kommersiell chef (CCO)
Den 18 augusti tillträder Christian Sandén som ny Chief Commercial Officer
(CCO) på AVTECH. Han efterträder Lars Wernblom som har haft rollen interimt
sedan februari 2024.
Under sin tid som interim sälj- och marknadschef har Lars Wernblom genomfört
betydande positiva förändringar i försäljningsorganisationen, vilket har
stärkt både struktur, resultat och teamets leveransförmåga. Hans insatser har
skapat en stabil grund och momentum för nästa steg i AVTECHs kommersiella
utveckling.
Christian har över 20 års erfarenhet av försäljning, marknadsföring och
kommersiellt ledarskap inom både etablerade och snabbväxande SaaS-företag.
Närmast kommer han från rollen som CCO på Braathens Regional Airways, och har
tidigare haft ledande befattningar inom försäljning och go-to-market på Telia,
Sekoia och Matilda Foodtech.
I sin nya roll tar Christian över ledarskapet för AVTECHs team inom
försäljning, marknadsföring, kundrelationer och kommersiell strategi. Han tar
plats i bolagets ledningsgrupp.
"Vi är mycket glada över att välkomna Christian Sandén till AVTECH som vår nya
kommersiella chef och medlem i ledningsgruppen. Han tillför värdefull
kompetens och erfarenhet som kommer att vara avgörande för vår fortsatta
tillväxtresa och för att möta våra kunders och marknadens högt ställda
förväntningar", säger David Rytter, VD på AVTECH.
AVTECH befinner sig i en dynamisk och spännande tillväxtfas. Denna rekrytering
är ett strategiskt steg i linje med bolagets ambition att ytterligare stärka
den kommersiella organisationen, ta större marknadsandelar och stärka sin
position på marknaden. Med de senaste tillskotten till ledningsgruppen ökar
AVTECH sin strategiska kapacitet, skalbarhet och förmåga att möta den ökande
efterfrågan och ta nästa språng i bolagets utvecklingsresa.
Pressmeddelanden finns tillgängliga på:
------------------------------------------------------------------------------
https://www.avtech.aero/press-release-swedish
För mer information, vänligen kontakta
------------------------------------------------------------------------------
David Rytter, VD, +46 (0) 8 544 104 80
Om AVTECH Sweden AB (publ)
------------------------------------------------------------------------------
AVTECH utvecklar produkter och tjänster för digitala flygtrafikledningssystem.
Kunder är den globala flygindustrins olika aktörer såsom flygbolag,
flygplatser, luftfartsverk, teknikföretag och flygplanstillverkare. Med hjälp
av bolagets produkter och tjänster kan varje enskild flygning eller hela
flygoperationen optimeras vad gäller ekonomi, buller och utsläpp,
effektivitet, punktlighet och säkerhet. Huvudkontoret ligger i Stockholm.
AVTECH Sweden AB (publ) är listat på NASDAQ First North Growth Market och har
utsett Redeye AB till bolagets Certified Adviser.
Bifogade filer
------------------------------------------------------------------------------
Ny Chief Commercial Officer på AVTECH Sweden AB (publ)
(https://storage.mfn.se/57292a40-0255-4bb4-ad21-524a7527f0e4/ny-chief-commercial-officer-pa-avtech-sweden-ab-publ.pdf)
------------------------------------------------------------------------------
news_id: 1ee5b802-f07f-4e8f-8dd3-beb6f56cddb9
group_id: 7284adb9-21d0-4c36-8f15-b14258a1d062
tags: [:regulatory], [:regulatory:listing], [sub:ci], [sub:ci:insider]
title: Witted Megacorp Oyj: Johdon liiketoimet - Harri Sieppi
------------------------------------------------------------------------------
Witted Megacorp Oyj | Yhtiötiedote | 19.06.2025 klo 15:00:00 EEST
Witted Megacorp Oyj - Johdon liiketoimet
____________________________________________
Ilmoitusvelvollinen
Nimi: Harri Sieppi
Asema: Toimitusjohtaja
Liikkeeseenlaskija: Witted Megacorp Oyj
LEI: 743700F9XG4MLT2YH467
Ilmoituksen luonne: ENSIMMÄINEN ILMOITUS
Viitenumero: 44720/4/4
____________________________________________
Liiketoimen päivämäärä: 2025-06-17
Kauppapaikka ei sovellu
Instrumenttityyppi: OSAKE
ISIN: FI4000517461
Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINEN
Liiketoimien yksityiskohtaiset tiedot
(1): Volyymi: 908 Yksikköhinta: 0 EUR
Liiketoimien yhdistetyt tiedot (1):
Volyymi: 908 Keskihinta: 0 EUR
------------------------------------------------------------------------------
news_id: b5c214fc-129d-424c-9bd8-18c0d6c7cc7e
group_id: fdfa4940-f92d-4bc4-805b-dd47c1545f45
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Exercise of Warrants of Series TO 2023/2025:2 Provides Intellego
Technologies AB (publ) with Approximately SEK 14.5 Million
------------------------------------------------------------------------------
Intellego Technologies AB (publ) (“Intellego” or the “Company”) today
announces the outcome of the exercise of warrants of series TO 2023/2025:2
(the “Warrants”), which were issued in July 2023. The warrants of series TO
2023/2025:2 were issued to an international institutional investor. All
322,581 warrants of series TO 2023/2025:2 have been exercised, resulting in
the subscription of 322,581 shares. Each warrant of series TO 2023/2025:2
entitled the holder to subscribe for one new share in the Company at a price
of SEK 45 per share. Through the exercise of the Warrants, Intellego receives
approximately SEK 14.5 million before issuing costs.
Background
As of July 19, 2023, the Board of Directors, with the support of the
authorization from the Annual General Meeting 2023, decided to carry out a
directed issue of units (shares and warrants of series TO 2023/2025:2) to an
international institutional investor. A total of 322,581 warrants of the
aforementioned series were issued. Each warrant entitled the holder to
subscribe for one (1) share at a price of SEK 45 per share during the period
from June 16, 2025, to June 27, 2025. All warrants of series TO 2023/2025:2
have been exercised for the subscription of a total of 322,581 shares in
Intellego. Through the exercise of the Warrants of series TO 2023/2025:2,
Intellego receives approximately SEK 14.5 million before issuing costs. The
original press release regarding the issuance of warrants of series TO
2023/2025:2 is available by clicking here
(https://mfn.se/a/intellego/intellego-genomfor-en-riktad-nyemission-av-aktier-och-teckningsoptioner-om-cirka-20-msek-till-teckningskurs-31-sek-per-aktie-till-en-strategisk-internationell-institutionell-investerare).
Number of shares, share capital and dilution
Through the exercise of the Warrants the number of shares in Intellego
increases by a total of 322,581 shares, from 30,417,814 shares to 30,740,395
shares and the share capital increases by approximately SEK 11,520.75, from
approximately SEK 1,086,350.51 to approximately SEK 1,097,871.26. The exercise
of the Warrants entails a dilution of approximately 1.05 percent of the total
number of shares and votes.
Contacts
------------------------------------------------------------------------------
For further information, please contact:
Claes Lindahl, CEO Intellego Technologies AB
E-mail: claes.lindahl@intellego-technologies.com
Phone: +46 735 344 634
About Us
------------------------------------------------------------------------------
Intellego Technologies develops and manufactures color indicators that show
the effect of irradiation with, among other things, invisible ultraviolet
light, UV light. Color indicators are used globally in, for example, the
disinfection industry, the sunscreen industry, and the manufacturing industry.
Intellego's indicators have been developed from the company's patented
photochromic ink, which can be adapted to different wavelengths of light and
various application areas across a range of different industries. Intellego
Technologies was founded in 2011, is headquartered in Stockholm, and is listed
on the Nasdaq First North Growth Market.
The company's Certified Adviser on the Nasdaq First North Growth Market
Stockholm is Mangold Fondkommission AB.
Intellego's website: https://intellego-technologies.com/en/
Subscribe to Intellego's press releases:
https://intellego-technologies.com/sv/pressmeddelanden/
Contact the communications team: communications@intellego-technologies.com
Attachments
------------------------------------------------------------------------------
Exercise of Warrants of Series TO 2023/2025:2 Provides Intellego Technologies
AB (publ) with Approximately SEK 14.5 Million
(https://storage.mfn.se/028128d8-e36d-4fd6-96ef-ad1a4d2bc877/exercise-of-warrants-of-series-to-2023-2025-2-provides-intellego-technologies-ab-publ-with-approximately-sek-14-5-million.pdf)
------------------------------------------------------------------------------
news_id: c3d9f746-d858-401f-b70b-725610336b9c
group_id: 9aab35e3-7abf-4655-9b9f-75a2a3bdd383
tags: []
title: Biovica - Adding cash and increased market distribution
------------------------------------------------------------------------------
Biovica continues to increase 12m rolling IVD test sales in Q4 of SEK 0.93m
(314% rolling 12m) and total sales of SEK 2.3m after adding ROU sales (test
and services). Biovica is also progressing with a guaranteed rights issue at
SEK 80m (gross) and advancing the sales outlook based on Tempus AI in the
Oncology segment, with a major partner in the IDN segment.
Read more and download the Research Update.
(https://www.redeye.se/research/1116016/biovica-adding-cash-and-increased-market-distribution?utm_source=MFN&utm_medium=pmcour)
Follow companies at Redeye to receive the latest equity research within Life
Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.
www.redeye.se/
Attachments
------------------------------------------------------------------------------
Biovica - Adding cash and increased market distribution
(https://storage.mfn.se/7192b271-90e9-4679-bd86-24f953cbaeef/biovica-adding-cash-and-increased-market-distribution.pdf)
------------------------------------------------------------------------------
news_id: 88ad2f47-2f3e-4e80-b6a3-20dafbe338ca
group_id: 4f11bec1-43b2-4e19-97b8-63afa171db08
tags: [:regulatory], [:regulatory:listing], [ext:nq], [ext:nq:listing],
[sub:ci], [sub:ci:other]
title: Diagonal Bio receives SEK 3.6 million through exercise of warrants of
series TO 2
------------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG,
JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN
ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF
THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER
MEASURES.
On 18 June 2025, the exercise period for Diagonal Bio AB's ("Diagonal Bio" or
"the Company") warrants of series TO 2 ("TO 2") ended. In total, 214,714,152
warrants of series TO 2 were exercised for subscription of new shares,
corresponding to approximately SEK 2.1 million, meaning an exercise rate of
approximately 59.3 percent. The underwriting commitments will thus be executed
with approximately SEK 1.5 million, corresponding to approximately 40.7
percent of the total number of TO 2. Thus, the TO 2 were exercised to 100
percent, meaning that Diagonal Bio will receive approximately SEK 3.6 million
before transaction related costs. In order to execute the underwriting
commitments, the Board of Directors of Diagonal Bio will thus resolve on a
directed issue of shares to the underwriters, covering both the executed
underwriting commitments and the compensation to the underwriters, such
resolution will be announced in a separate press release.
“The warrant exercise provides Diagonal Bio with the capital required to move
forward as planned. We appreciate the continued support from our shareholders
and view this as a solid step in ensuring we can deliver on our strategic
priorities.” - Karin Wehlin, CEO of Diagonal Bio AB (publ)
In January/February 2025, Diagonal Bio carried out a rights issue of units and
a directed issue of units. Each unit issued in the rights issue and the
directed issue, as well as in a directed issue to underwriters in the rights
issue, consisted of eighteen (18) shares and eight (8) warrants of series TO
2. Through the rights issue, the directed issue and the directed issue to the
underwriters in the rights issue combined, a total of 361,889,384 TO 2 were
issued. Each TO 2 entitled to subscription of one new share in Diagonal Bio to
an exercise price of SEK 0.01 during the exercise period which took place from
4 June 2025 until and including 18 June 2025.
In total, 214,714,152 TO 2 were exercised for subscription of new shares,
corresponding to approximately SEK 2.1 million, meaning an exercise rate of
approximately 59.3 percent. The underwriting commitments will thus be executed
with approximately SEK 1.5 million, corresponding to approximately 40.7
percent of the total number of TO 2. Thus, in total the TO 2 were exercised to
100 percent, meaning that Diagonal Bio will receive approximately SEK 3.6
million before transaction related costs.
Svea Bank AB’s exercise of TO 2 results in that Svea Bank AB exceeds 10
percent of the shares and votes in the Company. Thus, Svea Bank AB will
initially be allocated shares so that their shareholding reaches 9.99 percent,
and settlement for the remainder of their allocation will take place following
the investment being approved or left without action by the Inspectorate of
Strategic Products (Sw. Inspektionen för strategiska produkter, ”ISP”) as the
Company’s business is considered worthy of protection under the Act (2023:560)
on the Screening of Foreign Direct Investments (Sw. lag (2023:560) om
granskning av utländska direktinvesteringar, the “FDI Act”).
Through the exercise of TO 2, the number of shares in Diagonal Bio will have
increased by 214,714,152 shares to a total of 1,429,679,479 shares and the
share capital will have increased by approximately SEK 734,777.37 to
approximately SEK 4,892,533.26. The dilution amounts to approximately 15
percent of the capital and votes.
Execution of underwriting commitments
In accordance with what was communicated by the Company on 16 May 2025,
underwriting commitments of approximately SEK 3.5 million have been entered
into to secure subscription of the TO 2. As the exercise rate amounted to
approximately 59.3 percent, the underwriting commitments entered into by the
Company will be executed with approximately SEK 1.5 million, corresponding to
approximately 40.7 percent of the total number of TO 2. The Board of Directors
will thus, based on the authorisation from the annual general meeting on 20
May 2025, resolve on a directed issue of 147,175,232 shares to the two
underwriters, Sebastian Clausin and Jens Olsson. In addition to this, the
underwriters will receive a compensation of 18 percent in the form of shares
for their respective underwriting commitments. A total of 62,467,306 shares
are intended to be issued as underwriting compensation. The total number of
shares issued in connection with the underwriting commitments thus amounts to
209,642,538. The subscription price in the directed issue will be SEK 0.01 per
share, which corresponds to the exercise price for TO 2. The resolution of the
directed issue will be announced in a separate press release at a later date.
For existing shareholders who have not exercised any warrants and are not
participating in the directed issue, the total dilution will amount to
approximately 25.9 percent based on the number of shares in the Company after
the exercise of TO 2 and the directed issue. The total number of shares in the
Company after the exercise of TO 2 and the directed issue amounts to
1,639,322,017 and the share capital amounts to approximately SEK 5,609,954.97.
Advisors
Navia Corporate Finance AB is the financial advisor in connection with the
exercise of warrants of series TO 2. Setterwalls Advokatbyrå AB is the legal
advisor to Diagonal Bio and Aqurat Fondkommission AB is the issuing agent.
For additional information about warrants of series TO 2, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company
with headquarters and offices in Lund. The Company develops the PANVIRAL®
platform to detect and diagnose small sections of pathogen genomes, for
example viruses, bacteria and fungi. The Company was founded with the goal of
reducing human suffering by revolutionising global diagnostics of
pathogen-borne diseases with proprietary technology. Diagonal Bio's patented
technology can also be used for the less regulated market segments via
LAMPlify®.
Important information
The information in this press release does not contain or constitute an offer
to acquire, subscribe or otherwise trade in shares, warrants or other
securities in Diagonal Bio. No action has been taken and measures will not be
taken to permit a public offering in any jurisdictions other than Sweden. Any
invitation to the persons concerned to subscribe for units in Diagonal Bio
will only be made through the memorandum that the Company published on 22
January 2025 on Diagonal Bio’s website www.diagonalbio.com. The memorandum
does not constitute a prospectus as defined in the provisions of Prospectus
Regulation (EU) 2017/1129 of the European Parliament and of the Council
(“Prospectus Regulation”) and has not been reviewed, registered or approved by
the Swedish Financial Supervisory Authority. The offering in the memorandum
was exempt from the prospectus obligation in accordance with Article 3 (2) of
the Prospectus Regulation and Chapter 2, Section 1 of the EU Prospectus
Regulation (Supplemental Provisions) Act (2019:414) due to the fact that the
amount offered by the Company to the public was less than EUR 2.5 million.
This release is not a prospectus in accordance with the definition in the
Prospectus Regulation and, accordingly, does not identify or suggest, or
purport to identify or suggest, the risks (direct or indirect) that may be
associated with an investment in shares, warrants or other securities in
Diagonal Bio. In order for investors to fully understand the potential risks
and benefits associated with a decision to participate in the TO 2, any
investment decision should only be made based on the information in the
memorandum. Thus, investors are encouraged to review the memorandum in its
entirety.
The information in this press release may not be released, distributed or
published, directly or indirectly, in or into the United States, Australia,
Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South
Africa, South Korea, Switzerland or any other jurisdiction in which such
action would be unlawful or would require registration or any other measures
than those required by Swedish law. Actions in violation of these restrictions
may constitute a violation of applicable securities laws. No shares, warrants
or other securities in Diagonal Bio have been registered, and no shares,
warrants or other securities will be registered, under the United States
Securities Act of 1933, as amended (the “Securities Act”) or the securities
legislation of any state or other jurisdiction in the United States of America
and no shares, warrants or other securities may be offered, sold or otherwise
transferred, directly or indirectly, in or into the United States, except
under an available exemption from, or in a transaction not subject to, the
registration requirements under the Securities Act and in compliance with the
securities legislation in the relevant state or any other jurisdiction of the
United States.
Within the European Economic Area (“EEA”), no public offering of shares,
warrants or other securities (“Securities”) is made in other countries than
Sweden. In other member states of the European Union (“EU”), such an offering
of Securities may only be made in accordance with the Prospectus Regulation.
In other member states of the EEA which have implemented the Prospectus
Regulation in its national legislation, any offer of Securities may only be
made in accordance with an applicable exemption in the Prospectus Regulation
and/or in accordance with an applicable exemption under a relevant national
implementation measure. In other member states of the EEA which have not
implemented the Prospectus Regulation in its national legislation, any offer
of Securities may only be made in accordance with an applicable exemption
under national law.
In the United Kingdom, this document and any other materials in relation to
the securities described herein is only being distributed to, and is only
directed at, and any investment or investment activity to which this document
relates is available only to, and will be engaged in only with, “qualified
investors” (within the meaning of the United Kingdom version of the EU
Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by
virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having
professional experience in matters relating to investments who fall within the
definition of “investment professionals” in Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”);
(ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of
the Order; or (iii) such other persons to whom such investment or investment
activity may lawfully be made available under the Order (all such persons
together being referred to as “relevant persons”). In the United Kingdom, any
investment or investment activity to which this communication relates is
available only to, and will be engaged in only with, relevant persons. Persons
who are not relevant persons should not take any action on the basis of this
press release and should not act or rely on it.
This press release may contain forward-looking statements which reflect the
Company’s current view on future events and financial and operational
development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”,
“plan”, “estimate” and other expressions which imply indications or
predictions of future development or trends, and which are not based on
historical facts, are intended to identify forward-looking statements.
Forward-looking statements inherently involve both known and unknown risks and
uncertainties as they depend on future events and circumstances.
Forward-looking statements do not guarantee future results or development and
the actual outcome could differ materially from the forward-looking
statements.
Since Diagonal Bio conducts essential services according to the FDI-act
certain investments in the TO 2 may require review by the ISP. More
information about this is available on Diagonal Bio’s website,
www.diagonalbio.com (http://www.diagonalbio.com/).
Attachments
Diagonal Bio receives SEK 3.6 million through exercise of warrants of series
TO 2
(https://storage.mfn.se/9885838f-40e2-448d-8997-70e7c097f63f/diagonal-bio-receives-sek-3-6-million-through-exercise-of-warrants-of-series-to-2.pdf)
------------------------------------------------------------------------------
news_id: ba8b6752-9b2f-4296-b83d-c66200bac8f1
group_id: 3823835d-6f76-4e5f-9a86-812461ee22e7
tags: [sub:ci], [sub:ci:other]
title: Q-linea on track for 2025 plan
------------------------------------------------------------------------------
Q-linea AB (publ) (OMX: QLINEA) today shared a Company and Market update.
Key messages
* Q2 instrument placements: Five newly-contracted units were placed, bringing
the total to 14 YTD (2024: 4, Q1 2025: 5, Q2 2025 to date: 5)
* On track to achieve 30–40 ASTar placements by end-2025; targeting an
additional 60–90 placements in 2026
* Commercial evaluations expanding across EMEA (France, Austria, Slovenia,
UAE, Saudi Arabia) and US
* Five major US institutions to present ASTar-related posters at ASM (American
Society for Microbiology) 2025, including Quest, Baylor Scott & White,
Memorial Sloan Kettering Cancer Center, PennState University and George
Washington University
* Capital raise successfully closed in May with >90% participation, netting
approx. 250 MSEK post-transaction costs
Italy | Crossing the Chasm
Italy continues to lead in adoption with three new hospital contracts and five
ASTar placements in Q2. This includes a tender win at Policlinico di Milano, a
leading medical facility in Lombardia. Our attention is now turning to
supporting the adoption into routine use across an increasingly robust
installed base. A key milestone is expected in July 2025 with a decision on
the Tuscan ESTAR tender (covering nine labs), which could elevate total
routine rapid AST sites in Italy to 20 – 25, approaching the 10 – 15 per cent
penetration point that typically precedes mass-market adoption.
Notably, Q-linea signed its first "direct-to-validation" contract, bypassing
an in-lab evaluation—an indicator of growing trust in the brand and underlying
technology. Early deployment feedback is robust, with sites reporting
measurable clinical and operational value. ASTar is establishing leadership in
Italy, being especially well-suited for the main microbiology testing hubs.
US | Customers are getting hands-on with ASTar
The quarter has been busy for the team with five new commercial evaluations
initiated and two evaluations completed. We now have five active contracting
processes ongoing following successful evaluations, several of which have
multi-site and/or multi-ASTar dimensions. Deployment preparations continue
with our large national reference laboratory customer with prioritization of
six systems to begin using ASTar.
External pilot initiatives are exploring the use of ASTar in gram-negative
isolate testing for research purposes with encouraging early results.
Global | Expanding commercial reach
Active and planned evaluation processes have begun in France, Austria,
Slovenia, UAE, and Saudi Arabia. Agile commercial models are being explored in
our expansion markets to enable faster market entry with minimal internal
overhead.
Responding to strong interest from customers and partners at ESCMID (European
Society of Clinical Microbiology and Infectious Diseases) in April, we have
initiated conversations on bringing ASTar to India and other markets in Asia.
I was also able to listen to hospital and lab managers in Canada during the
CACMID (Canadian Association for Clinical Microbiology and Infectious
Diseases) conference in Calgary. These markets have longer lead times, but it
is noteworthy that Q-linea is being approached by experienced players with a
keen interest to support local market access and distribution activities.
Competitive landscape | Market differentiation is emerging
Q-linea is benefiting from rising interest in rapid AST, as are other players.
In addition to 14 contracted ASTar units globally, GradienTech has up to six
instruments in routine clinical use in Europe and BioMérieux recently
announced its first US commercial contract for the REVEAL rapid AST system.
Customer criteria for platform selection are solidifying and ASTar is uniquely
well-placed to serve the market across a range of workflow, clinical
performance and economic attributes. Conversely, technologies that were
designed against alternative customer needs are experiencing challenges. Our
team reports that the Accelerate Pheno and Selux NGP platforms are in
commercial pause to regroup, the former under Chapter 11 in the US.
In parallel, several announcements of grants or capital raises for investment
in future rapid AST solutions underscore the belief in the potential of a
market estimated at SEK 6 – 9 billion. We anticipate the market will continue
to focus down on the platforms and technologies that best meet the complex
needs of the modern microbiology laboratory.
Clinical evidence | ASTar users are speaking for themselves
We are proud that seven posters at the US ASM Microbe 2025 conference this
month will feature ASTar. Five of these are published by ASTar users in the
US, including Quest Diagnostics, a leading national reference laboratory,
Memorial Sloan Kettering Cancer Center in New York, Baylor Scott & White, a
50+ hospital IDN (Integrated Delivery Network) based in Texas, and leading
east coast academic medical centres Pennsylvania State University and George
Washington University. This is an unprecedented body of independent research
in rapid AST.
Additional LIFETIMES study data presented by the Q-linea scientific team will
show time-to-optimised-therapy 1.3 days (>30 hours) faster than current
standard of care. Previous studies have demonstrated that ASTar delivers
actionable results 34 – 40 hours sooner than standard of care and the new data
confirm clinical teams act on these results, modifying treatment for 29 per
cent of patients.
Financial update | Successful exercise of warrants from Unit Rights Issue
Over 90 per cent of shareholders exercised their warrants in May, providing
Q-linea with 59.5 MSEK (before transaction costs). The warrant exercise
concludes a 260 MSEK equity raise (initial proceeds for units was 204 MSEK and
warrant exercise 59,5 MSEK) during 2025, that provides Q-linea with resources
to continue to deliver on our growth plan.
We continue to explore non-dilutive funding opportunities to support ongoing
commercialisation and future product innovation.
Thank you for your continued support.
Best regards,
Stuart Gander, on behalf of the Q-linea team
President & CEO
For more information, please contact:
------------------------------------------------------------------------------
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com (mailto:stuart.gander@qlinea.com)
+1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
------------------------------------------------------------------------------
Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the
time-sensitive workflows faced during the treatment of patients with
bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the
time to optimal antimicrobial therapies and ensure that patients receive the
correct treatments sooner — when time matters most. We are helping to create
sustainable healthcare, now and in the future, and safeguard the effectiveness
of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy
and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA
510(k) cleared. For more information, please visit www.qlinea.com
Attachments
------------------------------------------------------------------------------
Q-linea on track for 2025 plan
(https://storage.mfn.se/45a96e00-5698-47a0-816b-7212b9f59086/q-linea-on-track-for-2025-plan.pdf)
------------------------------------------------------------------------------
news_id: 3cb19273-f9e7-470d-bbcc-8f94c292cac6
group_id: 3823835d-6f76-4e5f-9a86-812461ee22e7
tags: [sub:ci], [sub:ci:other]
title: Q-linea utvecklas som planerat 2025
------------------------------------------------------------------------------
Q-linea AB (publ) (OMX: QLINEA) har idag publicerat en företags- och
marknadsuppdatering.
Huvudbudskap
* Placering av instrument under Q2: Fem nyligen kontrakterade enheter innebär
att det totala antalet uppgår till 14 hittills i år (2024: 4, Q1 2025: 5, Q2
2025 hittills: 5)
* På god väg att uppnå 30–40 ASTar-placeringar i slutet av 2025. Målet är att
nå ytterligare 60–90 kontrakterade enheter under 2026
* Kommersiella utvärderingar expanderar i EMEA (Frankrike, Österrike,
Slovenien, Förenade Arabemiraten, Saudiarabien) och USA
* Fem stora amerikanska institutioner kommer att presentera ASTar-relaterade
posters på ASM (American Society for Microbiology) 2025, inklusive Quest,
Baylor Scott & White, Memorial Sloan Kettering Cancer Center, PennState
University och George Washington University
* Kapitalanskaffningen slutfördes framgångsrikt i maj med >90 procent
deltagande, vilket ger ett tillskott på cirka 250 MSEK efter
transaktionskostnader
Italien | Stark utveckling
Italien fortsätter att vara ledande och visa vägen med tre nya sjukhuskontrakt
och fem ASTar-placeringar under Q2. Detta inkluderar en upphandling vid
Policlinico di Milano, en ledande medicinsk anläggning i Lombardiet. Vårt
fokus riktas nu mot att stödja införandet av rutinmässig användning i vår
installerade bas. En viktig milstolpe med beslut om det toskanska
ESTAR-anbudet (som omfattar nio laboratorier) förväntas i juli 2025, vilket
kan höja det totala antalet platser i Italien som använder snabb AST till
20–25, och närma sig den andel på 10–15 procent som vanligtvis föregår en
bredare, allmän implementering.
Noterbart är att Q-linea tecknade sitt första "direct-to-validation"-kontrakt,
vilket kringgick en utvärdering i labbet – en indikator på växande förtroende
för varumärket och den underliggande tekniken. Återkopplingen från tidig
implementering är robust, med anläggningar som rapporterar mätbart kliniskt
och operativt värde. ASTar håller på att etablera sig som ledande i Italien
och är särskilt väl lämpat för de viktigaste mikrobiologiska testnaven.
USA | Kunder får praktisk erfarenhet av ASTar
Kvartalet har varit hektiskt för teamet med fem nya kommersiella utvärderingar
initierade och två slutförda utvärderingar. Vi har nu fem aktiva
kontraktsprocesser som pågår efter framgångsrika utvärderingar, varav flera
har dimensioner för flera platser och/eller flera ASTar. Förberedelserna för
utrullningen fortsätter med vår stora nationella referenslaboratoriekund med
prioritering av sex system som ska börja använda ASTar.
Externa pilotinitiativ undersöker användningen av ASTar i gramnegativ
isolattestning för forskningsändamål med uppmuntrande tidiga resultat.
Globalt | Utökar den kommersiella räckvidden
Aktiva och planerade utvärderingsprocesser har påbörjats i Frankrike,
Österrike, Slovenien, Förenade Arabemiraten och Saudiarabien. Agila
kommersiella modeller utvärderas på våra expansionsmarknader för att
möjliggöra snabbare marknadsinträde till minimala omkostnader.
Som svar på det starka intresset från kunder och partners på ESCMID (European
Society of Clinical Microbiology and Infectious Diseases) i april har vi
inlett samtal om att ta ASTar till Indien och andra marknader i Asien. Jag
fick också möjlighet att lyssna på sjukhus- och labbchefer i Kanada under
CACMID-konferensen (Canadian Association for Clinical Microbiology and
Infectious Diseases) i Calgary. Dessa marknader har längre ledtider, men det
är värt att notera att Q-linea kontaktas av erfarna aktörer med ett stort
intresse för att stödja lokalt marknadstillträde och distributionsaktiviteter.
Konkurrenssituation | Marknaden differentieras
Q-linea gynnas av det ökande intresset för snabb AST, liksom andra aktörer.
Utöver 14 kontrakterade ASTar-enheter globalt har GradienTech upp till sex
instrument i rutinmässig klinisk användning i Europa och BioMérieux
tillkännagav nyligen sitt första kommersiella kontrakt i USA för det snabba
AST-systemet REVEAL.
Kundkriterier för val av plattform håller på att formas och ASTar är unikt väl
positionerat för att betjäna marknaden inom en rad olika kriterier som
arbetsflöden, klinisk prestanda och ekonomiska attribut. Omvänt upplever
teknik som utformats för alternativa kundbehov utmaningar. Vårt team
rapporterar att Accelerate Pheno- och Selux NGP-plattformarna är i kommersiell
paus för att omgruppera, de förstnämnda under Chapter 11 i USA.
Parallellt har flera utlysningar gjorts om bidrag eller kapitalanskaffningar
för investeringar i framtida snabba AST-lösningar vilket understryker tron på
potentialen i en marknad som uppskattas till 6 – 9 miljarder kronor. Vi
förväntar oss att marknaden kommer att fortsätta att fokusera på de
plattformar och tekniker som bäst uppfyller de komplexa behoven i det moderna
mikrobiologiska laboratoriet.
Klinisk evidens | ASTar-användare talar för sig själva
Vi är stolta över att sju posters på den amerikanska ASM Microbe
2025-konferensen denna månad kommer att innehålla ASTar. Fem av dessa är
publicerade av ASTar-användare i USA, inklusive Quest Diagnostics, ett ledande
nationellt referenslaboratorium, Memorial Sloan Kettering Cancer Center i New
York, Baylor Scott & White, ett 50+ sjukhus IDN (Integrated Delivery Network)
baserat i Texas, och ledande akademiska medicinska centra på östkusten
Pennsylvania State University och George Washington University. Detta är en
aldrig tidigare skådad mängd oberoende forskning inom snabb AST.
Ytterligare data från LIFETIMES-studien som presenteras av Q-lineas
forskargrupp kommer att visa att behandlingen är 1,3 dagar (>30 timmar)
snabbare än nuvarande standardbehandling. Tidigare studier har visat att ASTar
ger användbara resultat 34 - 40 timmar tidigare än standardbehandling och de
nya uppgifterna bekräftar att kliniska team agerar på dessa resultat och
modifierar behandlingen för 29 procent av patienterna.
Finansiell uppdatering | Framgångsrikt genomförande av företrädesemission
Över 90 procent av aktieägarna nyttjade sina teckningsoptioner i maj, vilket
tillförde Q-linea 59,5 MSEK (före transaktionskostnader). Nyttjandet av
teckningsoptionen avslutar en kapitalanskaffning om 260 MSEK (initial likvid
för units uppgick till 204 MSEK och teckningsoptionsinlösen 59,5 MSEK) under
2025, vilket ger Q-linea resurser för att fortsätta leverera på vår
tillväxtplan.
Vi fortsätter att utforska finansieringsmöjligheter utan utspädning för att
stödja pågående kommersialisering och framtida produktinnovation.
Tack för ert fortsatta stöd.
Vänliga hälsningar
Stuart Gander, på uppdrag av Q-linea-teamet
Koncernchef
För mer information, vänligen kontakta:
------------------------------------------------------------------------------
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com (mailto:stuart.gander@qlinea.com)
+1 857 409 7463
Christer Samuelsson, CFO / IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+ 46 (0) 70-600 15 20
Om Q-linea
------------------------------------------------------------------------------
Q-lineas ASTar® för snabb resistensbestämning kortar svarstiderna vid
diagnostik av tidskritiska sjukdomstillstånd som blodomloppsinfektioner och
sepsis. Sjukhus använder ASTar för att avsevärt minska tiden till optimal
antibiotikabehandling och se till att patienter får rätt behandling, med rätt
dos, i rätt tid. Vi bidrar till en hållbar sjukvård, nu och i framtiden, och
värnar om att antibiotika är effektivt även för kommande generationer.
Q-linea har sitt huvudkontor i Uppsala, Sverige, regionala kontor i Italien
och USA, samt partnerskap över hela världen.
ASTar Instrument och ASTar BC G- Consumables kit är CE-IVD-märkta och FDA
510(k)-godkända. För mer information, besök www.qlinea.com.
Bifogade filer
------------------------------------------------------------------------------
Q-linea utvecklas som planerat 2025
(https://storage.mfn.se/1d39d7f4-6faa-40af-a133-5e21664d7283/q-linea-utvecklas-som-planerat-2025.pdf)
------------------------------------------------------------------------------
news_id: 8beab324-c31b-4671-96a0-e16295a237db
group_id: c5cbfa4e-3808-4c22-81bd-e367a89e646e
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: Goodbye Kansas Studios receives large order for game trailer and
In-Game content from new international customer
------------------------------------------------------------------------------
Goodbye Kansas Studios has received a significant order from a new
international customer for the production of a game trailer, In-Game content
and motion capture for a game project. The customer has confirmed the order
and the parties are now finalizing the formal process to sign the contract.
The total value of the order amounts to approximately SEK 31 million. The
project will commence immediately and run until the first quarter of 2026.
"Our proven ability to deliver outstanding creative solutions has created the
prerequisites to win this order for a major project from a new customer. We
continue to generate strategically important orders in a highly competitive
market, thanks to our strong brand and a track record that is hard to beat,"
says Stefan Danieli, CEO of Goodbye Kansas Group.
For additional information, please contact:
Stefan Danieli, CEO, Goodbye Kansas Group
E-mail: stefan.danieli@goodbyekansas.com
Direct: +46 701 98 10 49
About Goodbye Kansas Group
Goodbye Kansas Group is a provider of technology-driven visual content,
developing visual effects (VFX), animations, game trailers and In-Game
solutions. The Group has some of the world's leading entertainment companies
as its clients. Goodbye Kansas Group is headquartered in Stockholm and is
listed on the Nasdaq First North Growth Market with Wildeco as Certified
Adviser.
www.goodbyekansasgroup.com (http://www.goodbyekansasgroup.com/)
This information is information that Goodbye Kansas Group AB (publ) is obliged
to make public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact persons set out
above, at 2025-06-19 13:30 CEST.
Attachments
------------------------------------------------------------------------------
Goodbye Kansas Studios receives large order for game trailer and In-Game
content from new international customer
(https://storage.mfn.se/e60921a9-104f-4765-81fd-273482b5c7a9/goodbye-kansas-studios-receives-large-order-for-game-trailer-and-in-game-content-from-new-international-customer.pdf)
------------------------------------------------------------------------------
news_id: 1737d49b-5b48-4fec-b60f-b66a57e833ce
group_id: c5cbfa4e-3808-4c22-81bd-e367a89e646e
tags: [:regulatory], [:regulatory:mar], [ext:nq], [ext:nq:inside-information],
[sub:ci], [sub:ci:other]
title: Goodbye Kansas Studios får stor order på speltrailer och
In-Game-innehåll från ny internationell kund
------------------------------------------------------------------------------
Goodbye Kansas Studios har fått en betydande order från en ny internationell
kund för produktion av en speltrailer, in-game-innehåll och motion capture för
ett spelprojekt. Kunden har bekräftat ordern och parterna slutför nu den
formella processen för att signera kontraktet. Värdet på ordern uppgår totalt
till cirka 31 MSEK. Projektet inleds omedelbart och kommer att pågå till och
med första kvartalet 2026.
“Vår omvittnade förmåga att skapa enastående kreativa lösningar har skapat
förutsättningar för att vinna denna order på ett stort projekt från en ny
kund. Vi fortsätter generera strategiskt viktiga ordrar trots hård konkurrens
tack vare vårt starka varumärke och en svårslagen track record,” säger Stefan
Danieli, VD för Goodbye Kansas Group.
För ytterligare information, vänligen kontakta:
Stefan Danieli, Koncernchef och VD, Goodbye Kansas Group
E-mail: stefan.danieli@goodbyekansas.com
Tel: +46 701 98 10 49
Goodbye Kansas Group
Goodbye Kansas Group är en leverantör av teknologidrivet visuellt innehåll och
utvecklar lösningar för visuella effekter (VFX), animation, speltrailers och
In-Game. Koncernen har några av världens ledande underhållningsbolag som
kunder. Goodbye Kansas Group har huvudkontor i Stockholm och är noterat på
Nasdaq First North Growth Market med Wildeco som Certified Adviser.
www.goodbyekansasgroup.com (http://www.goodbyekansasgroup.com/)
Denna information är sådan information som Goodbye Kansas Group AB (publ) är
skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning.
Informationen lämnades, genom ovanstående kontaktpersoners försorg, för
offentliggörande den 2025-06-19 13:30 CEST.
Bifogade filer
------------------------------------------------------------------------------
Goodbye Kansas Studios får stor order på speltrailer och In-Game-innehåll från
ny internationell kund
(https://storage.mfn.se/94431b97-40ed-4d52-ac74-089a88dfd1b6/goodbye-kansas-studios-far-stor-order-pa-speltrailer-och-in-game-innehall-fran-ny-internationell-kund.pdf)